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Personalized medicine concerns the tailoring of prevention, diagnosis, and treatment 
of disease to the individual’s characteristics, needs, and preferences. The concept of 
personalized medicine is not new. From the time of Hippocrates (~400 B.C.E.), doc-
tors have been aware that patients with similar symptoms may suffer from different 
diseases; and similarly, that patients with the same disease may respond differently to 
given treatments.1 In cancer care, clinicians have long used the location of the tumor 
and the stage of disease with which a patient presents to direct initial and adjuvant 
treatment. The stage of disease can be summarized by the extent to which the tumor 
has spread beyond its original site. For patients with a localized or low-stage tumor, sur-
gical resection can be curative. In contrast, when the cancer has spread throughout the 
body, surgery alone is not effective, whereas systemic therapy such as chemotherapy 
may be. Over time, tumor location and disease stage have been combined with multiple 
other clinicopathological features to provide an increasingly comprehensive profile of a 
specific tumor. Such features include the histological tumor type and grade (a measure 
of the appearance and growth patterns of tumor cells), the invasion of cancer cells into 
lymph and/or blood vessels, and the expression of specific proteins as determined by 
immunohistochemical analyses. The resulting clinicopathological profile has since been 
used to predict how a particular cancer will behave and consequently, to assess how 
best to treat an individual patient.
While the concept of personalized medicine based on clinicopathological characteristics 
in cancer is not new, the genomic data that can be incorporated into clinical decision 
making is a rapidly expanding field. Sanger sequencing has been the traditional method 
of genomic analysis: with this method, 500 to 600 base pairs of DNA can be sequenced 
per reaction (to put this into perspective, the human genome consists of three billion 
base pairs). In the past two decades, newer methods of genomic analysis have been 
introduced that can sequence longer fragments of DNA in a single run. As multiple 
DNA sequencing platforms were developed around the same time, fierce competition 
between manufacturers arose to increase the length and output of the sequences, and 
at the same time, to lower the costs. These new and cheaper sequencing technologies 
enabled an unprecedented expansion of our knowledge of the human genome.2,3 
Cancer can, in essence, be considered a disease of the genome in a specific organ or 
tissue. Much of the contemporary research on cancer has focused on using the genomic 
data to identify and understand the molecular basis of this disease. This has led to a 
more advanced form of personalized medicine, now often also termed precision medi-
cine, in which the individual’s tumor characteristics not only include clinicopathological 
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data but also the molecular profile of the specific cancer. Such a combination can even 
more accurately predict a patient’s prognosis and the likelihood of response of the tu-
mor to conventional treatment (e.g. chemo- or radiotherapy). Moreover, it may predict 
response to specific targeted therapies, directed against molecular alterations identified 
in the patient’s tumor.
The benefits through the application of precision medicine have been clearly demon-
strated in breast cancer. In this tumor type, molecular profiling has been implemented to 
provide more precise estimates of patient outcomes. Together with clinical and morpho-
logical features (including age, tumor size, grade, and lymph node status), determination 
of hormone receptor status and of human epidermal growth factor 2 (HER2) expression 
(overexpression as surrogate marker for gene amplification) are the standard of care. 
Both markers are used to predict a patient’s prognosis and to stratify for conventional 
and targeted (adjuvant) treatments.4 Moreover, this integrated molecular approach has 
been further refined by the use of gene expression profiles such as the MammaPrint or 
OncotypeDX. These profiles provide additional prognostic information, and, in certain 
patients, allow for tailored treatments.5-9 
In summary, the use of molecular biomarkers has the potential to improve treatment 
response and prognostic forecasting. Although for some cancers, molecular profiling 
has already been implemented in clinical practice, for other cancer types, including 
endometrial cancer, this is not yet the standard of care. This chapter describes the epide-
miology, diagnosis, and (adjuvant) treatment options in endometrial cancer. Moreover, 
it describes our current knowledge of molecular alterations and how these may improve 
personalized medicine in endometrial cancer.
endometrial cancer
Epidemiology
Endometrial cancer arises from the epithelial lining of the uterus, called the endometri-
um. It is the most common gynecological malignancy in the Western world, accounting 
for approximately 1900 new cases in the Netherlands each year.4 Due to the increasing 
obesity and ageing of the population, two important risk factors for the development 
of endometrial cancer, the incidence of endometrial cancer has been rising rapidly (36% 
increase since 2000 in the Netherlands, Figure 1).10-13 This disease typically afflicts older 
women - incidence peaks between 65 and 75 years of age - who present with postmeno-
pausal bleeding.4,11 This symptom is recognized by both patients and physicians as an 
indication for prompt referral and investigation, and leads to diagnosis of endometrial 
cancer in an early stage of disease in the majority (~75%) of patients.11,12 Prognosis for 
these patients is favorable, with a five-year overall survival of 85-90%. For women with 
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recurrent or metastatic disease, however, outcomes are poor, with a five-year overall 
survival of ~20% for patients with distant metastases.12 Because of the favorable prog-
nosis of early-stage disease, the overall mortality rate is relatively low: approximately 
460 women die of endometrial cancer in the Netherlands each year. This contrasts with 
other gynecological malignancies such as ovarian cancer, where ~75% of patients die of 
the disease.11
Diagnosis and primary treatment
Endometrial cancer is diagnosed by histopathological assessment of endometrial tissue 
obtained through sampling of the endometrium by biopsy or curettage. After diagnosis, 
standard treatment consists of surgery, during which the uterus, both ovaries and fal-
lopian tubes are removed (abdominal or laparoscopic total hysterectomy and bilateral 
salpingo-oophorectomy).4 The indication for adjuvant treatment is currently based on 
a patient’s risk of disease recurrence as estimated by clinicopathological risk factors. 
Risk factors include tumor type, tumor grade, stage of disease, age of the patient, and 
lymphovascular space invasion. These factors are described in more detail below.
Clinicopathological risk factors
Histological type
Historically, endometrial carcinomas can be divided morphologically into two main 
tumor types: endometrioid and non-endometrioid endometrial cancers (Figure 2).14 
Endometrioid carcinomas, the most common subtype (~80% of cases), are cancers that 
morphologically resemble the normal endometrium. This subtype is associated with 
unopposed estrogen stimulation and usually arises in the background of endometrial 
hyperplasia. In contrast, non-endometrioid endometrial cancers are estrogen-indepen-
dent tumors that often arise in atrophic endometrium and have various histological 
subtypes, including serous and clear cell carcinomas.14,15 Hamilton et al., among others, 



























Figure 1. Incidence and mortality of endometrial cancer in the Netherlands per 100,000 women in the 
period 1990 – 2016.11
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reported that while 13% of endometrial cancers showed non-endometrioid histology 
in their study, these cases accounted for 47% of endometrial cancer deaths.16 Thus, 
compared to endometrioid-type tumors, non-endometrioid endometrial cancers have 
an aggressive clinical course and account for a disproportionate number of endometrial 
cancer deaths.
FIGO grade
Endometrioid endometrial cancers are graded according to the International Federation 
of Gynecology and Obstetrics (FIGO) classification based on the percentage of non-
squamous solid growth and on the degree of nuclear atypia in comparison to normal 
endometrium (Figure 2A-B).12,15,17 An endometrioid endometrial cancer consisting of a 
predominantly glandular architecture with no or minimal solid growth (≤5%) is con-
sidered grade 1, whereas endometrial cancers with 6-50% or >50% solid growth are 
designated grade 2 and 3, respectively. When nuclear atypia is notable (e.g. nuclei differ 
greatly in size and shape) and when this atypia does not correspond to the architectural 
A B
DC
Figure 2. Histological classification of endometrial cancers.
Common histological subtypes of endometrial cancer are endometrioid-type (A and B), serous (C), and 
clear cell (D) carcinomas. Furthermore, endometrioid endometrial cancers are graded based on the pres-
ence of solid growth and nuclear atypia: examples of a grade 1 (A) and grade 3 (B) endometrioid endome-
trial cancer are shown. Figures A, B, and D are at x20 magnification, C at x10.
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grade, the grade of the endometrial cancer can be raised by one. For every stage of 
disease, high-grade endometrial cancers (grade 3) have a poorer clinical outcome.12,18 
FIGO stage
The FIGO staging system uses clinical, surgical and pathological findings to classify 
endometrial cancers into four stages based on the extent of tumor growth (Table 1). 
This classification takes invasion of the tumor in the myometrium into account, invasion 
of tumor in cervical stroma and/or serosa, involvement of the adnexae, of pelvic and/or 
para-aortic lymph nodes, and of surrounding or distant organs and tissues. Evidently, 
survival decreases with increasing stage.12 
Age at diagnosis
The age of the patient is another determinant of prognosis in endometrial cancer. Age 
is associated with other prognostic factors such as tumor type: endometrial cancers of 
elderly women are more often of non-endometrioid histology. Despite this association, 
although it remains to be clarified how this is reflected in the underlying tumor biology, 
age is an independent prognostic factor in endometrial cancer. Patients with an age at 
diagnosis of 60 years or more have a higher risk of both locoregional (vaginal or pelvic) 
and distant recurrences and more often succumb to endometrial cancer than those 
younger than 60 years at diagnosis.19-22 
table 1. FIGO 2009 staging of endometrial cancer.12,17
Stage description
Stage I Tumor confined to the corpus uteri
IA No or less than one half myometrial invasion
IB Invasion equal to or greater than the outer one-half of the myometrium
Stage II Tumor invades the cervical stroma but does not extend beyond the uterus
Stage III Local and/or regional spread of the tumor
IIIA Tumor invades the serosa and/or adnexae
IIIB Vaginal and/or parametrial involvement
IIIC Metastases to pelvic and/or para-aortic lymph nodes
IIIC1 Metastases to pelvic lymph nodes
IIIC2 Metastases to para-aortic lymph nodes with or without positive pelvic lymph nodes
Stage IV Tumor invades bladder and/or bowel mucosa, and/or distant metastases
IVA Tumor invades the bladder or bowel mucosa
IVB Distant metastases, including intra-abdominal metastases and/or inguinal lymph nodes
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Lymphovascular space invasion
Finally, over the past three decades, many independent studies have shown the 
prognostic significance of lymphovascular space invasion in endometrial cancer.23-30 
Lymphovascular space invasion can be defined as the presence of cancerous cells in a 
space lined by endothelial cells outside the immediate invasive border.24 The presence 
of substantial lymphovascular space invasion is an important risk factor for lymph node 
involvement, local recurrence (even in the absence of lymph node metastases) and dis-
tant metastases.23-30 Although a standard definition and an optimal scoring method of 
lymphovascular space invasion remain to be developed, a comparison of different scor-
ing methods determined a three-tiered scoring system to be the most straightforward 
and to have the strongest prognostic power.24 
Adjuvant therapy
Together, these clinicopathological risk factors are used to group patients according to 
their risk of endometrial cancer recurrence with consequent implications for adjuvant 
treatment (Table 2).31 In this risk assessment, patients with early-stage, endometrioid-
type endometrial cancers are stratified into low-, (high-)intermediate-, and high-risk 
groups. Patients with more advanced-stage disease and women with non-endometrioid-
type cancers are all classified as being at high risk. For patients with low-risk endometrial 
cancer, no additional treatment is recommended as their risk of recurrence after hyster-
ectomy is low.19,32-34 Therapeutic options considered in the adjuvant setting for (high-)
intermediate and high-risk disease are radiotherapy (either vaginal brachytherapy or 
external beam radiotherapy), chemotherapy or a combination.
In patients with intermediate-risk endometrial cancer, large randomized controlled trials 
showed that external beam radiotherapy significantly decreases the risk of locoregional 
recurrence (vaginal and/or pelvic recurrences): in the PORTEC-1 trial, the five-year risk 
was 14% without additional treatment and 4% with radiotherapy. However, radiotherapy 
does not improve survival in early-stage disease: overall survival is approximately 80-85% 
after five years, both with and without adjuvant treatment. In addition, most recurrences 
are local (predominantly found at the vaginal vault), and the majority can be effectively 
salvaged.19,33,34 In the PORTEC-2 trial, vaginal brachytherapy has been shown to reduce 
the risk of vaginal recurrence as effectively as external beam radiotherapy: five-year 
recurrence rates were less than 2% for both vaginal brachytherapy and external beam 
radiotherapy.35 However, vaginal brachytherapy causes significantly less bowel toxicity 
than external beam radiotherapy, and quality of life remains high, with rates similar to 
a norm population matched for age and gender.36,37 Therefore, vaginal brachytherapy 




In a pooled analysis of long-term outcomes of the PORTEC-1 and -2 trials, patients with 
early-stage grade 3 disease and/or with substantial lymphovascular space invasion 
had significantly increased pelvic regional and distant recurrence rates. For the 5% of 
patients who had substantial lymphovascular space invasion, the risk of pelvic regional 
recurrence was 15% after five years, compared to 2% for those without lymphovascular 
space invasion.24 These patients are therefore considered at high-intermediate risk in 
the current risk classification according to the recent ESMO-ESGO-ESTRO consensus 
guidelines. For patients with high-intermediate-risk endometrial cancer with substantial 
lymphovascular space invasion, external beam radiotherapy is recommended to maxi-
mize pelvic control.31
Controversy remains concerning the optimal adjuvant therapy for patients with high-risk 
endometrial cancer, which includes those with early-stage grade 3 disease with deep 
invasion, those with more advanced stages, and those with non-endometrioid-type 
cancers. Two trials compared pelvic external beam radiotherapy to chemotherapy (con-
sisting of three to five cycles of cyclophosphamide, doxorubicin and cisplatin) and found 
no difference between the arms regarding overall and progression-free survival.20,21 In a 
multicenter randomized trial, sequential external beam radiotherapy and different re-
table 2. Risk groups in endometrial cancer to guide the use of adjuvant treatment according to the ESMO-
ESGO-ESTRO consensus guidelines 2016.31
risk group description Adjuvant treatment recommendations
Low Stage I endometrioid, grade 1-2, <50% 
myometrial invasion, LVSI negative
No adjuvant treatment recommended
Intermediate Stage I endometrioid, grade 1-2, ≥50% 
myometrial invasion, LVSI negative
Vaginal brachytherapy
No adjuvant treatment is an option, 
especially for patients aged <60 years
High-intermediate Stage I endometrioid, grade 3, <50% 
myometrial invasion, regardless of LVSI 
status
Stage I endometrioid, 1-2, LVSI 
unequivocally positive, regardless of 
depth of myometrial invasion
External beam radiotherapy when LVSI 
positive
Vaginal brachytherapy when grade 3 and 
LVSI negative
High Stage I endometrioid, grade 3, ≥50% 
myometrial invasion, regardless of LVSI 
status
Stage II endometrioid
Stage III endometrioid, no residual 
disease
Non-endometrioid (serous, clear cell, 
undifferentiated, carcinosarcoma)
External beam radiotherapy
Consider adjuvant and concurrent 
chemotherapy (standard: carboplatin and 
paclitaxel)
Consider vaginal brachytherapy boost 
when stage II
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gimes of chemotherapy (predominantly platinum-based) was compared to radiotherapy 
alone; the combination resulted in a significantly higher five-year progression-free sur-
vival (78% vs. 69%).39 Two randomized controlled trials in which combined radiotherapy 
and chemotherapy is compared to either external beam radiotherapy (PORTEC-3) or 
chemotherapy (GOG-0258) alone, have recently presented preliminary results. The GOG-
0258 trial for stage III-IVA endometrial cancer found that, although chemotherapy com-
bined with radiotherapy reduced the risk of vaginal, pelvic, and para-aortic recurrences, 
it did not increase the recurrence-free survival compared to chemotherapy alone.40 
In the PORTEC-3 trial, which included stage I-III high-risk disease, a trend towards an 
improved five-year failure-free survival (i.e. relapse or endometrial cancer-related death) 
was found with concurrent chemotherapy and radiotherapy. In women with stage III 
disease, the addition of chemotherapy significantly improved the failure-free survival by 
11% after five years.41 While awaiting the long-term outcomes of these studies, external 
beam radiotherapy is recommended to maximize locoregional control. To decrease the 
rate of distant metastases, adjuvant platinum-based chemotherapy can be considered, 
especially for stage III disease and for those with non-endometrioid-type cancers. Cur-
rent literature supports the use of combined radiotherapy and chemotherapy rather 
than either modality alone.31 
Despite the use of this clinicopathological risk assessment, over- and undertreatment 
remain an important clinical problem. On one hand, approximately seven endometrial 
cancer patients need to be treated with vaginal brachytherapy to prevent one vaginal 
recurrence. This results in unnecessary treatment-associated costs and toxicities: six of 
out of the seven patients treated would not have had a recurrence regardless of the 
vaginal brachytherapy.32,35,42 On the other hand, approximately 7% of patients with 
intermediate-risk endometrial cancer develop distant metastases within five years that 
might have been prevented with tailored adjuvant treatment.32 Similarly to the model 
used in breast cancer described at the beginning of this chapter, recent studies pro-
posed the use of molecular biomarkers in an integrated risk model to more accurately 
predict the clinical outcome of endometrial cancer patients.
Molecular (integrated) classification
In 2013, The Cancer Genome Atlas (TCGA) proposed a new classification of endometrial 
cancer based on genomic, transcriptomic and proteomic analysis of 373 endometrial 
cancers (Figure 3A-B). This classification included four distinct molecular subgroups with 
prognostic significance: (1) a group characterized by mutations in the exonuclease 
domain of the gene encoding the catalytic subunit of DNA polymerase epsilon (POLE), 
which have a very high mutational burden (‘ultramutated’), a specific mutational sig-
nature, but also a very good clinical outcome; (2) a microsatellite-unstable (MSI) group, 
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which shows a hypermutated phenotype, many insertions and deletions due to defects 
in mismatch repair, and has an intermediate prognosis; (3) a copy-number low group 
with a lower mutational burden, a microsatellite-stable phenotype, and an intermediate 
to favorable outcome; and (4) a copy-number high group, which contains the majority 
of non-endometrioid (mostly serous) cancers, has a low mutation rate, is associated with 
TP53 mutations, and has the poorest clinical outcome.43 The clinical follow-up data in 
the TCGA study were, however, limited. Furthermore, while the employed methodolo-
gies were useful to identify the molecular subgroups, they are costly and cannot easily 
be implemented in routine clinical practice. Therefore, different studies validated this 
molecular classification and its prognostic implications in independent cohorts using 
surrogate markers, which can be analyzed on formalin-fixed paraffin-embedded (FFPE) 
tissues as described below.42,44-46 
Stelloo et al. defined the TCGA molecular subgroups on FFPE tumor samples by clini-
cally applicable methods: POLE-mutant cases were identified by Sanger sequencing of 
a part of the POLE exonuclease domain, microsatellite-unstable cases by microsatel-
lite instability assay and immunohistochemistry of the mismatch repair proteins, and 
copy-number high cases by immunohistochemical analysis of p53.42,45 Identification of 
these cases leaves a POLE-wild-type, microsatellite-stable, p53-wild-type group that was 
called ‘copy-number low’ in the TCGA study or ‘no specific molecular profile’ (NSMP), as 
no driver mutation has been identified for this group.45 Similarly to the TCGA study, Stel-
loo et al. showed highly significant differences in recurrence and survival rates between 
the molecular subgroups (Figure 3C).42 The use of surrogate markers in FFPE samples 
to establish the molecular classification was further supported in subsequent studies, 
which also replicated its prognostic impact.44,46 
Both Stelloo et al. and Talhouk et al. compared risk models based on this molecular 
classification to models based on clinicopathological or combined molecular and clini-
copathological characteristics and assessed their ability to predict clinical outcomes.42,44 
Both studies showed that a model integrating both molecular alterations and clinico-
pathological risk factors most strongly improved the risk assessment of endometrial 
cancer patients.42,44 The study from Stelloo et al., based on the pooled PORTEC-1 and -2 
trials, proposed the inclusion of lymphovascular space invasion status, expression of L1 
cell adhesion molecule, and CTNNB1 mutational status in addition to the TCGA molecu-
lar subgroups in the integrated risk classification. L1 cell adhesion molecule (L1CAM; 
CD171) is a membrane glycoprotein of the immunoglobulin superfamily, whose expres-
sion in endometrial cancer is strongly related to disease progression and recurrence.47-51 
CTNNB1 exon 3 mutations lead to activation of Wnt/β-catenin signaling, and characterize 



















































































































































































































































































































































































































molecular integrated risk model, stage I endometrial cancers at (high-)intermediate risk 
could be reclassified to favorable, intermediate, or unfavorable risk groups. This lead 
to 55% of patients at intermediate risk of recurrence being reassigned to the favorable 
risk group: these patients may not benefit from adjuvant treatment. Moreover, 15% of 
patients were reclassified to the unfavorable group: these patients may benefit from 
more extensive adjuvant treatment.42 This model is currently prospectively evaluated in 
the multicenter randomized PORTEC-4a trial and may substantially reduce unnecessary 
adjuvant treatment in endometrial cancer.54 
SubjeCt, AImS And outlIne oF thIS theSIS
Personalized medicine in cancer care can be improved upon by combining molecular 
biomarkers with clinicopathological characteristics to better predict a patient’s prog-
nosis and/or response to treatment. The Cancer Genome Atlas paved the way towards 
such an even more personalized approach in endometrial cancer: a molecular classifi-
cation was proposed in which four distinct subgroups were identified with prognostic 
significance.43 One of the molecular subgroups in endometrial cancer as proposed by 
The Cancer Genome Atlas was novel, and was characterized by mutations in the POLE 
proofreading exonuclease domain.43,55-57 Moreover, The Cancer Genome Atlas found that 
POLE exonuclease domain-mutant cancers are characterized by a very high mutational 
burden, which is amongst the highest found in human cancers.43,55,58 Genomic instability 
and mutability are central to cancer development and progression.59 Therefore, it was 
striking that, despite this so-called ‘ultramutated’ phenotype, multiple independent 
studies showed that patients with POLE exonuclease domain-mutant endometrial can-
cers have a very good clinical outcome.42-46,60-62 
The aims of this thesis were to gain insight into somatic POLE exonuclease domain muta-
tions in endometrial cancer and especially into the underlying mechanism(s) by which 
these POLE mutations contribute to the observed favorable clinical outcome. These 
insights may facilitate the implementation of POLE exonuclease domain mutations as an 
(Figure 3 continued) (A) Genomic, transcriptomic, and proteomic analysis of 373 endometrial cancers by 
The Cancer Genome Atlas (TCGA) identified four distinct molecular subgroups. Molecular and clinicopatho-
logical characteristics are depicted for each molecular subgroup. (B) Progression-free survival for the differ-
ent molecular subgroups from the TCGA study is shown. (C) Disease-specific survival for the four molecular 
subgroups, identified with clinically applicable surrogate markers, in a pooled analysis of two large ran-
domized controlled trials (PORTEC-1 and PORTEC-2) of endometrial cancer is depicted. Figures A and B are 
adapted from TCGA, Nature 2013 (reprinted under the Creative Commons license).43 Figure C is adapted 
from Stelloo et al., Clin Can Res 2016 with permission from the American Association for Cancer Research.42 
Abbreviations: CN, copy number.
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important prognostic biomarker in routine clinical practice. Moreover, it may provide a 
deeper understanding of molecular mechanisms underlying endometrial cancer, which 
may lead to the discovery of new therapeutic options. Finally, as POLE exonuclease 
domain mutations are found in a wide variety of human malignancies (for example 
colorectal cancer), these findings may be generalizable to other cancer types as well.
In chapter 2, the current understanding of the mechanisms and the consequences of 
POLE exonuclease domain mutations in human cancers is reviewed. Furthermore, chapter 
2 reports on the potential usefulness of these mutations as novel cancer biomarkers and 
therapeutic targets. Chapter 3 describes a histopathological and immunohistochemical 
characterization of POLE exonuclease domain-mutant endometrial cancers to aid their 
detection in routine clinical practice. Chapter 4 shows how enhanced immunogenicity 
may contribute to the favorable clinical outcome of POLE exonuclease domain-mutant 
endometrial cancers. Chapter 5 focuses on validation of the results obtained from chap-
ter 3 and on the possible utility of immunotherapeutic strategies in a series of high-risk 
endometrial cancer. Chapter 6 describes the sensitivity to adjuvant treatment strategies 
of POLE exonuclease domain-mutant cancers and its impact on clinical outcome. Chap-
ter 7 focuses on the timing of POLE exonuclease domain mutations in carcinogenesis. 
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AbStrACt
Although it has long been recognized that the exonucleolytic proofreading activity 
intrinsic to the replicative DNA polymerases Pol δ and Pol ε is essential for faithful rep-
lication of DNA, evidence that defective DNA polymerase proofreading contributes to 
human malignancy has been limited. However, recent studies have shown that germline 
mutations in the proofreading domains of Pol δ and Pol ε predispose to cancer, and that 
somatic Pol ε proofreading domain mutations occur in multiple sporadic tumors, where 
they underlie a phenotype of ‘ultramutation’ and favorable prognosis. In this review, 
we summarize the current understanding of the mechanisms and consequences of 
polymerase proofreading domain mutations in human malignancies, and highlight the 
potential utility of these variants as novel cancer biomarkers and therapeutic targets.
N.b. Italicized words or phrases are defined in the Glossary following the main text and 
references.
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A PAnoPly oF errorS: PolymerASe ProoFreAdIng domAIn mutAtIonS 
In CAnCer
Accurate replication of DNA before cell division is a prerequisite for the suppression of 
mutagenesis and tumor development. The remarkable fidelity of eukaryotic DNA rep-
lication – estimated at one incorrect base for every 109 to 1010 nucleotides replicated1 
– results from a combination of highly accurate base incorporation and exonuclease 
proofreading by the replicative DNA polymerases Pol δ and Pol ε, and post-replication 
surveillance by the DNA mismatch repair (MMR) apparatus.2,3 Defects in either poly-
merase proofreading or MMR increase the mutation rate in Saccharomyces cerevisiae and 
cause tumors in mice.4-8 Although the importance of MMR deficiency (MMR-D) in human 
cancer has been recognized for more than two decades,9,10 until recently, evidence that 
defective polymerase proofreading contributes to human malignancy has been scarce.11 
However, over the last three years, studies have shown that germline mutations in the 
proofreading domains of POLD1 and POLE (which encode the catalytic subunits of Pol 
δ and Pol ε, respectively, in humans) predispose to colorectal cancer (CRC) and other 
malignancies.12 Somatic POLE proofreading domain mutations are found in 7-12% of en-
dometrial cancers (ECs), in 1-2% of CRCs, and occasionally in tumors of the breast, stom-
ach, pancreas and brain, where they define a distinct, ultramutated tumor subgroup.13-19 
POLE proofreading domain mutations predict favorable prognosis in EC,20-24 and may 
also do so in glioblastoma,14 possibly because the exceptional number of mutations in 
these cancers causes an enrichment of antigenic neopeptides, leading to an enhanced 
antitumor immune response.25,26 
In this review, we summarize the current understanding of the mechanisms and con-
sequences of replicative DNA polymerase proofreading domain mutations in human 
malignancies. Although we provide an outline of the organization and function of 
replicative DNA polymerases as a background, we do not cover this subject in detail 
as it has been described comprehensively in several excellent reviews.27-30 Instead, we 
highlight the distinctive clinicopathological and molecular characteristics of replicative 
DNA polymerase proofreading domain-mutant tumors, and focus on the potential util-
ity of these variants as novel cancer biomarkers and targets for therapy.
dnA polymerase proofreading
Pol δ and Pol ε are the principal eukaryotic DNA replicases, and together are responsible 
for the bulk of DNA replication, following priming by Pol α.31-34 They are B family poly-
merases and, unlike Pol α, have a 3’-5’ exonuclease activity that proofreads the newly 
synthesized DNA strand.3,35 Both Pol δ and Pol ε comprise four subunits in humans, the 
largest of which contains the catalytic and proofreading exonuclease active sites, and 
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is encoded in humans by POLD1 and POLE, respectively.36 The other smaller subunits 
(encoded in humans by POLD2, POLD3 and POLD4, and by POLE2, POLE3 and POLE4) 
also perform several important or essential roles. In the case of Pol δ, they stabilize the 
holoenzyme complex and stimulate DNA polymerase activity via interactions with the 
replication processivity factor proliferating cell nuclear antigen (PCNA).37-39 The essential 
second subunit of Pol ε mediates the interaction with GINS and may help to target the Pol 
ε holoenzyme to the leading strand during the initiation of DNA replication,40-42 whereas 
the non-essential third and fourth subunits are critical for binding double-stranded DNA 
and for processive DNA synthesis and processive 3’-5’ exonuclease degradation.43 
Studies of mutant Pol ε and Pol δ polymerases with particular error signatures in S. 
cerevisiae and Schizosaccharomyces pombe have suggested a model of DNA replication 
in which Pol δ replicates the lagging strand following priming by Pol1 (the functional 
equivalent of the catalytic subunit of human Pol α), whereas Pol ε replicates the leading 
strand.44-46 This division of labor has been corroborated by analyses of yeast mutants 
engineered to misincorporate ribonucleoside triphosphates (rNTPs; reviewed in 47) and 
by biochemical reconstitution experiments,48,49 and is broadly accepted. Indeed, further 
support for this model – albeit indirect – was provided by the crystal structure of S. 
cerevisiae Pol ε catalytic subunit (Pol2), which revealed the existence of a domain absent 
in the corresponding Pol δ subunit (Pol3) that could explain its enhanced processivity.50 
However, these roles have been questioned by a very recent publication, which suggests 
that previous results may have been confused by differential MMR and proposes that Pol 
δ replicates both the leading and lagging strands, whereas the functions of Pol ε are lim-
ited to repair synthesis and proofreading of the leading strand.51 Although the precise 
contribution of Pol ε to leading strand replication awaits definitive clarification, current 
data are concordant in indicating that its exonuclease domain preferentially proofreads 
the leading strand.27,51 In addition to their roles in DNA replication, in both yeast and 
humans both Pol δ and Pol ε also function in base excision repair (BER),52,53 nucleotide 
excision repair (NER),54,55 MMR56-58 and double-strand break repair.59,60 Pol ε has also been 
implicated in cell cycle checkpoint regulation and propagation of chromatin modifica-
tion states (reviewed in 61), thus mutations affecting this protein could potentially affect 
a wider range of cellular activities than just replication fidelity.
The proofreading function of both Pol δ and Pol ε requires several highly conserved exo 
motifs in their exonuclease domains, within which lie the catalytic site residues that are 
essential for exonuclease activity (D316 and E318 in Pol δ, and D275 and E277 in Pol ε, 
in humans; Figure 1).27,28 Misincorporation of a base into the primer strand results in 
pausing of the polymerase (due to reduced efficiency in extending a mispaired primer 
terminus) and a switch from the catalytic to the exonuclease domain.62 The incorrect 
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base is then excised and the correct base inserted before DNA synthesis continues.62 
Multiple studies in model organisms have confi rmed the essential role of DNA poly-
merase proofreading in the maintenance of genomic stability. In S. cerevisiae, mutants of 
Pol δ and Pol ε containing alanine substitutions of the exonuclease active site residues 
have no exonuclease activity, and cells expressing these variants show a ~100-fold 
increase in mutation rate.4,63,64 Mice harboring the equivalent substitutions show an 
Figure 1. Frequency and location of germline and somatic Pol δ and Pol ε proofreading exonuclease do-
main mutations in cancers.
A schematic representation of the exonuclease domains of Pol δ (A) and Pol ε (B) showing conserved exo 
motifs (I-V), exo I active site residues, and the position and frequency of germline and somatic mutations. 
In the lower panels, the positions of germline (blue) and somatic (red) proofreading domain mutations 
are mapped to the Saccharomyces cerevisiae Pol δ (C, Protein Data Bank identifi er (PDB ID) 3IAY116) and 
Pol ε (D, PBD ID 4M8O50) exonuclease domain structures. Single-stranded DNA from the aligned bacterio-
phage T4 polymerase complex (PDB ID 1NOY118) is shown in yellow. The exo I motif active site residues are 
highlighted in magenta (with exception of mutated Pol δ active site residue D316, which is also the site of 
germline mutations). Note that Pol ε residues L424V and P436R/S are the site of both germline and somatic 
mutations and are colored according to which alteration is more frequent.
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increased mutation rate and develop tumors.6-8 Notably, cancers only develop in ani-
mals homozygous for proofreading-null Pold1 or Pole alleles (the mouse orthologues of 
POLD1 and POLE),6-8 and the tumor spectrum that they develop differs between the two: 
Pold1-mutant mice develop lymphomas and carcinomas of the skin and lung,7 whereas 
Pole mutants are prone to intestinal tumors and histiocytic sarcomas.6 A simple explana-
tion for these phenotypes is that defective proofreading leads to an increased mutation 
rate, as some misincorporated nucleotides escape subsequent correction by MMR, but 
the reality may be more complicated. For instance, studies in S. cerevisiae indicate that 
elevation of deoxyribonucleoside triphosphate (dNTP) levels by cell cycle checkpoint 
activation is responsible for the mutator phenotype of proofreading-defective DNA 
polymerases.65,66
Proofreading domain mutations in cancer
In 2012, exome sequencing of 224 sporadic CRCs by The Cancer Genome Atlas (TCGA), 
and a similar analysis of 72 CRC exomes, revealed a subset of ultramutated, yet micro-
satellite-stable tumors with recurrent somatic mutations within the POLE exonuclease 
domain.13,16 The most common of these involved the replacement of proline by either 
arginine or histidine at codon 286 (POLE P286R/H), and recurring substitutions were also 
found at codons 411 (POLE V411L) and 459 (POLE S459F; Table 1).13,16 Subsequently, two 
studies detected heterozygous somatic POLE proofreading domain mutations, includ-
ing the P286R and V411L substitutions, in ~7% of sporadic ECs, where they were also 
associated with ultramutation and microsatellite stability (Table 1).15,17 These mutations 
localized to highly conserved or invariant residues within, or close to, the exo motifs that 
are essential for proofreading activity, and they were predicted to perturb DNA binding 
by structural mapping (Figure 1B,D).15 In parallel with these reports, an independent 
study used linkage analysis and whole genome sequencing to show that families with 
multiple colorectal tumors but without known predisposition mutations carried hetero-
zygous germline mutations that caused substitutions in the proofreading domains of 
POLD1 (POLD1 S478N) and POLE (POLE L424V; Table 2).12 Interestingly, the POLD1 muta-
tion was also associated with EC. Similar to the somatic POLE variants, these mutations 
affected highly conserved residues in or adjacent to the exo motifs at the DNA-binding 
interface (Figure 1A,C).12 Furthermore, the germline variant alleles have been shown to 
reduce proofreading activity and cause a mutator phenotype in yeast.12,64
Current data suggest that germline POLE and POLD1 mutations are present in 0.5-2% of 
patients in intestinal polyposis and CRC cohorts enriched for familial disease.12,67-69 The 
POLE L424V mutation seems to be the most common deleterious germline variant, with 
21 independent carriers identified to date.68,70,71 Although predominantly associated 
with CRC, this variant also predisposes to EC, and it may confer moderately increased 
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Within exo I motif 2.38 Yes64 NR 7,349 
(44-14,654)





Flanking exo I motif 2.57 Yes82 Yes18 5,147
(738-16,248)






Flanking exo I motif 2.67 NR NR 5,429
(4,918–15,545)





Exo II active site 2.19 NR Yes18,120 2,934 100 100 CRC11,13 
V411L
(1231G→C/T)
Flanking exo IV 
motif
2.66 NR Yes18 6,294
(955–14,074)






Exo IV active site 2.66 Yes64 Yes18,120 163
(85–6,724)
50 100 EC17 and BrC119 
P436R
(1307C→G)
Exo V motif 3.53 NR Yes120 6,131 100 100 CRC13 and EC21 
M444K
(1331T→A)
Flanking exo V motif 2.15 NR NR 1,204 100 100 EC17 
A456P 
(1366G→C)




Within exo III motif 2.52 NR Yes18,120 4,780
(1,868–9,907)
100 75 CRC,13,18,121 
GBM,14 and AA77 
*Data from exome sequencing studies.
‡PhyloP (phylogenetic conservation) scores were calculated per nucleotide using the alignment of 46 ver-
tebrates dbNSFPv23. For P436R the variant mapped to the third position of a codon so the average PhyloP 
score for the codon is displayed.
§Data from studies of B family polymerases.
IINumber of exomes sequenced: POLD1 C319Y, 2; POLE P286R/H/L, 16; POLE S297F/Y, 5; POLE F367S, 1; POLE 
V411L, 10; POLE L424V/I, 3; POLE P436R, 1; POLE M444K, 1; POLE A456P, 1; POLE S459F, 4.
Abbreviations: AA, anaplastic astrocytoma; BrC, breast cancer; CC, squamous cell cervical carcinoma; CRC, 
colorectal cancer; EC, endometrial cancer; EOC, endometrioid ovarian carcinoma; GBM, glioblastoma; GC, 
gastric cancer; MM, multiple myeloma; MSS, microsatellite stable; NA, not applicable; NR, not reported.
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risk of many other tumor types (including carcinomas of the breast, stomach and ovary, 
brain tumors, and duodenal adenomas and carcinomas; Table 2). The demonstration of 
de novo POLE L424V mutations70,71 and the absence of a detectable haplotype shared 
among apparently unrelated families12 suggests that this is a mutational hot spot. Other 
recently reported germline POLE mutations include N363K, which maps to the exo II 
motif active site and is associated with CRC and pancreatic cancer;72 Y458F, which affects 
the exo III motif active site and predisposes to multiple tumor types;73 and W347C, which 
lies outside the exo motifs and has been associated with melanoma (Figure 1B,D; Table 
2).74 POLE N363K and POLE Y458F are highly penetrant, being associated with malig-
nancy in 11 of 12 and 9 of 13 carriers, respectively (Table 2).72,73 The importance of the 
W347C variant is uncertain, as it seems to display lower penetrance, with six unaffected 
carriers in the family, and it does not seem to confer a strong risk of CRC (<10% cases), 
despite evidence of pathogenicity in S. pombe.74
Although no additional POLD1 S478N carriers have been reported since 2012, five other 
pathogenic germline POLD1 proofreading domain mutations have been identified (Fig-
ure 1A,C; Table 2). One of these, a recurrent mutation at codon 474 (POLD1 L474P),67,70 
affects the equivalent residue to POLE L424V, and another, POLD1 D316G, affects the exo 
I motif active site.67 The cancer risk in carriers of germline POLD1 proofreading domain 
mutations seems to be limited to CRC and EC, with no evidence of a predisposition to 
duodenal or ovarian malignancies.67,70 However, caution is required, as the modest num-
ber of germline POLD1 variant carriers makes phenotypic characterization less certain 
than it is for POLE variant carriers. Interestingly, similar to the POLE active site variants, 
the germline POLD1 D316G mutation appears to be highly penetrant (malignancy in 4 
of 4 carriers).67 
Somatic POLE proofreading domain mutations occur in ~1-2% of CRCs13,16 and 7-12% 
of ECs,15,17,20-23 and they have also been detected in ultramutated tumors of the brain, 
pancreas, ovary, breast and stomach,14,18,75 as well as in uterine carcinosarcomas.76 The 
most common POLE variants are the P286R and V411L substitutions (Figure 1B,D; Table 
1); other recurrent substitutions include S297F, A456P and S459F. Most of these occur 
within, or close to, the exo motifs; however, unlike the germline mutations, the catalytic 
sites themselves are seldom affected.13,15 In contrast to POLE, to date only two cases of 
possibly pathogenic somatic POLD1 proofreading domain mutations have been identi-
fied. The first is a C319Y variant detected in an ultramutated pediatric glioblastoma from 
a patient with biallelic congenital MMR-D (CMMR-D) due to a compound heterozygous 
mutation in mutS homolog 6 (MSH6: c.3984_3987dupGTCA;c.3959_3962delCAAG).77 
The POLD1 C319Y mutation has also been detected in a myeloma with a normal muta-
tion burden,78 and its functional effect is uncertain at present. The second is a D316N 
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substitution in a highly mutated sporadic gastric cancer.79 This tumor displays a high 
proportion of insertions and deletions (indels), and as the POLD1 variant allele fraction 
is only 0.13, it is unclear to what extent this substitution has contributed to the mutation 
burden in this tumor.
The difference in the frequency of somatic proofreading domain mutations between 
POLD1 and POLE is both notable and unexplained. It seems unlikely to be due to bias in 
the tumor types analyzed to date: the exomes of more than 400 lung adenocarcinomas 
– a common tumor type in Pold1-proofreading-null mice – have been sequenced at the 
time of writing.80,81 Given the current uncertainty regarding the roles of Pol δ and Pol ε 
at the replication fork,51 it will be intriguing to see whether future studies reveal to what 
extent, if any, this discrepancy reflects differential contributions of the two polymerases 
to DNA replication and repair, or other processes.
Functional insights into pathogenicity 
The deleterious consequences of cancer-associated polymerase proofreading domain 
mutations on exonuclease activity and mutation rate have been confirmed by functional 
studies. In cell-free assays, the somatically occurring POLE P286R/H and POLE S459F mu-
tations reduce exonuclease activity to levels similar to those of a proofreading-null POLE 
construct with substitution of both exo I active site residues, whereas the somatic POLE 
V411L and POLE F367S variants and the POLE L424V variant (which can be either somatic 
or germline) substantially reduce, but do not eliminate, exonuclease function.18 Interest-
ingly, the substitution equivalent to human POLE P286R was recently shown to confer 
an exceptionally strong mutator phenotype in S. cerevisiae.82 This far exceeded that 
of the proofreading-null allele, suggesting that POLE P286R may exert effects beyond 
proofreading alone.82 Importantly, in this study the mutation rate was also substantially 
increased in diploid strains heterozygous for the POLE P286R analogue.82 These results 
provide a possible explanation for why mice with proofreading-null Pole alleles only de-
velop tumors in the homozygous state,6 yet somatic POLE proofreading domain muta-
tions in human cancers seem to be mostly, if not all, heterozygous changes.15,18 This may 
also explain the paucity of exonuclease active site mutations in sporadic cancers. Given 
these exciting data, the results of similar analyses of other cancer-associated mutations 
are eagerly awaited.
Clinicopathological characteristics 
Intestinal polyposis seems to be more severe in carriers of germline POLE proofread-
ing domain mutations than in those with POLD1 proofreading domain variants (10-50 
compared with <20 colonic polyps per patient, respectively); however, in both cases 
the polyps themselves are typically of unremarkable histology.12 Similarly, with the ex-
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ception of young age at onset (typically <50 years), CRCs and other malignancies in 
these patients do not seem to display any distinguishing clinicopathological features, 
although the number of cases studied to date is limited.12 Tumors with somatic POLE 
proofreading domain mutations also show a strong tendency to occur in young patients 
and, when examined, typically exhibit several other notable characteristics, including an 
association with high tumor grade, a prominent lymphocytic infiltrate and the presence 
of multiple bizarre multinucleated giant cells.14,25,83 
An association of somatic POLE proofreading domain mutations with good prognosis 
was first suggested by the EC study from TCGA.17 This has since been confirmed in EC 
by several groups20-24 and was also proposed for glioblastomas by a recent report.14 As 
many patients in these series received adjuvant radiotherapy, either alone or in com-
bination with chemotherapy, it is currently not possible to draw definitive conclusions 
on whether POLE proofreading domain mutation status is a prognostic or predictive 
biomarker, or indeed both. However, the lack of recurrences of high-grade POLE proof-
reading domain-mutant ECs in two large clinical trials in which chemotherapy was not 
used, and in a subset of patients who did not receive radiotherapy in one of these studies 
,20 suggests that POLE proofreading domain mutations may portend a good prognosis 
in the absence of postoperative treatment. While this is reminiscent of the favorable 
clinical outcome of hypermutated early-stage, MMR-D CRCs,84,85 it should be noted that 
the impact of MMR-D on EC prognosis is unclear,22,86,87 and the prognostic import of 
POLE proofreading domain mutations in CRC awaits confirmation.
molecular characteristics 
Although the number of tumors from germline POLD1 and POLE proofreading domain 
mutations analyzed to date is relatively modest, most have been found to be microsat-
ellite stable;12 however, microsatellite instability (MSI) has been noted in some cases.71 
Analysis of the mutation spectrum has been limited to the tumors from POLE L424V 
and POLD1 S478N carriers, which revealed a phenotype of base substitutions and mis-
sense substitutions with relatively few frameshift mutations.12 As noted above, the most 
striking feature of tumors with somatic POLE proofreading domain mutations is their 
ultramutation.13,16,18,19 Similar to the tumors from germline POLE variant carriers, these 
are predominantly base substitution mutations,13,15,16,18,19 and they occur within a unique 
mutation signature with a 100-fold increase in C→A transversions in the context TCT and 
a 30-fold increase in C→T transitions in the context of TCG.15,18,19 This results in a strong 
bias for particular amino acid changes, with an overrepresentation of serine to tyrosine or 
leucine, and arginine to isoleucine or glutamine substitutions, and a substantial increase 
in glutamic acid to stop codon mutations.18 These manifest as a distinctive pattern of 
missense and truncation mutations in oncoproteins and tumor suppressors, including: 
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PI3K catalytic subunit-α (PIK3CA) R88Q; PTEN R130Q; adenomatous polyposis coli (APC) 
R1114X and APC Q1338X; MSH6 E946X and MSH6 E1322X; F-box and WD repeat domain-
containing 7 (FBXW7) E369X; and TP53 R213X.12,13,15,16,18,88
Sporadic POLE proofreading domain-mutant cancers display few copy number al-
terations (CNAs) and, similar to tumors in germline variant carriers, a strong tendency 
to microsatellite stability, despite frequent mutations in MMR genes.13,15-17 Accumulating 
evidence suggests that the interaction between defective DNA polymerase proofread-
ing and MMR is complex and may depend on the extent to which the function of 
each activity is compromised. For example, whereas the combination of mutator DNA 
polymerases and partial MMR function causes attenuated growth in S. cerevisiae,89 the 
combination with complete MMR loss is synthetically lethal in S. cerevisiae and mice.6,89,90 
Interestingly, a recent study of patients with CMMR-D who developed glioblastomas 
showed that these tumors occurred following the acquisition of DNA polymerase 
proofreading domain mutations and were ultramutated, yet predominantly microsatel-
lite stable.77 Most of the germline MMR mutations in these cases involved either PMS1 
homolog 2 (PMS2) or MSH6, whereas sporadic DNA polymerase proofreading domain-
mutant tumors tend to acquire MSH6 mutations.13,17,77 Loss of MSH6 or PMS2 function 
generally causes a milder mutator phenotype, sometimes lacking MSI, than loss of other 
MMR components such as mutS homolog 2 (MSH2) and mutL homolog 1 (MLH1).89,91 
Although it is tempting to speculate that the combination of defective proofreading 
and profound MMR deficiency may result in a mutation rate that exceeds the optimum 
for tumor fitness,92,93 empirical verification of this is currently lacking, and it must be 
noted that although they are rare, tumors with DNA polymerase proofreading domain 
mutations and MSI have been reported.21,71,77 It will be of particular interest to determine 
the timing and clonality of both events in these cancers, and to examine whether these 
tumors harbor secondary antimutator mutations that permit continued viability, as has 
been demonstrated in yeast.89,94
Challenges in determining pathogenicity 
Although the number of confirmed germline POLD1 and POLE proofreading domain 
mutations has grown since their initial report in 2012 (Table 2; also curated in the Leiden 
Open Variation Database (LOVD)), differentiation of pathogenic from non-pathogenic 
variants in a patient with clinical features that suggest the possibility of DNA polymerase 
proofreading domain mutations and family history remains challenging. The Exome Ag-
gregation Consortium (ExAC) database currently lists 56 missense or loss-of-function 
variants mapping to the exonuclease domains of POLD1 and 75 such variants mapping 
to the POLE exonuclease domain, all of which have a population frequency of <1%. Most 
of these are likely to have no impact on the proofreading function of these enzymes. In-
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deed, of the germline variants reviewed here, only POLD1 D316H is present in the ExAC 
database, at a frequency of 0.001% (being present in only 1 of 98,012 alleles genotyped). 
Therefore, filtering variants according to their presence in ExAC and similar databases 
will be of limited utility, as it will only exclude variants with relatively high frequencies, 
such as those with a frequency of >0.1%. Instead, we suggest that the following criteria 
should ideally be satisfied to prove pathogenicity of a variant: first, segregation with 
affection status in pedigrees; second, conservation of the affected residue between hu-
man DNA polymerases and those from other species; third, evidence of functional effect 
from at least one of the following: analysis of corresponding residue in model organisms, 
cell-free exonuclease assays or other polymerase assays;18,95 and fourth, demonstration 
of elevated base substitution frequency by sequencing of tumor DNA.
Confirming the pathogenicity of somatic DNA polymerase proofreading domain muta-
tions may also be difficult. Both POLD1 and POLE are large genes, and they are likely to 
acquire somatic mutations secondary to other causes of increased mutation burden, 
such as MMR-D. Given the association of somatic POLE proofreading domain mutations 
with prognosis,14,17,20-24 it is important to differentiate these pathogenic variants from 
passenger mutations that are of no functional consequence, particularly given examples 
in the recent literature where a functional role has been inferred for POLD1 and POLE 
variants of uncertain pathogenicity.96 
On the basis of their analysis of TCGA data, Shinbrot and colleagues18 have proposed 
criteria to identify bona fide pathogenic somatic POLE proofreading domain mutations. 
These include: ultramutation (often exceeding 100 mutations per megabase); an in-
creased proportion of C→A transversions, exceeding 20% of all substitutions (although 
it should be noted that the most common substitutions are typically C→T transitions); 
and POLE mutation at a residue that is recurrently mutated in cancer (Figure 1A; Table 
1). While most POLE proofreading domain-mutant cancers display these characteristics, 
we advocate a degree of flexibility in their application, as the predominant mutations 
caused by proofreading-deficient human Pol ε in vitro are T→A transversions,97 and it 
is possible that novel pathogenic POLE proofreading domain mutations could cause a 
different mutational signature. We also suggest that consideration should be given to 
other features that may indicate a pathogenic variant including: a preponderance of 
missense mutations (that is, a relative absence of indels); the presence of characteristic 
flanking nucleotide bias;15,18,19 and a relative lack of CNA.15,17 Although the coexistence 
of MSI does not preclude the presence of a deleterious DNA polymerase proofreading 
variant, it should prompt careful evaluation of its pathogenicity, ideally using bioinfor-
matic predictors (for example, MutationTaster,98 SIFT99 and Polyphen100) and structural 
mapping using the conserved yeast Pol ε structure.50 Although some tumors carrying 
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bona fide pathogenic POLE proofreading domain mutations will fall outside this clas-
sification,21 we believe that it represents a reasonable starting point that can be refined 
and improved as further data are accumulated in the future.
A role in early tumorigenesis?
The association of germline variants with malignancy12 suggests that DNA polymerase 
proofreading domain mutations are able to initiate cancer, and current data, although 
limited, are consistent with somatic POLE proofreading domain mutations occurring as 
an early event in sporadic tumors. Analysis of the variant allele fraction in glioblastomas 
suggests that POLE proofreading domain mutations are present in the earliest persisting 
clone,14,77 and genes in which driver mutations are known to occur early in CRC and EC 
frequently display evidence of the POLE proofreading domain mutation signature.13-18 In-
terestingly, analysis of tumors from patients with CMMR-D suggests that the acquisition 
of somatic pathogenic DNA polymerase proofreading domain mutations is associated 
with rapid tumor growth,77 consistent with the prediction of mathematical models that 
a strong mutator phenotype confers a preferential advantage in early tumorigenesis.1,101 
Further insights into the timing and consequences of polymerase proofreading domain 
mutations may be provided by analysis of pre-cancers and multiregion sequencing of 
tumors carrying these variants.
explaining associations with prognosis
As noted previously, in addition to ultramutation and good prognosis, POLE proofread-
ing domain-mutant tumors frequently display a prominent lymphocytic infiltrate,14,25,83 
similar to that observed in MMR-D CRCs.102 Recent characterization of this in EC has 
shown that this infiltrate comprises a population of CD8+ cytotoxic lymphocytes and 
is accompanied by increased expression of cytotoxic lymphocyte differentiation 
markers (such as T-box 21 (TBX21) and eomesodermin (EOMES)), and effectors (such 
as interferon-γ (IFNG), perforin 1 (PRF1) and granzyme B (GZMB)) compared with other 
ECs .25 Bioinformatics analysis revealed that the number of ‘antigenic mutations’ – that 
is, mutations in expressed genes that encode neopeptides predicted to bind major 
histocompatibility complex (MHC) molecules – is substantially greater in POLE proof-
reading domain-mutant tumors than in other ECs, providing a potential explanation 
for these results.25,26 Interestingly, POLE proofreading domain-mutant tumors displayed 
increased expression of genes encoding multiple immunosuppressive checkpoints — 
including programmed cell death protein 1 (PDCD1), PD-1 ligand 1 (PDL1), cytotoxic T 
lymphocyte-associated antigen 4 (CTLA4), lymphocyte activation gene 3 protein (LAG3), 
T cell immunoglobulin mucin receptor 3 (TIM3; also known as HAVCR3) and T cell im-
munoreceptor with immunoglobulin and ITIM domains (TIGIT)25 — suggesting that up-
regulation of these molecules may be required for tumor growth. It will be important to 
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investigate whether these findings are observed in POLE proofreading domain-mutant 
tumors of other tissues and to investigate whether tumors from carriers of germline 
DNA polymerase proofreading variants display evidence of enhanced immunogenicity 
that may affect their prognosis.
Another possible contributor to the favorable outcome of DNA polymerase proofread-
ing domain-mutant tumors relates directly to their mutator phenotype. Studies of 
mutator Pol ε and Pol δ variants in yeast have demonstrated the existence of an ‘error 
threshold’ that, if exceeded, results in reduced viability.89,90,94 The combination of defec-
tive DNA polymerase proofreading and complete loss of MMR is lethal as it exceeds this 
threshold.89,94 Interestingly, sequential biopsy of cancers in patients with CMMR-D dem-
onstrated that although the acquisition of somatic DNA polymerase proofreading do-
main mutations was associated with the dramatic accumulation of mutations and rapid 
tumor growth, the total mutation burden subsequently seemed to plateau.77 The upper 
limit of 10,000–20,000 exonic mutations suggested by this study is highly concordant 
with the number of mutations observed in sporadic POLE proofreading domain-mutant 
adult cancers.19 Tumor mutation burden is not simply a reflection of mutation rate (it 
also reflects the number of cell divisions during tumor development), and the relation-
ship between the two in DNA polymerase-mutant tumors in uncertain. Nevertheless, it 
may be speculated that while the proofreading-deficient mutator phenotype confers a 
growth advantage in early tumorigenesis, it compromises fitness in later-stage cancers. 
This may be explained by an intriguing recent study that used mathematical model-
ling to predict the effect of passenger mutations on the fitness of (non-hypermutated) 
tumors.103 This showed that whereas strongly deleterious passenger mutations are 
subject to negative selection, those with individually moderate negative effects are able 
to fixate (become fixed into the genome), and collectively are predicted to exert a nega-
tive impact on tumor growth.103 As this model was based on tumors with only relatively 
small numbers of protein-coding mutations (an average of 10-366 per tumor type), it 
will be interesting to examine the effect of passenger mutations on the fitness of DNA 
polymerase proofreading domain-mutant tumors.
Clinical management 
Diagnosis
The polymerase proofreading-associated polyposis (PPAP) phenotype overlaps with that 
of Lynch syndrome and MUTYH-associated polyposis, and screening and management 
algorithms are broadly similar. Valle and colleagues70 have proposed that screening of 
the POLD1 and POLE exonuclease domains is indicated in patients with polyposis (10-
100 adenomas) and/or those with early-onset CRC (diagnosis before the age of 50), who 
lack germline mutations in MMR genes, APC or MUTYH. The concomitant presence of 
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extracolonic tumors (Table 2), particularly EC and stomach or duodenal tumors, should 
increase clinical suspicion of germline POLD1 or POLE proofreading domain mutations. 
However, at present there is insufficient evidence to recommend screening of patients 
who lack colonic phenotypes. Similar to patients with Lynch syndrome,104 carriers of 
germline POLD1 and POLE proofreading domain mutations should be offered colo-
noscopies at one- to two-year intervals from the age of 25 and upper gastrointestinal 
endoscopy to check for duodenal tumors (particularly in carriers of POLE proofreading 
domain variants). Although EC screening is not of proven benefit for this cohort, women 
with germline POLD1 and POLE proofreading domain mutations might pragmatically be 
offered this from the age of 40, and clinicians should be aware of the potential increased 
risk of ovarian, brain and breast cancers in these patients, with consideration given to 
preventive measures if available.
The distinctive characteristics of tumors with somatic POLE proofreading domain 
mutations also have potential implications for patient management. Most notably, the 
association with good prognosis in EC17,20-24 suggests that POLE proofreading domain 
mutations might identify a group of patients who are less likely to benefit from adjuvant 
treatment following surgery. This is clinically relevant, as POLE mutations are more com-
mon in tumors defined as ‘high risk’ by conventional criteria,20,22 for which postoperative 
radiotherapy and chemotherapy are often recommended. However, as noted earlier, the 
possibility that the favorable outcome of these tumors reflects increased sensitivity to 
treatment cannot be excluded at present, and further preclinical and clinical studies will 
be required before POLE proofreading domain mutations can be used to guide manage-
ment in EC. Similar studies will also be needed to confirm the utility of POLE mutation 
status as a biomarker in other cancer types.
Therapeutic targeting 
The remarkable mutation burden of POLE proofreading domain-mutant tumors also 
raises the possibility that they may be particularly sensitive to specific therapeutic 
strategies. Perhaps the most obvious of these is the use of immune checkpoint inhibi-
tors that target immunosuppressive molecules such as PD-1 and PD-L1. These agents 
have recently demonstrated striking activity against highly mutated MMR-D CRCs, 
melanomas and non-small cell lung cancers (NSCLCs),105-108 in which response seems to 
correlate with increased tumor antigenic mutation burden96,109 and the density of pre-
treatment intratumoral infiltration by CD8+, PD-1+ and PD-L1+ lymphocytes.110 These are 
all prominent features of POLE proofreading domain-mutant tumors,25,26 suggesting that 
these cancers may be excellent candidates for drugs targeting PD-1-PD-L1 signaling. 
Furthermore, the recent demonstration that immune checkpoint inhibition may be po-
tentiated by radiotherapy111 suggests that investigation of these combinations against 
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DNA polymerase proofreading domain-mutant cancers in preclinical models and clinical 
trials may be worthwhile.
Another potential therapeutic strategy against DNA polymerase proofreading domain-
mutant cancers relates to the concept of the error threshold discussed earlier. In theory, 
agents such as mutagenic nucleosides or inhibitors of DNA repair112 could be used to in-
crease the mutation rate in these tumors to a level that exceeds this threshold, resulting 
in lethal mutagenesis and loss of viability.93 Clearly, in the first instance such a strategy 
would be appropriate only in patients with incurable disease who lack other treatment 
options, although in selected cases this may be worthy of exploration.93 Preclinical 
studies suggest that a similar effect may result from modification of the dNTP pool;67,113 
however, differences in nucleotide synthesis and the DNA damage response between 
yeast and humans mean that further work is required before the possible utility of this 
approach in humans can be predicted.
Given the modest frequency of DNA polymerase proofreading domain mutations over-
all, any therapeutic study is likely to have to recruit patients with multiple tumor types 
(a design frequently referred to as a basket trial114) or to combine proofreading-deficient 
tumors with other hypermutated cancers, such as those with defective MMR.
Conclusions and future directions
Evidence has only recently emerged to support the longstanding postulate that defec-
tive DNA polymerase proofreading may contribute to human cancer.115 Nevertheless, 
it is now clear that germline mutations in the exonuclease domains of POLD1 and 
POLE predispose to polyposis, CRC and other malignancies,12,67-73 and that somatic 
POLE proofreading domain mutations cause ultramutation in sporadic ECs, CRCs and 
several other cancers.13-19 The exceptional mutation load in somatic POLE proofreading 
domain-mutant ECs is associated with an enhanced immune response25,26 and an excel-
lent prognosis.17,20-24 The possibility that mutation rate in these tumors approaches the 
maximum compatible with continued viability is an intriguing one, the investigation 
of which may provide novel insights into the consequences of a mutator phenotype in 
cancer. It will also be of interest to determine whether the ultramutator phenotype in 
DNA polymerase proofreading domain-mutant tumors represents an Achilles’ heel that 
can be exploited for therapy, as has recently been suggested.77 
From a clinical perspective, PPAP should be considered and tested for in patients with 
unexplained polyposis and/or early-onset CRC, particularly if family members have EC or 
other extracolonic cancers suggestive of germline POLD1 or POLE proofreading domain 
mutations.70 Meanwhile, somatic DNA polymerase proofreading domain mutations 
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exemplify the challenge of implementing precision medicine. For example, the modest 
frequency of POLE proofreading domain mutations in EC (7-12%) has limited the power 
of some studies to evaluate their impact on prognosis,21 a problem that is likely to prove 
even greater in other tumors in which these mutations are less common. As most novel 
cancer variants occur at a similarly low frequency (<10%), evaluation of these as prog-
nostic and predictive biomarkers will require large-scale collaborations and coordinated 
analysis. At a more basic level, the results of studies performed to date pose several fun-
damental questions. For example, why are somatic mutations largely restricted to POLE, 
whereas germline variants of both POLE and POLD1 cause cancer? Why are substitutions 
of the exo motif catalytic sites proportionally more common among germline than 
among somatic proofreading domain mutations? Why does the mutator phenotype 
associated with POLE P286R exceed that associated with the exonuclease-null allele? 
Determining the answers to these questions will be a priority for future studies.
During the past three years, defects in DNA polymerase proofreading have been rec-
ognized to drive tumorigenesis in a small but important fraction of common cancers. 
Given the rapid progress in the field, we are optimistic that the next three years will see 
similar advances in our understanding of this novel tumor subgroup, with consequent 
benefits for patients.
ACknowledgementS
We would like to thank Jonathan Grimes for help in generating the Pol δ and Pol ε 
structures and Niels de Wind for helpful comments on the manuscript. Work in the host 
laboratories is supported by an Academy of Medical Sciences/Health Foundation Clini-
cian Scientist Fellowship Award (to D.N. Church), Cancer Research UK (programme grant 
C6199/A10417; to I.P.M. Tomlinson), the European Research Council (EVOCAN grant 
agreement: 340560 to I.P.M. Tomlinson), the Dutch Cancer Society (grant ref: UL2012-
5719 to T. Bosse) and the Medical Research Council (grant ref: MR/L016591/1 to S.E. 
Kearsey) and core funding to the Wellcome Trust Centre for Human Genetics from the 




 1. Loeb LA. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 
1991;51(12):3075-3079.
 2. Kunkel TA. DNA replication fidelity. J Biol Chem 2004;279(17):16895-16898.
 3. Loeb LA, Monnat RJ, Jr. DNA polymerases and human disease. Nat Rev Genet 2008;9(8):594-604.
 4. Morrison A, Johnson AL, Johnston LH, Sugino A. Pathway correcting DNA replication errors in 
Saccharomyces cerevisiae. EMBO J 1993;12(4):1467-1473.
 5. Edelmann W, Yang K, Umar A, Heyer J, Lau K, Fan K, et al. Mutation in the mismatch repair gene 
Msh6 causes cancer susceptibility. Cell 1997;91(4):467-477.
 6. Albertson TM, Ogawa M, Bugni JM, Hays LE, Chen Y, Wang Y, et al. DNA polymerase epsilon and 
delta proofreading suppress discrete mutator and cancer phenotypes in mice. Proc Natl Acad Sci 
USA 2009;106(40):17101-17104.
 7. Goldsby RE, Hays LE, Chen X, Olmsted EA, Slayton WB, Spangrude GJ, et al. High incidence of 
epithelial cancers in mice deficient for DNA polymerase delta proofreading. Proc Natl Acad Sci 
USA 2002;99(24):15560-15565.
 8. Goldsby RE, Lawrence NA, Hays LE, Olmsted EA, Chen X, Singh M, et al. Defective DNA polymerase-
delta proofreading causes cancer susceptibility in mice. Nat Med 2001;7(6):638-639.
 9. Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, et al. The human mutator 
gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 
1993;75(5):1027-1038.
 10. Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP, et al. Clues to the patho-
genesis of familial colorectal cancer. Science 1993;260(5109):812-816.
 11. Yoshida R, Miyashita K, Inoue M, Shimamoto A, Yan Z, Egashira A, et al. Concurrent genetic altera-
tions in DNA polymerase proofreading and mismatch repair in human colorectal cancer. Eur J 
Hum Genet 2011;19(3):320-325.
 12. Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, et al. Germline mutations 
affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and 
carcinomas. Nat Genet 2013;45(2):136-144.
 13. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of hu-
man colon and rectal cancer. Nature 2012;487(7407):330-337.
 14. Erson-Omay EZ, Caglayan AO, Schultz N, Weinhold N, Omay SB, Ozduman K, et al. Somatic POLE 
mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis. 
Neuro Oncol 2015;17(10):1356-1364.
 15. Church DN, Briggs SE, Palles C, Domingo E, Kearsey SJ, Grimes JM, et al. DNA polymerase 
epsilon and delta exonuclease domain mutations in endometrial cancer. Hum Mol Genet 
2013;22(14):2820-2828.
 16. Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, et al. Recurrent R-spondin 
fusions in colon cancer. Nature 2012;488(7413):660-664.
 17. The Cancer Genome Atlas Research Network. Integrated genomic characterization of endome-
trial carcinoma. Nature 2013;497(7447):67-73.
 18. Shinbrot E, Henninger EE, Weinhold N, Covington KR, Goksenin AY, Schultz N, et al. Exonuclease 
mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and 
human origins of replication. Genome Res 2014;24(11):1740-1750.
 19. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of 
mutational processes in human cancer. Nature 2013;500(7463):415-421.
Polymerase proofreading domain mutations in cancer 49
2
 20. Church DN, Stelloo E, Nout RA, Valtcheva N, Depreeuw J, ter Haar N, et al. Prognostic significance 
of POLE proofreading mutations in endometrial cancer. J Natl Cancer Inst 2015;107(1):402.
 21. Billingsley CC, Cohn DE, Mutch DG, Stephens JA, Suarez AA, Goodfellow PJ. Polymerase varepsilon 
(POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome 
testing. Cancer 2015;121(3):386-394.
 22. Stelloo E, Bosse T, Nout RA, MacKay HJ, Church DN, Nijman HW, et al. Refining prognosis and 
identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod 
Pathol 2015;28(6):836-844.
 23. Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, et al. A clinically applicable 
molecular-based classification for endometrial cancers. Br J Cancer 2015;113(2):299-310.
 24. Meng B, Hoang LN, McIntyre JB, Duggan MA, Nelson GS, Lee CH, et al. POLE exonuclease domain 
mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the 
endometrium. Gynecol Oncol 2014;134(1):15-19.
 25. van Gool IC, Eggink FA, Freeman-Mills L, Stelloo E, Marchi E, de Bruyn M, et al. POLE Proofread-
ing Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. Clin Cancer Res 
2015;21(14):3347-3355.
 26. Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, et al. Association of polymerase 
e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of 
tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol 2015;1(9):1319-
1323.
 27. Henninger EE, Pursell ZF. DNA polymerase epsilon and its roles in genome stability. IUBMB Life 
2014;66(5):339-351.
 28. Prindle MJ, Loeb LA. DNA polymerase delta in DNA replication and genome maintenance. Environ 
Mol Mutagen 2012;53(9):666-682.
 29. Pavlov YI, Shcherbakova PV. DNA polymerases at the eukaryotic fork - 20 years later. Mutat Res 
2010;685(1-2):45-53.
 30. Johansson E, Dixon N. Replicative DNA polymerases. Cold Spring Harb Perspect Biol 
2013;5(6):a012799.
 31. Morrison A, Araki H, Clark AB, Hamatake RK, Sugino A. A third essential DNA polymerase in S. 
cerevisiae. Cell 1990;62(6):1143-1151.
 32. Budd M, Campbell JL. Temperature-sensitive mutations in the yeast DNA polymerase I gene. Proc 
Natl Acad Sci USA 1987;84(9):2838-2842.
 33. Budd ME, Campbell JL. DNA polymerases delta and epsilon are required for chromosomal replica-
tion in Saccharomyces cerevisiae. Mol Cell Biol 1993;13(1):496-505.
 34. Francesconi S, Park H, Wang TS. Fission yeast with DNA polymerase delta temperature-sensitive 
alleles exhibits cell division cycle phenotype. Nucleic Acids Res 1993;21(16):3821-3828.
 35. Bernad A, Blanco L, Lazaro JM, Martin G, Salas M. A conserved 3’-5’ exonuclease active site in 
prokaryotic and eukaryotic DNA polymerases. Cell 1989;59(1):219-228.
 36. Shevelev IV, Hubscher U. The 3’-5’ exonucleases. Nat Rev Mol Cell Biol 2002;3(5):364-376.
 37. Baranovskiy AG, Babayeva ND, Liston VG, Rogozin IB, Koonin EV, Pavlov YI, et al. X-ray structure of 
the complex of regulatory subunits of human DNA polymerase delta. Cell Cycle 2008;7(19):3026-
3036.
 38. Podust VN, Chang LS, Ott R, Dianov GL, Fanning E. Reconstitution of human DNA polymerase 
delta using recombinant baculoviruses: the p12 subunit potentiates DNA polymerizing activity 
of the four-subunit enzyme. J Biol Chem 2002;277(6):3894-3901.
 39. Zhou Y, Meng X, Zhang S, Lee EY, Lee MY. Characterization of human DNA polymerase delta and its 
50 Chapter 2
subassemblies reconstituted by expression in the MultiBac system. PLoS One 2012;7(6):e39156.
 40. Garbacz M, Araki H, Flis K, Bebenek A, Zawada AE, Jonczyk P, et al. Fidelity consequences of the 
impaired interaction between DNA polymerase epsilon and the GINS complex. DNA Repair 
(Amst) 2015;29:23-35.
 41. Langston LD, Zhang D, Yurieva O, Georgescu RE, Finkelstein J, Yao NY, et al. CMG helicase and DNA 
polymerase epsilon form a functional 15-subunit holoenzyme for eukaryotic leading-strand DNA 
replication. Proc Natl Acad Sci USA 2014;111(43):15390-15395.
 42. Sengupta S, van Deursen F, de Piccoli G, Labib K. Dpb2 integrates the leading-strand DNA poly-
merase into the eukaryotic replisome. Curr Biol 2013;23(7):543-552.
 43. Aksenova A, Volkov K, Maceluch J, Pursell ZF, Rogozin IB, Kunkel TA, et al. Mismatch repair-
independent increase in spontaneous mutagenesis in yeast lacking non-essential subunits of 
DNA polymerase epsilon. PLoS Genet 2010;6(11):e1001209.
 44. Pursell ZF, Isoz I, Lundstrom EB, Johansson E, Kunkel TA. Yeast DNA polymerase epsilon partici-
pates in leading-strand DNA replication. Science 2007;317(5834):127-130.
 45. Nick McElhinny SA, Gordenin DA, Stith CM, Burgers PM, Kunkel TA. Division of labor at the eukary-
otic replication fork. Mol Cell 2008;30(2):137-144.
 46. Miyabe I, Kunkel TA, Carr AM. The major roles of DNA polymerases epsilon and delta at the eu-
karyotic replication fork are evolutionarily conserved. PLoS Genet 2011;7(12):e1002407.
 47. Vazquez E, Antequera F. Replication dynamics in fission and budding yeasts through DNA poly-
merase tracking. Bioessays 2015;37(10):1067-1073.
 48. Georgescu RE, Schauer GD, Yao NY, Langston LD, Yurieva O, Zhang D, et al. Reconstitution of a 
eukaryotic replisome reveals suppression mechanisms that define leading/lagging strand opera-
tion. Elife 2015;4:e04988.
 49. Georgescu RE, Langston L, Yao NY, Yurieva O, Zhang D, Finkelstein J, et al. Mechanism of asymmet-
ric polymerase assembly at the eukaryotic replication fork. Nat Struct Mol Biol 2014;21(8):664-
670.
 50. Hogg M, Osterman P, Bylund GO, Ganai RA, Lundstrom EB, Sauer-Eriksson AE, et al. Struc-
tural basis for processive DNA synthesis by yeast DNA polymerase varepsilon. Nat Struct Mol Biol 
2014;21(1):49-55.
 51. Johnson RE, Klassen R, Prakash L, Prakash S. A major role of DNA polymerase delta in replication 
of both the leading and lagging DNA strands. Mol Cell 2015;59(2):163-175.
 52. Blank A, Kim B, Loeb LA. DNA polymerase delta is required for base excision repair of DNA meth-
ylation damage in Saccharomyces cerevisiae. Proc Natl Acad Sci USA 1994;91(19):9047-9051.
 53. Stucki M, Pascucci B, Parlanti E, Fortini P, Wilson SH, Hubscher U, et al. Mammalian base excision 
repair by DNA polymerases delta and epsilon. Oncogene 1998;17(7):835-843.
 54. Nishida C, Reinhard P, Linn S. DNA repair synthesis in human fibroblasts requires DNA polymerase 
delta. J Biol Chem 1988;263(1):501-510.
 55. Lehmann AR. DNA polymerases and repair synthesis in NER in human cells. DNA Repair (Amst) 
2011;10(7):730-733.
 56. Tran HT, Gordenin DA, Resnick MA. The 3’-5’ exonucleases of DNA polymerases delta and epsilon 
and the 5’-3’ exonuclease Exo1 have major roles in postreplication mutation avoidance in Sac-
charomyces cerevisiae. Mol Cell Biol 1999;19(3):2000-2007.
 57. Bowen N, Smith CE, Srivatsan A, Willcox S, Griffith JD, Kolodner RD. Reconstitution of long and 
short patch mismatch repair reactions using Saccharomyces cerevisiae proteins. Proc Natl Acad 
Sci USA 2013;110(46):18472-18477.
 58. Zhang Y, Yuan F, Presnell SR, Tian K, Gao Y, Tomkinson AE, et al. Reconstitution of 5’-directed hu-
Polymerase proofreading domain mutations in cancer 51
2
man mismatch repair in a purified system. Cell 2005;122(5):693-705.
 59. Costantino L, Sotiriou SK, Rantala JK, Magin S, Mladenov E, Helleday T, et al. Break-induced 
replication repair of damaged forks induces genomic duplications in human cells. Science 
2014;343(6166):88-91.
 60. Lydeard JR, Jain S, Yamaguchi M, Haber JE. Break-induced replication and telomerase-indepen-
dent telomere maintenance require Pol32. Nature 2007;448(7155):820-823.
 61. Pursell ZF, Kunkel TA. DNA polymerase epsilon: a polymerase of unusual size (and complexity). 
Prog Nucleic Acid Res Mol Biol 2008;82:101-145.
 62. Ganai RA, Bylund GO, Johansson E. Switching between polymerase and exonuclease sites in DNA 
polymerase epsilon. Nucleic Acids Res 2015;43(2):932-942.
 63. Simon M, Giot L, Faye G. The 3’ to 5’ exonuclease activity located in the DNA polymerase delta 
subunit of Saccharomyces cerevisiae is required for accurate replication. EMBO J 1991;10(8):2165-
2170.
 64. Murphy K, Darmawan H, Schultz A, Fidalgo da Silva E, Reha-Krantz LJ. A method to select for 
mutator DNA polymerase deltas in Saccharomyces cerevisiae. Genome 2006;49(4):403-410.
 65. Datta A, Schmeits JL, Amin NS, Lau PJ, Myung K, Kolodner RD. Checkpoint-dependent activation 
of mutagenic repair in Saccharomyces cerevisiae pol3-01 mutants. Mol Cell 2000;6(3):593-603.
 66. Williams LN, Marjavaara L, Knowels GM, Schultz EM, Fox EJ, Chabes A, et al. dNTP pool levels 
modulate mutator phenotypes of error-prone DNA polymerase epsilon variants. Proc Natl Acad 
Sci USA 2015;112(19):E2457-2466.
 67. Bellido F, Pineda M, Aiza G, Valdes-Mas R, Navarro M, Puente DA, et al. POLE and POLD1 mutations 
in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and 
recommendations for genetic testing and surveillance. Genet Med 2016;18(4):325-332.
 68. Spier I, Holzapfel S, Altmuller J, Zhao B, Horpaopan S, Vogt S, et al. Frequency and phenotypic 
spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with 
colorectal adenomas and carcinomas. Int J Cancer 2015;137(2):320-331.
 69. Chubb D, Broderick P, Frampton M, Kinnersley B, Sherborne A, Penegar S, et al. Genetic diagnosis 
of high-penetrance susceptibility for colorectal cancer (CRC) is achievable for a high proportion 
of familial CRC by exome sequencing. J Clin Oncol 2015;33(5):426-432.
 70. Valle L, Hernandez-Illan E, Bellido F, Aiza G, Castillejo A, Castillejo MI, et al. New insights into 
POLE and POLD1 germline mutations in familial colorectal cancer and polyposis. Hum Mol Genet 
2014;23(13):3506-3512.
 71. Elsayed FA, Kets CM, Ruano D, van den Akker B, Mensenkamp AR, Schrumpf M, et al. Germline 
variants in POLE are associated with early onset mismatch repair deficient colorectal cancer. Eur J 
Hum Genet 2015;23(8):1080-1084.
 72. Rohlin A, Zagoras T, Nilsson S, Lundstam U, Wahlstrom J, Hulten L, et al. A mutation in POLE 
predisposing to a multi-tumour phenotype. Int J Oncol 2014;45(1):77-81.
 73. Hansen MF, Johansen J, Bjornevoll I, Sylvander AE, Steinsbekk KS, Saetrom P, et al. A novel POLE 
mutation associated with cancers of colon, pancreas, ovaries and small intestine. Fam Cancer 
2015;14(3):437-448.
 74. Aoude LG, Heitzer E, Johansson P, Gartside M, Wadt K, Pritchard AL, et al. POLE mutations in 
families predisposed to cutaneous melanoma. Fam Cancer 2015;14(4):621-628.
 75. Zou Y, Liu FY, Liu H, Wang F, Li W, Huang MZ, et al. Frequent POLE1 p.S297F mutation in Chinese 
patients with ovarian endometrioid carcinoma. Mutat Res 2014;761:49-52.
 76. Jones S, Stransky N, McCord CL, Cerami E, Lagowski J, Kelly D, et al. Genomic analyses of gynaeco-
logic carcinosarcomas reveal frequent mutations in chromatin remodelling genes. Nat Commun 
52 Chapter 2
2014;5:5006.
 77. Shlien A, Campbell BB, de Borja R, Alexandrov LB, Merico D, Wedge D, et al. Combined hereditary 
and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutat-
ed cancers. Nat Genet 2015;47(3):257-262.
 78. The Cancer Genome Atlas Research Network. Widespread genetic heterogeneity in multiple 
myeloma: implications for targeted therapy. Cancer Cell 2014;25(1):91-101.
 79. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of 
gastric adenocarcinoma. Nature 2014;513(7517):202-209.
 80. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, et al. Mapping the hall-
marks of lung adenocarcinoma with massively parallel sequencing. Cell 2012;150(6):1107-1120.
 81. The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adeno-
carcinoma. Nature 2014;511(7511):543-550.
 82. Kane DP, Shcherbakova PV. A common cancer-associated DNA polymerase epsilon mutation 
causes an exceptionally strong mutator phenotype, indicating fidelity defects distinct from loss 
of proofreading. Cancer Res 2014;74(7):1895-1901.
 83. Hussein YR, Weigelt B, Levine DA, Schoolmeester JK, Dao LN, Balzer BL, et al. Clinicopathological 
analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. 
Mod Pathol 2015;28(4):505-514.
 84. Bertagnolli MM, Redston M, Compton CC, Niedzwiecki D, Mayer RJ, Goldberg RM, et al. Microsat-
ellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation 
of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. J Clin Oncol 
2011;29(23):3153-3162.
 85. Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, et al. Value of mismatch 
repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in 
colorectal cancer. J Clin Oncol 2011;29(10):1261-1270.
 86. Nelson GS, Pink A, Lee S, Han G, Morris D, Ogilvie T, et al. MMR deficiency is common in high-
grade endometrioid carcinomas and is associated with an unfavorable outcome. Gynecol Oncol 
2013;131(2):309-314.
 87. Diaz-Padilla I, Romero N, Amir E, Matias-Guiu X, Vilar E, Muggia F, et al. Mismatch repair status and 
clinical outcome in endometrial cancer: a systematic review and meta-analysis. Crit Rev Oncol 
Hematol 2013;88(1):154-167.
 88. Heitzer E, Tomlinson I. Replicative DNA polymerase mutations in cancer. Curr Opin Genet Dev 
2014;24:107-113.
 89. Williams LN, Herr AJ, Preston BD. Emergence of DNA polymerase epsilon antimutators that 
escape error-induced extinction in yeast. Genetics 2013;193(3):751-770.
 90. Herr AJ, Kennedy SR, Knowels GM, Schultz EM, Preston BD. DNA replication error-induced extinc-
tion of diploid yeast. Genetics 2014;196(3):677-691.
 91. Heyer J, Yang K, Lipkin M, Edelmann W, Kucherlapati R. Mouse models for colorectal cancer. 
Oncogene 1999;18(38):5325-5333.
 92. Sole RV, Deisboeck TS. An error catastrophe in cancer? J Theor Biol 2004;228(1):47-54.
 93. Loeb LA. Human cancers express mutator phenotypes: origin, consequences and targeting. Nat 
Rev Cancer 2011;11(6):450-457.
 94. Herr AJ, Ogawa M, Lawrence NA, Williams LN, Eggington JM, Singh M, et al. Mutator suppression 
and escape from replication error-induced extinction in yeast. PLoS Genet 2011;7(10):e1002282.
 95. Ghodgaonkar MM, Kehl P, Ventura I, Hu L, Bignami M, Jiricny J. Phenotypic characterization of 
missense polymerase-delta mutations using an inducible protein-replacement system. Nat Com-
Polymerase proofreading domain mutations in cancer 53
2
mun 2014;5:4990.
 96. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Mutational landscape de-
termines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348(6230):124-
128.
 97. Korona DA, Lecompte KG, Pursell ZF. The high fidelity and unique error signature of human DNA 
polymerase epsilon. Nucleic Acids Res 2011;39(5):1763-1773.
 98. Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the 
deep-sequencing age. Nat Methods 2014;11(4):361-362.
 99. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein 
function using the SIFT algorithm. Nat Protoc 2009;4(7):1073-1081.
 100. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server 
for predicting damaging missense mutations. Nat Methods 2010;7(4):248-249.
 101. Fox EJ, Prindle MJ, Loeb LA. Do mutator mutations fuel tumorigenesis? Cancer Metastasis Rev 
2013;32(3-4):353-361.
 102. Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, et al. The vigorous immune 
microenvironment of microsatellite instable colon cancer is balanced by multiple counter-
inhibitory checkpoints. Cancer Discov 2015;5(1):43-51.
 103. McFarland CD, Mirny LA, Korolev KS. Tug-of-war between driver and passenger mutations in 
cancer and other adaptive processes. Proc Natl Acad Sci USA 2014;111(42):15138-15143.
 104. Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, et al. Revised guidelines for the 
clinical management of Lynch syndrome (HNPCC): recommendations by a group of European 
experts. Gut 2013;62(6):812-823.
 105. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with 
lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369(2):134-144.
 106. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-
L1 antibody in patients with advanced cancer. N Engl J Med 2012;366(26):2455-2465.
 107. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, 
and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443-2454.
 108. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with 
mismatch-repair deficiency. N Engl J Med 2015;372(26):2509-2520.
 109. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clini-
cal response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371(23):2189-2199.
 110. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces 
responses by inhibiting adaptive immune resistance. Nature 2014;515(7528):568-571.
 111. Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and 
dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 
2015;520(7547):373-377.
 112. Jin YH, Clark AB, Slebos RJ, Al-Refai H, Taylor JA, Kunkel TA, et al. Cadmium is a mutagen that acts 
by inhibiting mismatch repair. Nat Genet 2003;34(3):326-329.
 113. Mertz TM, Sharma S, Chabes A, Shcherbakova PV. Colon cancer-associated mutator DNA poly-
merase delta variant causes expansion of dNTP pools increasing its own infidelity. Proc Natl Acad 
Sci USA 2015;112(19):E2467-2476.
 114. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in Multiple Nonmela-
noma Cancers with BRAF V600 Mutations. N Engl J Med 2015;373(8):726-736.
 115. Loeb LA, Bielas JH, Beckman RA. Cancers exhibit a mutator phenotype: clinical implications. 
Cancer Res 2008;68(10):3551-3557.
54 Chapter 2
 116. Swan MK, Johnson RE, Prakash L, Prakash S, Aggarwal AK. Structural basis of high-fidelity DNA 
synthesis by yeast DNA polymerase delta. Nat Struct Mol Biol 2009;16(9):979-986.
 117. Wang J, Yu P, Lin TC, Konigsberg WH, Steitz TA. Crystal structures of an NH2-terminal fragment of 
T4 DNA polymerase and its complexes with single-stranded DNA and with divalent metal ions. 
Biochemistry 1996;35(25):8110-8119.
 118. Hoang LN, McConechy MK, Kobel M, Anglesio M, Senz J, Maassen M, et al. Polymerase epsilon 
exonuclease domain mutations in ovarian endometrioid carcinoma. Int J Gynecol Cancer 
2015;25(7):1187-1193.
 119. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics 
portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 
2012;2(5):401-404.
 120. Abdus Sattar AK, Lin TC, Jones C, Konigsberg WH. Functional consequences and exonuclease 
kinetic parameters of point mutations in bacteriophage T4 DNA polymerase. Biochemistry 
1996;35(51):16621-16629.
 121. Stenzinger A, Pfarr N, Endris V, Penzel R, Jansen L, Wolf T, et al. Mutations in POLE and survival of 
colorectal cancer patients - link to disease stage and treatment. Cancer Med 2014;3(6):1527-1538.
Polymerase proofreading domain mutations in cancer 55
2
gloSSAry
Antimutator mutations – mutations that result in an increase in the fidelity of DNA 
replication; examples have been reported in both Escherichia coli and Saccharomyces 
cerevisiae, although their occurrence in human cancer is currently not proved.
B family polymerases – replicative and repair DNA polymerases that are grouped on the 
basis of sequence and structural similarities, and include the prokaryotic DNA poly-
merase Pol II, and the eukaryotic DNA polymerases Pol ζ, Pol α, Pol δ and Pol ε.
Basket trial – also known as a bucket trial. A study in which patients with a specific 
molecular marker are recruited for treatment with a corresponding targeted therapy, 
irrespective of tumor histology or tissue of origin.
GINS – a multiprotein complex essential for eukaryotic DNA replication. The name is 
derived from the Japanese go, ichi, ni and san (meaning five, one, two and three), and 
refers to the constituent components in budding yeast: Sld5, Psf1, Psf2 and Psf3.
Intestinal polyposis – a phenotype of multiple colonic polyps and increased risk of 
colorectal cancer that may be due to a germline mutation in a known predisposition 
gene (for example, adenomatous polyposis coli (APC) or MUTYH) or may lack an obvious 
genetic cause.
Lynch syndrome – a tumor predisposition syndrome caused by germline mutation of 
mismatch repair genes, which manifests as increased risk of carcinomas of the colon and 
rectum, endometrium, ovary, stomach and several other organs.
Microsatellite instability (MSI) –the presence of small insertions and deletions (indels) at 
repetitive DNA microsatellites that result from defective DNA mismatch repair.
Microsatellite-stable – absence of small insertions and deletions (indels) at repetitive 
DNA microsatellites as a result of proficient DNA mismatch repair.
Mismatch repair (MMR) – a mechanism of post-replicative DNA repair that removes mis-
matched bases and small insertions and deletions (indels) from the newly synthesized 
DNA strand.
Multinucleated giant cells – abnormally large cells with multiple nuclei and typically bi-
zarre morphology that are observed in association with chronic inflammation and some 
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types of malignancy.
Mutational hot spot – a genomic region that is the site of mutations in cancers at a 
frequency greater than that expected by chance: for example, codon 600 in the serine/
threonine kinase BRAF.
Mutator phenotype – elevation of the mutation rate above that expected for normally 
dividing cells. It has been argued that the acquisition of a mutator phenotype is a char-
acteristic of many cancers.
MUTYH-associated polyposis – a syndrome characterized by multiple intestinal adeno-
mas and an increased risk of colorectal carcinoma. It is caused by germline mutations in 
the base excision repair gene MUTYH.
Neoepitope – novel epitopes, created by somatic mutations in tumors, that are capable 
of eliciting an antitumor immune response.
Polymerase proofreading-associated polyposis (PPAP) – a high-penetrance, dominantly 
inherited condition characterized by multiple colorectal adenomas and carcinomas, 
caused by germline mutations in the genes encoding the catalytic subunits of the DNA 
polymerases Pol δ and Pol ε (POLD1 and POLE, respectively).
Synthetically lethal – a type of genetic interaction in which the combination of mutations 
in two genes results in cell death, whereas cells harboring only one of the mutations are 
viable.
Ultramutated – describes tumors with an exceptional frequency of mutations, often 
exceeding 100 mutations per megabase and often caused by mutations in the gene 
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POLE exonuclease domain mutations identify a subset of endometrial cancer (EC) 
patients with an excellent prognosis. The use of this biomarker has been suggested to 
refine adjuvant treatment decisions, but the necessary sequencing is not widely per-
formed and is relatively expensive. Therefore, we aimed to identify histopathological 
and immunohistochemical characteristics to aid the detection of POLE-mutant ECs.
methods
Fifty-one POLE-mutant endometrioid, 67 POLE-wild-type endometrioid and 15 POLE-
wild-type serous ECs were included (total N=133). An expert gynecological pathologist, 
blinded to molecular features, evaluated each case (two or more slides) for sixteen mor-
phological characteristics. Immunohistochemistry was performed for p53, p16, MLH1, 
MSH2, MSH6, and PMS2.
results
POLE-mutant ECs were characterized by a prominent immune infiltrate: 80% showed 
peritumoral lymphocytes and 59% tumor-infiltrating lymphocytes, as compared with 
43% and 28% of POLE-wild-type endometrioid ECs, and 27% and 13% of serous counter-
parts (P<0.01, all comparisons). Of POLE-mutant ECs, 33% contained tumor giant cells; 
this proportion was significantly higher than that in POLE-wild-type endometrioid ECs 
(10%, P=0.003), but not significantly different from that in serous ECs (53%). Serous-like 
features were as often (focally) present in POLE-mutant as in POLE-wild-type endome-
trioid ECs (6-24%, depending on the feature). The majority of POLE-mutant ECs showed 
wild-type p53 (86%), negative/focal p16 (82%) and normal mismatch repair protein 
expression (90%).
Conclusions
A simple combination of morphological and immunohistochemical characteristics 
(tumor type, grade, peritumoral lymphocytes, MLH1, p53 expression) can assist in pre-
screening for POLE exonuclease domain mutations in EC, increasing the probability of 
a mutation being detected from 7% to 33%. This facilitates the use of this important 
prognostic biomarker in routine pathology.
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Histopathological characterization of POLE-mutant endometrial cancers
IntroduCtIon
An integrated clinicopathological and molecular classification has the potential to refine 
the clinical risk prediction of endometrial cancer (EC) patients and to provide more 
tailored treatment recommendations.1-3 One of the important prognostic subgroups 
included in this classification, constituting 7-12% of ECs, is characterized by somatic 
mutations in the exonuclease domain of the POLE gene.4-6 POLE encodes the catalytic 
subunit of DNA polymerase ε.7 Mutations in the exonuclease domain of POLE (severely) 
reduce proofreading activity during DNA replication, and thereby contribute to a very 
high mutational burden, which is among the highest found in human cancers (a so-
called ‘ultramutator’ phenotype).6,8 Moreover, POLE-mutant ECs occur at a relatively 
young age and are often high-grade tumors.9 It is thus not surprising that, on the basis 
of current guidelines, the majority of patients with POLE-mutant ECs would be offered 
adjuvant radiotherapy, and approximately one-third would be offered some form of 
chemotherapy.10 
Despite the aggressive appearance of these tumors, multiple independent studies have 
shown that patients with POLE-mutant ECs have an excellent prognosis, with a five-year 
disease-specific survival rate of 98-100%.2,5,6,9,11 As this prognostic benefit is suggested 
to be independent of adjuvant therapy, no or less intensive adjuvant treatment may 
suffice for early-stage POLE-mutant ECs.9,12 This potential of POLE mutations to reduce 
overtreatment may spare a relatively young patient group from the toxicities of adjuvant 
therapy. In addition to the prognostic importance, recent studies have demonstrated 
that POLE-mutant ECs show a strong antitumor immune response, but also upregulation 
of markers involved in immune suppression, including programmed death 1 and pro-
grammed death-ligand 1.13-16 Therefore, although POLE-mutant ECs rarely recur, patients 
with (recurring or metastatic) POLE-mutant ECs may be good candidates for immune 
checkpoint inhibition, as demonstrated in recent case reports.17,18 These prognostic and 
potentially predictive implications make the identification of POLE exonuclease domain 
mutations in EC essential.
Screening for POLE mutations is performed by sequencing of the exonuclease domain 
(exons 9-14). This technique is not widely available in routine pathology laboratories and 
is relatively expensive, hampering the clinical use of this important biomarker. Two previ-
ous studies aimed to identify clinicopathological and/or morphological features of ECs 
with POLE mutations.10,19 Hussein et al., for example, noted the presence of ‘bizarre/giant 
tumor cell nuclei’ in POLE-mutant ECs, and of foci with severe nuclear atypia, suggesting 
that this could lead to concerns about serous carcinomas.19 However, in both studies, the 
pathologists evaluated only POLE-mutant ECs: scoring for the morphological features was 
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not performed blindly. Also, for the majority of cases, the number of slides assessed for 
each case was unknown. Therefore, we performed a blinded in-depth characterization of 
a large series of POLE-mutant ECs, with multiple slides available for each case. In this study, 
we sought to identify histopathological and immunohistochemical characteristics of ECs 
carrying POLE exonuclease domain mutations, to aid their detection in EC.
mAterIAlS And methodS
Patient selection
ECs from the PORTEC-1 and PORTEC-2 studies, and from an EC series of the Leiden 
University Medical Center archives (2001-2015), were collected after approval by the 
institutional review board.20,21 For all ECs, histological type, tumor grade and stage of 
disease (classified according to the World Health Organization and FIGO classifications) 
were reviewed by an expert gynecological pathologist.20-24 Cases were considered for 
inclusion in this study when a minimum of two different hematoxylin and eosin (H&E)-
stained slides of the EC were available. Moreover, molecular analyses - POLE mutational 
status, the presence of microsatellite instability, and p53 expression - were conducted 
prior to this study (details in Supplementary Methods and Supplementary Table 1).1,9,13,25 
From these EC cohorts, by use of the available data as described above, cases were 
selected for the current study. First, all previously identified ECs with pathogenic POLE 
exonuclease domain mutations were included, resulting in 51 POLE-mutant tumors for 
analysis (details on the included substitutions in Supplementary Table 2). To address any 
morphological similarities between POLE-mutant and serous ECs, a control group of POLE-
wild-type serous ECs was included (N=15). Furthermore, POLE-wild-type endometrioid 
ECs were included to represent the other, previously identified molecular subgroups.6 
These cases were proportionally matched on tumor grade with the POLE-mutant group, 
allowing reliable comparison of morphological characteristics between the groups. 
This resulted in the inclusion of 35 microsatellite-unstable and 32 microsatellite-stable 
endometrial cancers (four p53-mutant and 28 with no specific molecular profile).
morphological characteristics
For all included cases, the presence of papillary growth, slit-like spaces and hobnailing 
was evaluated. In addition, when such a feature was present, the percentage of the tumor 
displaying the characteristic was noted, estimated over all available slides of a case. Cyto-
nuclear atypia was classified as marked, rather than mild or moderate, when the majority 
of the tumor cells displayed strongly pleomorphic nuclei. When, at scanning magnification 
(x5), easily identifiable mitotic figures or apoptotic bodies were present, this was noted 
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as brisk mitotic activity and brisk apoptotic activity, respectively. Tumor giant cells were 
identified in ECs containing mononuclear or multinucleated cells (size range 10-40 times 
the size of a lymphocyte) with large, bizarre, often hyperchromatic nuclei in at least one 
slide of the tumor. As with brisk mitotic and apoptotic activity, tumor-infiltrating lympho-
cytes (TILs) and peritumoral lymphocytes were present when these features were readily 
detectable upon scanning of the slides (magnification: x5). TILs are found intraepitheli-
ally within the tumor, whereas peritumoral lymphocytes appear as lymphoid aggregates 
adjacent or close to the invasive margin of the tumor. The predominant invasion type was 
categorized into no invasion, broad front invasion, microcystic elongated and fragmented 
invasion, adenomyosis-like, or infiltrating glands.26,27 
ECs were examined for the presence of necrosis and for the presence (isolated, focal or 
scattered) of squamous and eosinophilic metaplasia. Squamous metaplasia presenting as 
morules (circumscribed, solid round, intraglandular nests composed of cells with (im)ma-
ture squamous differentiation) were denoted separately.28 The percentage of solid growth 
was estimated over all available slides for each case, and was categorized as ≤5%, 6-50%, 
and >50% according to the FIGO classification.22,23 Myometrial invasion, dichotomized 
with a cut-off of 50%, was either evaluated as part of the inclusion criteria of the PORTEC-1 
and PORTEC-2 trials or extracted from the pathology reports.20,21 Lymphovascular space 
invasion was defined as the presence of tumor cells in a space lined by endothelial cells 
outside the immediate invasive border of the tumor, and was classified as absent, focal or 
substantial, as described previously.29 All slides were blindly scored for each morphologi-
cal characteristic by an expert gynecological pathologist (T.B.).
Immunohistochemical analyses
One formalin-fixed paraffin-embedded tissue block containing representative tumor 
tissue was selected for each case for immunohistochemistry. Immunohistochemistry 
for p53, MLH1, MSH2, MSH6, PMS2, and p16 was performed as described previously; 
procedures, primary antibodies, and scoring methods are show in the Supplementary 
Methods.1,30-32
Statistical analyses
Continuous variables were compared by use of the Kruskal-Wallis and Mann-Whitney 
U tests (with Bonferroni correction for multiple comparisons). Associations between 
categorical variables were tested by use of χ2 statistics or Fisher’s exact test. Logic regres-
sion was performed on all morphological and immunohistochemical features to identify 
a combination of characteristics that best predict POLE exonuclease domain mutational 
status using the R statistical software package LogicReg version 1.5.9 (further details are 
given in the Supplementary Methods).33,34 
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reSultS
The clinicopathological characteristics of the 133 included ECs are summarized in Table 
1. All POLE-mutant cases were classified as endometrioid ECs after central review, despite 
not being selected for tumor type. In the original pathology reports, 49 of 51 (96.1%) 
POLE-mutant ECs were considered to be endometrioid-type as well, while two high-grade 
ECs were originally classified as serous and clear cell, respectively. A median of four slides 
(range 2-13) of each case was blindly assessed for all morphological characteristics.
table 1. Clinicopathological characteristics of the study population and of the included molecular/histo-






















64.8 (36 – 85) 62.1 (36 – 
81)
65 (40 – 84) 73.7 (61 – 85) 0.497§ 0.001§
FIGO 2009, n (%)  
I-II 119 (89.5) 49 (96.1) 61 (91.0) 9 (60.0) 0.463 0.001
III-IV 14 (10.5) 2 (3.9) 6 (9.0) 6 (40.0)
Tumor type, n (%)  
Endometrioid 117 (88.0) 51 (100) 66 (98.5) 0 (0.0) 1 <0.001




1 (0.8) 0 (0.0) 1 (1.5) 0 (0.0)
Tumor grade, n (%)
Low (grade 1 
or 2)
88 (66.2) 35 (68.6) 53 (79.1) 0 (0.0) 0.195 <0.001
High (grade 3) 45 (33.8) 16 (31.4) 14 (20.9) 15 (100)
Slides assessed, 
median (range) 
4 (2 – 13) 4 (2 – 11) 4 (2 – 10) 3 (2 – 13) NAII NAII
*Clinicopathological characteristics are shown for the total study population as well as for each molecu-
lar/histopathological subgroup. The included subgroups are: POLE-mutant, POLE-wild-type endometrioid 
(microsatellite-unstable, p53-mutant or with no specific molecular profile), and POLE -wild-type serous en-
dometrial cancers. The POLE-wild-type endometrioid group is denominated ‘endometrioid’ throughout this 
article, despite the single mixed epithelial case.
‡P values are calculated over POLE -mutant and POLE-wild-type endometrioid (POLE vs. endometrioid) or 
over POLE-mutant and POLE-wild-type serous (POLE vs. serous) endometrial cancers, respectively.
3Bonferroni adjusted P<0.0167 to indicate statistical significance.
IIThe non-parametric Kruskal-Wallis test revealed no significant differences in the number of slides assessed 
between the three subgroups (P=0.384). Therefore, no pairwise comparisons were performed.
Abbreviations: NA, not applicable.
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POLE-mutant ECs showed peritumoral lymphocytes in 80% of cases (Figure 1A-C; Table 
2). The presence of peritumoral lymphocytes was strongly associated with POLE muta-
tion both in comparison with both POLE-wild-type serous ECs (27%, P<0.001) and POLE-
wild-type endometrioid ECs (43%, P<0.001). Similarly, an increased presence of TILs was 
found in POLE-mutant ECs (59%) in comparison with POLE-wild-type endometrioid ECs 
(28%) and serous ECs (13%, P=0.001 and P=0.003 respectively; Figure 1D-E). Moreover, 
peritumoral lymphocytes and TILs were present signifi cantly more often in POLE-mutant 
ECs than in microsatellite-unstable cases included in the POLE-wild-type endometrioid 
EC group (respectively: 80% vs. 57%, P=0.020; and 59% vs. 34%, P=0.025).
Figure 1. Peritumoral and tumor-infi ltrating lymphocytes in POLE-mutant endometrial cancers.
The presence of a prominent peritumoral lymphocytic infi ltrate in a low-grade (grade 2) endometrioid-
type POLE-mutant endometrial cancer is shown (A, magnifi cation: x10), with insets of Crohn’s-like infi ltrate 
(B, magnifi cation: x40) and of the peritumoral lymphocytes (C, magnifi cation: x40). Examples of tumor-
infi ltrating lymphocytes in POLE-mutant endometrial cancers are shown (D, low-grade endometrioid-type; 
and E, high-grade endometrioid-type; both magnifi cation: x20).
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Although tumor giant cells were most frequently found in POLE-wild-type serous ECs 
(53%), 33% of POLE-mutant ECs also contained these cells (P=0.227; Figure 2; Table 2). 
Among POLE-mutant and POLE-wild-type endometrioid ECs, however, the presence 
of tumor giant cells was signifi cantly associated with POLE mutation (33% vs. 10%, 
P=0.003). Tumor giant cells showed keratin positivity, while being negative for β-human 
chorionic gonadotropin (β-hCG; Supplementary Figure 1).
Among the endometrioid ECs, no diff erences were found between POLE-mutant and 
POLE-wild-type cases with regard to serous-like features (i.e. papillary growth, slit-like 
spaces, hobnailing, marked cytonuclear atypia, and brisk mitotic activity): there were no 
diff erences in either the presence of each feature separately (Table 2), or the percentage 
of tumor showing a feature (data not shown), or the presence of three or more features 
in the same case (12% of POLE-mutant ECs vs. 9% of POLE-wild-type ECs, P=0.761). In 
contrast, the presence of serous-like features, the percentage at which they are seen in 
the cancer, as well as their co-occurrence correlated strongly with POLE-wild-type serous 
Figure 2. Tumor giant cells in POLE-wild-type serous and POLE-mutant endometrial cancers.
Examples of tumor giant cells in two diff erent (POLE-wild-type) serous endometrial cancers are shown (A 
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ECs as compared with POLE-mutant ECs (P<0.05 for all associations; Table 2).
With regard to the invasion type, broad front invasion was associated with POLE-mutant 
ECs, in contrast to POLE-wild-type serous ECs (51% vs. 20%, P=0.042), but did not differ 
among the endometrioid ECs (Table 2; Supplementary Table 3). Similarly, squamous 
metaplasia was associated with POLE-mutant ECs in comparison with POLE-wild-type 
serous ECs (29% vs. 0%, P=0.015), but did not differ between POLE-mutant and POLE-
wild-type endometrioid ECs (Table 2).
We next sought to determine whether immunohistochemistry for markers that are com-
monly used in diagnostic pathology could aid in the detection of POLE mutations in 
EC. Approximately 16% of POLE-mutant ECs showed p53-mutant-like expression (five 
of eight cases showed subclonal p53-mutant-like expression), as compared with 6% 
of POLE -wild-type endometrioid ECs (P=0.123) and 80% of POLE-wild-type serous ECs 
(P<0.001; Table 3). Immunohistochemistry for p16 revealed similar results: strong and 
table 2. Presence of morphological characteristics in POLE exonuclease domain-mutant endometrial can-















Peritumoral lymphocytes 41 (80.4) 29 (43.3) 4 (26.7) <0.001 <0.001
Tumor-infiltrating 
lymphocytes
30 (58.8) 19 (28.4) 2 (13.3) 0.001 0.003
Tumor giant cells 17 (33.3) 7 (10.4) 8 (53.3) 0.003 0.227
Papillary growth 7 (13.7) 7 (10.4) 13 (86.7) 0.775 <0.001
Hobnailing 6 (11.8) 4 (6.0) 10 (66.7) 0.325 <0.001
Slit-like spaces 11 (21.6) 11 (16.4) 13 (86.7) 0.477 <0.001
Marked cytonuclear atypia 12 (23.5) 12 (17.9) 10 (66.7) 0.453 0.004
Brisk mitotic activity 12 (23.5) 14 (20.9) 9 (60.0) 0.732 0.012
Brisk apoptotic activity 6 (11.8) 10 (14.9) 0 (0.0) 0.787 0.323
Broad front invasion type 26 (51.0) 27 (40.3) 3 (20.0) 0.248 0.042
Squamous metaplasia 15 (29.4) 20 (29.9) 0 (0.0) 0.959 0.015
Solid growth (≥5%) 31 (60.8) 32 (47.8) 7 (46.7) 0.160 0.382
Necrosis 21 (41.2) 29 (43.3) 8 (53.3) 0.819 0.555
Myometrial invasion (>50%) 30 (58.8) 34 (50.7) 8 (53.3) 0.383 0.771
Substantial lymphovascular 
space invasion
7 (13.7) 9 (13.4) 4 (26.7) 1 0.254
The number and percentage of cases in which a morphological characteristic is present is indicated for each 
molecular/histopathological subgroup (for definitions of each characteristic, see Materials and methods).
*P values are calculated over POLE -mutant and POLE-wild-type endometrioid (POLE vs. endometrioid) or 
over POLE-mutant and POLE-wild-type serous (POLE vs. serous) endometrial cancers, respectively.
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diffuse p16 expression did not differ between POLE-mutant ECs and POLE -wild-type 
endometrioid ECs (18% vs. 13% respectively, P=0.609), but it was strongly associated 
with serous ECs when POLE-mutant ECs were compared with POLE-wild-type serous ECs 
(18% vs. 73% respectively, P<0.001). Moreover, POLE-mutant ECs showing three or more 
serous-like features (n=6) all showed p53-wild-type expression and negative or focal p16 
expression (Figure 3), whereas the serous ECs with a less prototypical serous morphol-
ogy (showing fewer than three serous-like features, n=4) all showed p53-mutant-like 
expression and/or strong and diffuse p16 expression.
With regard to DNA mismatch repair status, 90% (46/51) of POLE-mutant ECs were mis-
match repair-proficient as suggested by normal expression of the four mismatch repair 
proteins (MLH1, PMS2, MSH2, and MSH6; Supplementary Table 4). Five POLE-mutant ECs 
showed abnormalities in mismatch repair protein expression: one showed loss of MLH1 
and PMS2, one loss of PMS2, two subclonal loss of MLH1 and PMS2 (deficiency of the two 
proteins found in the same tumor area), and one subclonal loss of MLH1 and complete 
loss of PMS2. All serous ECs showed normal expression of the mismatch repair proteins. 
One POLE-wild-type p53-mutant EC showed subclonal loss of MLH1 and PMS2 (3%).
A combination of morphological and immunohistochemical characteristics that best 
predicts POLE mutational status was identified by performing logic regression. We found 
that a logic model including five such characteristics had the best predictive capability 
(lowest misclassification rate). With the use of this number and a simulated annealing 
algorithm, the best Boolean combination of characteristics to predict POLE mutational 
status was as follows: (MLH1 wild-type expression or p53-wild-type expression) and 
table 3. Results of immunohistochemistry for p53 and p16 on POLE exonuclease domain-mutant com-
















Wild-type 43 (84.3) 63 (94.0) 3 (20.0) 0.123 <0.001
Mutant 8 (15.7) 4 (6.0) 12 (80.0)
p16
Negative/focal 42 (82.4) 58 (86.6) 4 (26.7) 0.609 <0.001
Diffuse 9 (17.6) 9 (13.4) 11 (73.3)
*P values are calculated over POLE -mutant and POLE-wild-type endometrioid (POLE vs. endometrioid) or 
over POLE-mutant and POLE-wild-type serous (POLE vs. serous) endometrial cancers, respectively.
‡p53 mutational status was based on immunohistochemistry, except for three cases (one POLE-mutant and 
two POLE -wild-type endometrioid) in which p53 expression was scored as indefinite. Sanger sequencing 
revealed no mutation in these cases.
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(endometrioid-type EC) and (peritumoral lymphocytes present or tumor grade 3). This 
model has an estimated sensitivity of 80% and specifi city of 88%. With a prevalence of 
POLE exonuclease domain mutations in EC of 7%, this yields a positive predictive value 
of 33%.
dISCuSSIon
We performed a blinded histopathological and immunohistochemical characterization 
of the largest series of POLE exonuclease domain-mutant ECs to date, also including 
POLE-wild-type endometrioid and serous EC control groups. Our study shows that POLE-
mutant ECs are characterized by the presence of a striking immune infi ltrate, consisting 
of peritumoral and TILs, and that one-third contains tumor giant cells. All POLE-mutant 
cases were classifi ed as endometrioid ECs, but, similarly to POLE-wild-type endome-
Figure 3. Immunohistochemistry of p53 and p16 in a POLE-mutant endometrioid endometrial cancer with 
serous-like features.
This fi gure shows one POLE-mutant tumor classifi ed as an endometrioid endometrial cancer (A) that also 
demonstrates serous-like features (B, papillary growth, hobnailing and slit-like spaces). Despite these se-
rous-like features, immunohistochemistry reveals p53-wild-type expression (C) and focal p16 positivity (D, 
all images magnifi cation: x20).
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trioid ECs, features suggestive of serous morphology can (focally) be present. On im-
munohistochemical investigation, the majority of POLE-mutant ECs show wild-type p53 
expression, negative or focal p16 expression, and normal expression of the mismatch 
repair proteins. A combination of these morphological and immunohistochemical char-
acteristics can be used to assist pre-screening for POLE exonuclease domain mutations 
when sequencing is not directly available.
POLE-mutant ECs show evidence of a prominent immune infiltrate, as illustrated by the 
remarkably high percentages of cases in which peritumoral lymphocytes or TILs were 
found (80% and 59%, respectively). Similarly, Bakhsh et al. found peritumoral lympho-
cytes in 79% of POLE-mutant ECs, and Hussein et al. described peritumoral lymphocytes 
and/or TILs in 84% of POLE-mutant ECs (as compared with 84% of POLE-mutant ECs in 
the current study).10,19 In addition, an increased lymphocytic infiltrate was found to be 
present in colorectal cancers with somatic POLE exonuclease domain mutations.35 This 
has been described for POLE-mutant glioblastomas as well, suggesting this infiltrate is a 
characteristic of POLE-mutant cancers regardless of tumor type.36 These findings are in 
line with the proposed mechanism by which POLE mutations contribute to the excellent 
clinical outcome of these patients: ultramutation results in the presentation of antigenic 
neopeptides by tumor cells, stimulating a cytolytic antitumor immune response.13,14,16 
The differences in the presence of peritumoral lymphocytes and TILs between POLE-
mutant ECs and POLE-wild-type serous and endometrioid ECs (including all proposed 
prognostic molecular subgroups) were strongly significant. Thus, the presence of a 
prominent immune infiltrate, readily identifiable on hematoxylin and eosin-stained 
slides, is a clear characteristic of POLE-mutant (endometrial) cancers.
Tumor giant cells were most frequently found in POLE-wild-type serous ECs (53%). This 
is in agreement with previous literature describing anaplastic tumor giant cells in ap-
proximately half of serous-type cancers of the uterus, but also of the Fallopian tube and 
ovary.37 The presence of tumor giant cells in POLE-mutant ECs was first described by 
Hussein et al. (40% of cases). These cells were reported to be present in POLE-mutant 
glioblastomas as well.36 The current study is, however, the first to date to associate tumor 
giant cells in a blinded fashion with POLE mutation status among endometrioid-type ECs 
(33% of POLE-mutant ECs vs. 10% of POLE-wild-type ECs).19 This study has demonstrated 
that these tumor giant cells do not represent osteoclast-like giant cells (no abundant 
eosinophilic cytoplasm and keratin-positive) or trophoblastic cells (β-hCG-negative) but 
that they are of epithelial origin, as indicated by their keratin positivity. A role for the 
markedly increased somatic mutational burden in the formation of tumor giant cells in 
POLE-mutant tumors seems plausible: the resultant genetic instability may interfere with 
normal cell cycle progression. This is, however, contradicted by the relatively infrequent 
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presence of tumor giant cells in mismatch repair-deficient ECs, which are expected to 
be hypermutated: only 6% of POLE-wild-type mismatch repair-deficient ECs contained 
tumor giant cells in this study, as compared with 16% of POLE-wild-type mismatch 
repair-proficient tumors.6 Tumor giant cells have been described in a limited number 
of ECs.38-42 These studies included cases with a high-grade endometrioid component, 
abundant immune infiltrate, and intact mismatch repair protein expression. On the basis 
of the current and earlier studies, these cases may, in part, represent unidentified POLE-
mutant ECs.9,19 
All POLE-mutant ECs included in this study were classified as endometrioid cancers. 
Although the exclusion criteria of the PORTEC-2 trial (exclusion of non-endometrioid 
ECs) may, in part, have influenced this, it is in agreement with previous literature 
that the vast majority of POLE-mutant endometrial cancers are of the endometrioid 
type.2,4-6,9-11,15,43 However, POLE-mutant ECs with a pure non-endometrioid morphology 
have also been described.2,4,5,10,43-48 Our study shows that features suggestive of serous 
morphology can, usually focally, be present in POLE-mutant endometrioid ECs, similarly 
to POLE-wild-type endometrioid ECs. Features of pseudo-glandular serous carcinoma, 
such as pseudo-stratification and scalloped luminal borders, were not evaluated in this 
study: although they overlap partly with the assessed serous-like features, this may be 
worthy of further exploration. Our results are supported by the study of Hussein et al. 
who, despite intratumoral heterogeneity, reported an endometrioid component in all 
but one of the included POLE-mutant cases (24/25).19 Whether POLE mutations do occur 
in pure non-endometrioid ECs or whether these represent misclassified endometrioid 
ECs with non-endometrioid-like features remains to be elucidated.
Our study has some limitations. First, all slides were evaluated by one gynecological 
pathologist. Therefore, the issue of interobserver variability was not addressed. How-
ever, this study, to a large degree, validated previous findings in a blinded manner. For 
the majority of features analyzed, we found similar results, suggesting a low degree of 
variability. Moreover, as described above, the inclusion criteria of the PORTEC trials may 
have influenced our case selection, resulting in predominantly low-stage, endometrioid 
ECs.20,21 However, arguably, low-stage disease and an endometrioid-type morphology 
may be characteristics of POLE-mutant ECs. Despite these limitations, this histopatho-
logical characterization contains the largest number of POLE-mutant ECs to date, is the 
first to characterize these tumors in a blinded fashion, and is strengthened by the avail-
ability of multiple slides for each case.
On the basis of the current and previous studies, a classical POLE-mutant EC will present 
at a relatively young age, as a low-stage high-grade endometrioid-type tumor with a 
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striking immune infiltrate, scattered tumor giant cells and a broad front invasion pattern. 
Immunohistochemistry of p53, p16 and the mismatch repair proteins can aid the detec-
tion of POLE mutations and will typically show wild-type p53, negative or focal p16, and 
normal mismatch repair protein expression. Because this approach is not conclusive, 
sequencing of the POLE exonuclease domain will remain the gold standard. However, in 
this study, we have shown that a certain combination of tumor type, grade, presence of 
peritumoral lymphocytes, and immunohistochemistry for MLH1 and p53 can increase 
the prior probability of detection of a POLE mutation almost five-fold. This underlines 
the potential of these morphological and immunohistochemical characteristics to assist 
in pre-screening for POLE exonuclease domain mutations in EC, facilitating the use of 
this important prognostic biomarker in routine pathology. Moreover, as some of these 
traits have also been described in other tumor types carrying POLE exonuclease domain 
mutations, the proposed combination of characteristics to aid the detection of these 
POLE mutations may be generalizable to other cancers.
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Slides (4μm) from formalin-fixed paraffin-embedded tissue blocks were deparaffinized in 
xylene, and rehydrated in a graded ethanol series. Endogenous peroxidases were inactivat-
ed in 0.3% H2O2/methanol. Antigen retrieval was performed by microwave oven treatment 
in 10 mmol/L Tris-EDTA pH 9.0 (p53, MLH1, MSH2, MSH6, PMS2) or in 10 mmol/L citrate 
buffer pH 6.0 (p16). Slides were incubated overnight with primary monoclonal antibod-
ies against p53 (clone DO-7, 1:2000, NeoMarkers), MLH1 (clone ES05, 1:100, DAKO), MSH2 
(clone FE11, 1:200, DAKO), MSH6 (clone EPR3945, 1:800, Genetex), p16 (clone E6H4, 1:50, 
Roche) at room temperature and against PMS2 (clone EP51, 1:75, DAKO) at 4°C. For the mis-
match repair proteins, sections were incubated for 15 minutes with Envision FLEX+ Linker 
Rabbit (DAKO, K8009; MSH6, PMS2) or Mouse (DAKO, K8021; MLH1, MSH2), followed by 
incubation with the secondary antibody. For all antibodies, BrightVision Poly-HRP-GAM/R/R 
(DPV0110HRP, ImmunoLogic) was used as secondary antibody (30 minutes incubation). A 
selected number of cases was automatically stained with beta-hCG (A0231, 1:10000, DAKO) 
or with cytokeratin (AE1/AE3, 1:100, DAKO) using Dako Autostainer Link 48 (Dako, Glostrup, 
Denmark). Slides were counterstained with hematoxylin, dehydrated and mounted.
All immunohistochemical stainings were evaluated by two observers (I.G., E.S.) indepen-
dently, blinded for patient and tumor characteristics. Discrepancies were resolved under 
a multihead microscope. P53 was scored mutant-like when >50% of the tumor cells 
showed strong positive nuclear staining, or when a discrete geographical area showed 
>50% tumor cell positivity (diffuse and subclonal mutant-like expression respec-
tively).30,31 If p53 was evaluated as ‘indefinite’, i.e. no p53 staining of the tumor, Sanger 
sequencing was performed (we acknowledge that with this method larger deletions 
may be missed). Expression of MLH1, MSH2, MSH6, PMS2 was classified as wild-type 
when the tumor cells showed nuclear protein expression, and as (subclonal) loss when 
(discrete geographical sheets of ) tumor cells were negative but stromal cells and/or im-
mune infiltrate (internal controls) showed positive nuclear staining. P16 was scored as 
negative when <10% of tumor cells showed nuclear and/or cytoplasmic staining, focal/
patchy when 10-30% of tumor cells were positive, and diffuse in case of nuclear and/or 
cytoplasmic expression in >30% of tumor cells.32 
dnA analyses
The prognostic molecular subgroups were assessed as described previously.1,5 In brief, 
tumor DNA was isolated from formalin-fixed paraffin-embedded tissue blocks by using 
a tissue microarrayer (Beecher Instruments). POLE exonuclease domain mutations were 
detected by Sanger sequencing of exons 9, 13, and 14 (primer details in Supplementary 
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Table 1). Microsatellite instability (MSI) was determined using the Promega MSI analysis 
system (version 1.2). Tumors with instability in two or more markers were defined as 
being microsatellite-unstable, whereas those with instability in one marker or less were 
classified as microsatellite-stable (MSS). TP53 sequencing of exons 5-8 was performed 
for those cases in which p53 was scored indefinite in immunohistochemistry.
Statistical analyses
Continuous variables were compared using the Kruskal-Wallis and Mann-Whitney U 
tests (with Bonferroni correction for multiple comparisons). Associations between cat-
egorical variables were tested using χ2 statistics or Fisher’s exact test. Logic regression 
was performed on all morphological and immunohistochemical features to identify a 
combination of characteristics that best predict POLE exonuclease domain mutational 
status using the R statistical software package LogicReg version 1.5.9.33,34 For this 
analysis, morphological characteristics solid growth, invasion type and lymphovascular 
space were made binary (solid growth: <5% vs. ≥5%; invasion type: broad front vs. other; 
lymphovascular space invasion: absent or focal vs. substantial). All included endometrial 
cancers were randomly split into a training (N=88) and test set (N=45). Leave-one-out 
cross-validation was performed on the training set to determine the optimal size of the 
logic model (number of leaves with the lowest misclassification rate). This number and 
a simulated annealing search algorithm were used to find the best Boolean combina-
tion of characteristics. The performance of the identified model was measured using 
sensitivity and specificity. All reported P values were two-sided with a P value of <0.05 
indicating statistical significance. Statistical tests were performed using IBM SPSS Statis-
tics software (version 23) and R (R Core Team (2013) – http://R-project.org/).
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Supplementary Figure 1. Immunohistochemistry for keratin and β-hCG on a POLE-mutant endometrial 
cancer.
The tumor giant cells are keratin-positive, indicating an epithelial origin (A) and β-hCG-negative, suggest-
ing they are not syncytiotrophoblastic cells (B, both magnifi cation: x20).
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Supplementary table 1. PCR primer details of POLE exon 9, 13 and 14 Sanger sequencing.
target (residues) Primer name Primer sequence Primer used for 
sequencing
Exon 9 POLE-Ex9Fw 5’– tgcttattttgtccccacag – 3’ Forward
(268-303) POLE-Ex9Rv 5’– tacttcccagaagccacctg – 3’ Reverse
Exon 13 POLE-Ex13Fw 5’– tctgttctcattctccttccag – 3’ Forward
(410-453) POLE-Ex13Rv 5’– cgggatgtggcttacgtg – 3’ Reverse
Exon 14 POLE-Ex14Fw 5’– tctggcgttctctcctcag – 3’ Forward
(454-491) POLE-Ex14Rv 5’– cgacaggacagataatgctcac – 3’ Reverse
Supplementary table 2. POLE exonuclease domain mutations identified in the study cohort.







Supplementary table 3. Invasion type, presence of eosinophilic metaplasia and morule in POLE-mutant 















Invasion type 0.325 0.162
No infiltration 0 (0.0) 1 (1.5) 0 (0.0) 1 NA
Broad front invasion 26 (51.0) 27 (40.3) 3 (20.0) 0.248 0.042
Infiltrating glands 20 (39.2) 36 (53.7) 10 (66.7) 0.118 0.080
MELF 4 (7.8) 3 (4.5) 2 (13.3) 0.464 0.612
Adenomyosis-like 1 (2.0) 0 (0.0) 0 (0.0) 0.432 1
Eosinophilic metaplasia
Absent 49 (96.1) 65 (97.0) 15 (100) 1 1
Present 2 (3.9) 2 (3.0) 0 (0.0)
Morules
Absent 51 (100) 64 (95.5) 15 (100) 0.257 NA
Present 0 (0.0) 3 (4.5) 0 (0.0)
*For the morphological characteristics, the number and percentage of cases in each category are shown 
for the included molecular/histopathological subgroups. The included subgroups are: POLE-mutant, POLE-
wild-type endometrioid (microsatellite-unstable, p53-mutant or with no specific molecular profile), and 
POLE -wild-type serous endometrial cancer.
‡P values are calculated over POLE -mutant and POLE-wild-type endometrioid (POLE vs. endometrioid) or 
over POLE-mutant and POLE-wild-type serous (POLE vs. serous) endometrial cancers, respectively.
Abbreviations: MELF – microcystic elongated and fragmented, NA – not applicable.
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Supplementary table 4. Mismatch repair protein expression based on immunohistochemistry in the mo-

















Wild-type 47 (92.2) 4 (11.4) 31 (96.9) 15 (100)
Subclonal loss 3 (5.9) 1 (2.9) 1 (3.1) 0 (0.0)
Loss 1 (2.0) 30 (85.7) 0 (0.0) 0 (0.0)
PMS2 
Wild-type 46 (90.2) 4 (11.4) 31 (96.9) 15 (100)
Subclonal loss 2 (3.9) 2 (5.7) 1 (3.1) 0 (0.0)
Loss 3 (5.9) 29 (82.9) 0 (0.0) 0 (0.0)
MSH2
Wild-type 51 (100) 30 (85.7) 32 (100) 15 (100)
Subclonal loss 0 (0.0) 1 (2.9) 0 (0.0) 0 (0.0)
Loss 0 (0.0) 4 (11.4) 0 (0.0) 0 (0.0)
MSH6
Wild-type 51 (100) 29 (82.9) 32 (100) 15 (100)
Subclonal loss 0 (0.0) 2 (5.7) 0 (0.0) 0 (0.0)
Loss 0 (0.0) 4 (11.4) 0 (0.0) 0 (0.0)
MMR status
Wild-type 46 (90.2) 1 (2.9)* 31 (96.9) 15 (100)
MLH1 & PMS2 (subclonal) loss 5 (9.8) 30 (85.7) 1 (3.1)‡ 0 (0.0)
MSH2 & MSH6 (subclonal) loss 0 (0.0) 4 (11.4) 0 (0.0) 0 (0.0)
*This endometrial cancer with positive expression in immunohistochemistry of the mismatch repair pro-
teins is considered microsatellite-unstable based on the presence of an MSI-high phenotype (Promega MSI 
analysis system).
‡Microsatellite instability assay (Promega MSI analysis system) showed a microsatellite-stable phenotype in 
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Recent studies have shown that 7 to 12% of endometrial cancers are ultramutated due 
to somatic mutation in the proofreading exonuclease domain of the DNA replicase 
POLE. Interestingly, these tumors have an excellent prognosis. In view of the emerging 
data linking mutation burden, immune response and clinical outcome in cancer, we 
investigated whether POLE-mutant endometrial cancers showed evidence of increased 
immunogenicity.
methods
We examined immune infiltration and activation according to tumor POLE proofreading 
mutation in a molecularly defined endometrial cancer cohort including 47 POLE-mutant 
tumors. We sought to confirm our results by analysis of RNAseq data from the TCGA 
endometrial cancer series and used the same series to examine whether differences in 
immune infiltration could be explained by an enrichment of immunogenic neoepitopes 
in POLE-mutant endometrial cancers.
results
Compared to other endometrial cancers, POLE mutants displayed an enhanced cytotoxic 
T cell response, evidenced by increased numbers of CD8+ tumor-infiltrating lymphocytes 
and CD8A expression, enrichment for a tumor-infiltrating T cell gene signature, and 
strong upregulation of the T cell cytotoxic differentiation and effector markers T-bet, 
Eomes, IFNG, PRF and granzyme B. This was accompanied by upregulation of T cell ex-
haustion markers, consistent with chronic antigen exposure. In silico analysis confirmed 
that POLE-mutant cancers are predicted to display more antigenic neoepitopes than 
other endometrial cancers, providing a potential explanation for our findings.
Conclusions
Ultramutated POLE proofreading-mutant endometrial cancers are characterized by a 
robust intratumoral T cell response, which correlates with, and may be caused by an 
enrichment of antigenic neopeptides. Our study provides a plausible mechanism for the 
excellent prognosis of these cancers.
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IntroduCtIon
Endometrial cancer is the commonest gynecological malignancy in the Western world, 
and affects approximately 150,000 women each year in Europe and the US combined.1 
Endometrial cancers have traditionally been classified into endometrioid and non-
endometrioid tumors according to clinical and histopathological criteria. However, 
recent work has shown that this dualistic model can be improved upon by a molecular 
classification into subgroups that more accurately reflect underlying tumor biology and 
clinical outcome.2,3
One interesting subgroup is the 7-12% of endometrial cancers with somatic mutation 
in the proofreading exonuclease domain of the DNA replicase POLE.2,4-6 Polymerase 
proofreading is essential for ensuring fidelity of DNA replication,7 and in keeping with its 
dysfunction, POLE proofreading-mutant cancers have a frequency of base substitution 
mutation among the highest in human cancer.2,8,9 POLE-mutant endometrial cancers 
display other distinctive features, including a characteristic mutation signature, with a 
preponderance of C→A transversions and bias for particular amino acid substitutions, 
and strong associations with endometrioid histology, high grade, and microsatellite 
stability (MSS).2,4-6,10 We and others have recently shown that, despite the association 
with high grade, POLE-mutant endometrial cancers have an excellent prognosis.5,6,11 
However, the reasons for this were unclear.
Although the ability of the immune system to suppress malignant disease has long been 
recognized,12 the last few years have seen a remarkable increase in our understanding 
of the complex and dynamic interplay between cancers and the host immune response. 
For example, preclinical and translational studies have confirmed that tumor missense 
mutations can lead to presentation of antigenic neoepitopes by MHC class I molecules, 
resulting in activation of T cell-mediated cytotoxicity.13-16 Consequently, mutations that 
cause strongly antigenic epitopes are likely to undergo negative selection in developing 
tumors.13,14 Cancers also demonstrate multiple alternative mechanisms of immune escape, 
including downregulation of HLA class I expression, and upregulation of immunosuppres-
sive molecules including PD-1/PD-L1, TIM3, LAG3 and TIGIT in a phenomenon referred 
to as adaptive immune resistance.17,18 Despite this, it is clear that in many cancers, the 
immune system retains a degree of control over tumor growth – illustrated by the associa-
tion between increased density of tumor-infiltrating lymphocytes (TILs), particularly CD8+ 
cytotoxic T cells, and favorable outcome in multiple cancer types, including endometrial 
cancer.19-22 Interestingly, a recent study has shown that CD8+ cell infiltration correlates 
strongly with the number of predicted antigenic mutations in tumors,23 suggesting 
that the immunogenicity of cancers is determined at least partly by their mutational 
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burden.24 These data are consistent with the observations that hypermutated, micro-
satellite-unstable (MSI) endometrial and colorectal cancers typically display greater TIL 
density than other tumors.25,26
During our previous studies,4-6 we noted that POLE-mutant endometrial cancers fre-
quently displayed strikingly high TIL density, often accompanied by a Crohn-like reac-
tion. Similar observations have recently been reported following pathological review 
of POLE-mutant TCGA endometrial cancers.27 We hypothesized that this may represent 
infiltration by cytotoxic T lymphocytes, which could in turn contribute to the favorable 
prognosis of these tumors. We also speculated that this might relate to an increase in an-
tigenic neoepitopes in POLE-mutant endometrial cancers secondary to ultramutation. 
We tested this using a molecularly defined cohort of endometrial cancers, including 47 
POLE-mutant tumors, and the recently published TCGA series.2
mAterIAlS And methodS
Patients and tumors
Tumors were selected from the PORTEC-1 and PORTEC-2 studies (n=5728,29) and en-
dometrial cancer series from the Leiden University Medical Center (LUMC, Leiden, the 
Netherlands; n=67) and the University Medical Center Groningen (UMCG, Groningen, 
the Netherlands; n=26), to provide similar numbers of low- (grade 1/2) and high-grade 
(grade 3) tumors of the common molecular subtypes: POLE-wild-type, microsatellite-
stable (MSS); POLE-wild-type, MSI; and POLE (proofreading)-mutant (Supplementary 
Table 1). All cases were of endometrioid histology (EEC), and all POLE-mutant tumors 
were MSS. Of 373 cases reported in the TCGA series, 245 had paired whole exome and 
RNAseq data and were informative for this analysis.2 Of these, 197 were EECs, four mixed 
EEC/non-endometrioid endometrial cancers (NEECs), and 44 serous (NEEC) cancers. 
Ethical approval for tumor molecular analysis was granted at the LUMC, UMCG, and by 
Oxfordshire Research Ethics Committee B (Approval No. 05\Q1605\66).
POLE mutation and microsatellite instability status
DNA was extracted from formalin-fixed paraffin-embedded (FFPE) blocks and sequenc-
ing of POLE hot spot exons 9 and 13 (which contain around 90% of pathogenic proof-
reading mutations) was performed in tumors from the PORTEC, LUMC, and UMCG series 
as previously reported.4,5 All mutations were confirmed in at least duplicate PCR reac-
tions. Details of whole exome sequencing performed by the TCGA have been previously 
reported.2 Pathogenic POLE proofreading mutations were defined as somatic variants 
within the exonuclease domain associated with ultramutation and a frequency of C→A 
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transversions of ≥20%.10
MSI status was determined in the PORTEC, LUMC, and UMCG cases by a five-marker 
panel of microsatellites as reported previously,30 with exception of four cases in which 
this failed, where status was determined by MLH1, MSH2, MSH6, and PMS2 immuno-
histochemistry (IHC).6 Determination of MSI in the TCGA series was by a seven-marker 
panel, with MSI-High defined as alteration at three or more markers.2 Classification of 
POLE-mutant TCGA endometrial cancers was also informed by results of recent analysis 
of mononucleotide repeats in 48 genes.10 In our analysis, only MSI-high cases were clas-
sified as MSI - we excluded one TCGA case for which MSI status could not be determined. 
The single tumor that displayed both POLE proofreading mutation and MSI by these 
criteria was assigned to the POLE-mutant group on the basis of its characteristic muta-
tion signature, in accordance with a recent report.10
histological assessment
Tumors were evaluated for the presence/absence of TILs and for Crohn-like reaction by a 
gynecological pathologist (T.B.) blinded to other clinicopathological data.
IhC and cell quantification
Following deparaffinization, antigen retrieval, and blocking of peroxidase activity, whole 
slides were incubated overnight at 4°C (CD8, CD3) or room temperature (TIA-1, HLA, FoxP3) 
with primary antibodies against CD8 (1:50, clone C8/144B, DAKO, Agilent technologies), 
CD3 (1:25, clone F7.2.38, DAKO), HCA2 and HC10 (both 1:800, kindly provided by Prof. 
Dr. J. Neefjes, the Netherlands Cancer Institute), FoxP3 (1:100, mAbcam 450, Abcam), and 
TIA-1 (1:400, clone 2G9A10F5, Beckman Coulter). Sections were subsequently incubated 
with either anti-mouse Envision+ reagent (K4000, DAKO) for 30 minutes (CD8 primary), 
RAMpo (1:100) and GARpo (1:100) secondary and tertiary antibodies (CD3 primary), or 
BrightVision-Poly/HRP (Poly-HRP-GAM/R/R; DPV0110HRP; ImmunoLogic; HCA2, HC10, 
FoxP3, and TIA-1) before 3,3-diaminobenzidine (DAB) treatment and hematoxylin coun-
terstaining. Slides were then dehydrated and mounted before digitalization (ScanScope, 
Aperio Technologies, or Ultra Fast Scanner 1.6 RA. Philips) and analysis.
CD8+, CD3+, FOXP3+, and TIA-1+ cell numbers were quantified in intraepithelial and 
intrastromal regions in the center of the tumor (CT) and the invasive margin (IM) as 
previously reported.19,22 For each region, the mean number of positive cells in eight 
high-power fields (HPF; 200μm x 200μm) was calculated. For analysis of HLA expression, 
the percentage of tumor cells with membranous HCA2 and HC10 staining was quanti-
fied as previously described.31 In each case, scoring was performed independently by 
two observers, blinded to other clinicopathological data.
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Immunofluorescence
Following deparaffinization, antigen retrieval, and blocking of peroxidase activity, whole 
slides were stained overnight at 4°C with primary antibody against TIA-1 (1:50, ab2712, 
Abcam). Sections were subsequently incubated with anti-mouse Envision+ reagent 
(K4000, DAKO) for 30 minutes and HRP visualized using cyanine 5 tyramide signal am-
plification (TSA) according to the manufacturer’s instructions (PerkinElmer). Next, whole 
slides were stained overnight with primary antibody against CD8 (1:25, clone C8/144B, 
DAKO) and a biotinylated antibody against fibronectin (1:50, ab6584, abcam). Slides 
were incubated with goat anti-mouse AF555 (1:150 Life Technologies) and streptavidin-
dylight488 (1:150, Thermo Scientific), counterstained with DAPI (Life Technologies) and 
mounted in prolong gold mounting medium (Life Technologies). Immunofluorescent 
slides were scanned using a TissueFaxs imaging system (TissueGnostics). Processed 
channels were merged using Adobe Photoshop CS5 (Adobe).
leukocyte methylation scores
Leukocyte methylation scores (syn180922332,33) were downloaded from Synapse (https://
www.synapse.org/) and annotated according to MSI and POLE status.
tCgA rnAseq data
Details of the TCGA RNA sequencing analysis have been previously reported.2 RSEM 
normalized34 and raw RNAseq count data were downloaded from FireBrowse (http://
firebrowse.org/?cohort=UCEC&download_dialog=true) accessed November 11, 2014. 
After removal of normal tissue controls and technical duplicates, 245 samples with RSEM 
normalized and 231 samples with raw count data were informative for analysis.
gene set enrichment analysis
TCGA raw counts were annotated by molecular subtype before normalization and rank-
ing of genes differentially expressed between POLE-mutant (n=16) and other (n=205) 
endometrial cancers using DESeq.35 Gene set enrichment analysis (GSEA36) was then 
performed with the PreRanking setting, using GO Biological Processes and C7 Immu-
nologic Signatures sets from the Molecular Signatures Database (MSigDB; http://www.
broadinstitute.org/gsea/msigdb/genesets.jsp?collection=BP), and a published 200-
gene T cell tumor infiltration gene signature.18
Prediction of antigenic neoepitopes
We created an algorithm to estimate the immunogenicity of individual tumors taking 
into account the following considerations: (i) to generate a functional neoepitope, a mis-
sense mutation must be expressed; (ii) most functional neoepitopes identified to date are 
predicted to bind MHC class I molecules (IC50<500 nmol/L) by NetMHCPan;23,37,38 and (iii) 
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the likelihood that a neoepitope is antigenic is reduced if the corresponding wild-type 
peptide also binds the MHC with similar affinity as T cells to the epitope may be centrally 
deleted or tolerized.39 Our strategy was similar to others reported recently.15,23,38,40 For 
each tumor, we calculated all possible 9mers for every missense mutation in expressed 
genes (defined as nonzero reads from RNAseq) and calculated the binding affinity of 
the mutant and corresponding wild-type peptide for HLA-A*02:01 (as a single model 
example HLA allele) using NetMHCPan 2.8.37 In the event that several peptides had an 
IC50<500 nmol/L, the strongest binder was used for analysis. We defined antigenic muta-
tions as neoepitopes predicted to bind MHC molecules (IC50<500 nmol/L) for which the 
corresponding wild-type peptide was not predicted to bind MHC (IC50>500 nmol/L).
Statistical analyses
We used the nonparametric Mann–Whitney U test for all comparisons of continuous data 
and Spearman rho to analyze correlation between variables. Categorical variables were 
compared using the Fisher exact test. All statistical tests were two sided, with a P value 
of <0.05 taken to indicate significance. Except where indicated, statistical tests were 
unadjusted. Statistical analyses were performed using STATA and Prism 6.0 (GraphPad).
reSultS
POLE proofreading-mutant endometrial cancers show increased lymphocytic 
infiltrate
Preliminary analysis of hematoxylin and eosin-stained sections suggested that POLE 
proofreading-mutant endometrial cancers frequently displayed a prominent lympho-
cytic infiltrate and Crohn-like lymphocytic reaction (Supplementary Figure 1A-B). Formal 
quantification of this in a set of 150 endometrial cancers comprising approximately equal 
numbers of POLE proofreading-mutant/microsatellite stable (POLE-mutant), POLE-wild-
type/MSI, and POLE-wild-type/MSS subtypes of low and high grade (Supplementary 
Table 1), confirmed that TILs were more frequent in POLE-mutant (22/47) than in both 
MSS (8/54; P=0.0009, Fisher exact test), and MSI (10/49; P=0.009) subtypes (Supplemen-
tary Figure 1C). Crohn-like reaction was also significantly more common in POLE-mutant 
than other tumors (P<0.001 both comparisons; Supplementary Figure 1D).
Increased density of intratumoral Cd8+ lymphocytes in POLE-mutant 
endometrial cancers
Mindful of the relationship between cytotoxic T cell infiltrate and favorable cancer 
outcome,19-22 and the excellent prognosis of POLE-mutant endometrial cancers,5,6,11 we 
next examined whether POLE mutants showed evidence of increased T cell infiltrate in 
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our endometrial cancer cohort. While as anticipated,25 CD8+ cell numbers in intraepi-
thelial and intrastromal compartments in the CT and the IM were higher in MSI than 
MSS endometrial cancers (P<0.0001 for all comparisons, Mann–Whitney U test), in POLE-
mutant tumors, the density of CD8+ infiltrate was frequently striking (Figure 1A), and 
significantly exceeded that of both MSS (P<0.0001 for all four regions) and MSI cancers 
in the CT (median 5.9 vs. 2.6 intraepithelial CD8+ cells per HPF, P=0.001; 26.0 vs. 13.5 
intrastromal CD8+ cells, P=0.002; Figure 1B). Furthermore, the proportion of tumors with 
numbers of CD8+ cells exceeding the median in all four regions was substantially higher 
in POLE-mutant (60.0%) than MSI (31.3%, P=0.007, Fisher exact test) and MSS tumors 
(7.2%, P<0.0001). Staining for CD3 and the cytolytic marker TIA-1 in a subset of cases 
confirmed increased T cell density in POLE-mutant tumors (Supplementary Figure 2A-B) 
and suggested that the infiltrate contained lymphocytes capable of cytotoxic activ-
ity (Supplementary Figure 3A-B). Co-immunofluorescence confirmed co-expression of 
TIA-1 in the CD8+ lymphocytes comprising the POLE-mutant tumor infiltrate (Figure 
2A–F), further supporting the conclusion that these cells were capable of mediating an 
antitumor effect.
Interestingly, in light of the correlation previously reported between B cell and T cell 
subsets at the IM,41 we found that dense CD20+ stromal infiltrate in this region was more 
common in POLE mutants (Supplementary Figure 4A), while a tendency to increased 
numbers of FOXP3+ cells in both MSI and POLE-mutant tumors (Supplementary Figure 
4B) was also notable, given that this has been associated with favorable cancer progno-
sis in some studies.41
Cytotoxic t cell infiltration and activation in POLE-mutant endometrial cancers 
in tCgA series
We sought to confirm our results using the TCGA endometrial cancer series,2 in which 
the improved clinical outcome of POLE-mutant tumors was first suggested (Figure 
3A). Of 244 informative tumors in this study, 157 were MSS, 69 MSI, and 18 POLE 
proofreading-mutant (the single tumor with both POLE proofreading mutation and MSI 
was categorized as POLE-mutant according to its mutation spectrum, in keeping with 
a recent report10). Forty-three of the MSS tumors were NEECs, while all MSI and POLE-
mutant endometrial cancers cases were EECs (Supplementary Table 1).
We first examined leukocyte methylation scores, which estimate the proportion of a het-
erogeneous tumor sample that consists of leukocytes.32,33 After confirming that scores 
correlated strongly with CD8A expression (ρ=0.65, P<0.0001), we noted that, following 
exclusion of MSI and POLE-mutant tumors, both leukocyte methylation scores and CD8A 
expression did not differ between EECs and NEECs (P=0.52 and P=0.16 respectively, 
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Figure 1. Increased CD8+ lymphocyte infiltration in POLE-mutant endometrial cancers.
(A) Results of CD8 IHC by endometrial cancer molecular subtype shown at low magnification (top) and high 
power views of the center of the tumor (CT) and invasive margin (IM). Arrows highlight intraepithelial CD8+ 
cells in POLE-mutant tumor. Scale bars, 500 μm (upper panel in A) and 100 μm (middle and bottom panels 
in A). (B) Quantification of CD8+ cell number in intraepithelial and intrastromal compartments in the CT 
and IM by endometrial cancer molecular subtype. Boxes represent the interquartile range (IQR), with the 
upper whisker indicating the 75th percentile plus 1.5xIQR, and the lower whisker the 25th percentile minus 
1.5xIQR. The median and mean values are indicated by a horizontal line and cross, respectively. Statistical 
comparison between groups was made by the unadjusted two-sided Mann–Whitney U test; *, **, and *** 
indicate P<0.05, P<0.01, and P<0.001, respectively.
92 Chapter 4
Mann–Whitney U test).We therefore included tumors of both histologies in the MSS 
cohort in all subsequent analyses. Leukocyte methylation scores were similar in MSI and 
MSS tumors (median 15.5% vs. 14.2%, P=0.2), in contrast with a significant increase in 
POLE mutants (median 23.3%; P=0.006 vs. MSS, P=0.07 vs. MSI; Figure 3B), concordant 
with our previous results. Given the biological differences between NEECs and EECs, we 
formally confirmed that these results were essentially unaltered following exclusion of 
the former from the MSS group (median 14.7%, P=0.008 vs. POLE-mutant endometrial 
cancers).
We proceeded to explore whether infiltration of POLE-mutant endometrial cancers by 
cytotoxic T cells was manifest as immune expression signatures and/or increased ex-
pression of key immunological genes. Agnostic pathway analysis of TCGA RNAseq data 
by GSEA demonstrated significant enrichment of immune-related pathways in POLE-
mutant endometrial cancers compared with other tumors, including Immune Response 
(normalized enrichment score (NES) 4.12 FDR q<0.0001) and Immune System Process 
(NES 3.77, q<0.0001). GSEA also confirmed that POLE-mutant cancers showed striking 
enrichment of a recently reported, highly specific 200-gene signature corresponding to 
tumor T cell infiltration (Figure 3C).18



















Figure 2. CD8+ TILs in POLE-mutant tumors show cytolytic potential.
(A) Low-magnification image of POLE-mutant tumor following co-immunofluorescence (co-IF) staining for 
DAPI (nuclei), fibronectin (extracellular matrix), CD8, and the cytolytic marker TIA-1. (B-F) Co-IF images of 
the tumor center following staining for all markers (B), DAPI (C), CD8 (D), and TIA-1 (E) confirming co-expres-
sion of TIA-1 by tumor-infiltrating CD8+ lymphocytes, also shown at high magnification (F).
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CXCL9  4.3 <0.0001 0.03
CXCL10  3.5 0.002 0.03
Eomes  2.3 0.008 0.05
P<0.0001
Figure 3. Clinical outcome and T cell response according to tumor molecular subtype in TCGA endometrial 
cancers.
(A) Kaplan–Meier curves demonstrating recurrence-free survival of POLE wild-type, MSS (N=147), MSI 
(N=63), and POLE proofreading domain-mutant (POLE, N=18) endometrial cancers in the TCGA series (note 
that survival data were not available for all cases). (B) Comparison between subgroups was made by the 
two-sided log-rank test. Leukocyte methylation scores according to endometrial cancer molecular subtype. 
Unadjusted comparison between groups was made by the two-sided Mann–Whitney U test. (C) GSEA of 
200-gene tumor-associated T-cell signature18 in POLE-mutant endometrial cancers compared with other 
tumors. Raw RNAseq counts were normalized and ranked using DESeq before GSEA analysis with PreRank-
ing. (D) Heatmap showing expression of immunologic genes according to endometrial cancer molecular 
subtype. RSEM-normalized RNAseq expression data were log2 transformed, zero centered and assigned 
unit variance. For each gene, the mean fold change in expression in POLE mutants relative to MSS endome-
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Focused analysis of genes involved in T cell-mediated cytotoxicity confirmed that, 
compared with MSS tumors, MSI endometrial cancers had higher expression of CD8A 
(2.1-fold, P=0.0005) and IFNγ (2.1 fold, P=0.0006) though expression of the cytotoxic dif-
ferentiation and activation markers T-bet (TBX21), Eomes, perforin, and granzymes B,H,K 
and M was either essentially unchanged (≤1.1-fold) or not significantly increased. In con-
trast, and once again consistent with our previous results, POLE mutants demonstrated 
substantial upregulation of CD8A (3.0-fold vs. all MSS tumors, P=0.002; 3.2-fold vs. MSS 
EECs only, P=0.004), accompanied by significant increases in T-bet (1.9-fold, P=0.006), 
Eomes (2.3-fold, P=0.008), IFNG (3.6-fold, P=0.0003), PRF (2.5-fold, P=0.001), granzymes 
B, H, K,and M (1.6- to 2.3-fold, P=0.002–0.02), and the IFNγ-induced cytokines CXCL9 
(4.3-fold, P<0.0001) and CXCL10 (3.5-fold, P=0.002; Figure 3D and Supplementary Figure 
5). Upregulation of most of these genes in tumors has been shown to predict good 
prognosis.19,41 POLE mutants also demonstrated striking upregulation of the T follicular 
helper genes CXCL13 (7.0-fold, P=0.0001) and CXCR5 (3.9-fold, P=0.0004), which have re-
cently been shown to strongly predict favorable outcome in colorectal cancer.41 Notably, 
despite limited numbers, in several cases, expression of cytotoxic markers and cytokines 
exemplifying effector status in POLE mutants significantly exceeded that in MSI tumors 
(e.g., PRF, P=0.02; GZMH P=0.04; CXCL9/10 both P=0.03; Figure 3D and Supplementary 
Figure 5). Collectively, these data not only corroborated our previous finding that POLE-
mutant tumors had greater T lymphocyte infiltration than other endometrial cancers, 
but also strengthened the conclusion that these lymphocytes were capable of exerting 
antitumor activity.
mechanisms of immune escape in POLE-mutant endometrial cancers
POLE-mutant cancers have significantly better prognosis than other endometrial can-
cers,5,6,11 as evidenced by the absence of recurrences in the TCGA series.2 However, the 
presentation of all patients in this study with clinically detectable tumors, in some cases 
with lymphatic spread, indicates that any immune response was, at best, only partially 
successful in suppressing POLE-mutant endometrial cancer growth. We therefore ex-
plored potential mechanisms of immune escape in these tumors.
We first considered the possibility that POLE-mutant endometrial cancers may escape 
from immune surveillance by loss or inactivation of components required for antigen 
presentation. Although 31.8% of POLE-mutant endometrial cancers in our study set 
of 150 endometrial cancers showed loss of HLA class I protein expression by IHC, this 
was not significantly different to that observed in MSI (28.6%, P=0.82, Fisher exact test) 
trial cancers was calculated and expression compared between POLE mutants, MSS, and MSI endometrial 
cancers by the unadjusted, two-sided Mann–Whitney U test; **P<0.01.
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or MSS tumors (20.0%, P=0.24) and was not reflected in increased CD8+ cell numbers. 
Similarly, although we found a tendency to overrepresentation of POLE mutants among 
TCGA endometrial cancers with HLA class I gene expression in the lowest quartile, this 
was also not significantly different from other molecular subtypes (P=0.07 vs. MSS).
Interestingly, although mutations in MHC pathway components were common in POLE-
mutant tumors in the TCGA series, most were of unlikely pathogenicity, with exception 
of two tumors with potentially functional variants. The first, a β2-microglobulin R117* 
mutation also detected in a POLE-mutant colorectal cancer,9 had a variant allele fraction 
of 0.59 and is likely to affect stability of the MHC complex by disruption of the interaction 
with the HLA heavy chain.42 The second, an HLA-B S112R substitution with variant allele 
fraction 0.71, lies near the F pocket essential for peptide display, and is predicted to be 
deleterious by both Mutation Assessor and SIFT (Supplementary Table 2). However, the 
effect of each variant on antigen presentation is, at present, uncertain.
We proceeded to examine whether the cytotoxic T cell response in POLE-mutant endo-
metrial cancers may be attenuated by upregulation of immunosuppressive mediators - a 
phenomenon termed adaptive immune resistance.17 We found that the T cell exhaus-
tion markers LAG3, TIM-3, and TIGIT, and the T cell inhibitors PD-1 and CTLA-4, were 
strongly correlated with CD8A expression across all endometrial cancers of all molecular 
subtypes (ρ=0.65 to 0.87; P<0.0001 for all cases), though the correlation with PD-L1 was 
more modest (ρ=0.34, P<0.0001; Supplementary Figure 6A). Interestingly, although 
expression of these markers in MSI compared with MSS endometrial cancers was either 
unchanged/minimally altered (TIM-3, CTLA4, PD-L1) or moderately increased (LAG3 
1.9-fold, P<0.002; TIGIT 2.2-fold, P<0.0001), in POLE mutants all were significantly and 
substantially upregulated (e.g., LAG3 2.9-fold, P<0.0001 vs. MSS, P<0.02 vs. MSI; TIGIT 
3.6-fold, P<0.0001 vs. MSS, P<0.15 vs. MSI; Figure 3D and Supplementary Figure 6B), 
consistent with prolonged antigen stimulation. However, as noted above, the overall 
increase in expression of cytotoxic effector markers suggested that this upregulation 
was insufficient to fully suppress the T cell response in POLE mutants.
POLE proofreading-mutant endometrial cancers are likely to display increased 
numbers of antigenic neopeptides
We hypothesized that the T cell response in POLE-mutant endometrial cancers might be 
due to an excess of antigenic neoepitopes as a consequence of ultramutation. To quan-
tify this, we analyzed the TCGA endometrial cancer series using a methodology similar 
to several recent studies.23,40 Our algorithm was based on three assumptions: first, that 
a mutation must be in an expressed gene to exert an effect; second, for a neopeptide to 
act as an antigen, it must bind MHC class I molecules (IC50<500 nmol/L); and third, that 
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neopeptides for which the corresponding wild-type peptide also binds MHC molecules 
are less likely to be immunogenic due to central deletion or tolerization.39
Applying these criteria, we found that 5.9% (7,880/134,473) of the total number of mis-
sense mutations in TCGA endometrial cancers were predicted to be potentially antigenic. 
Of these, 73% (5767) occurred in POLE-mutant tumors, reflected in a significantly higher 
number of antigenic mutations per cancer compared with both MSI and MSS subtypes 
(median 365.5 vs. 16 vs. 2 respectively, P<0.0001 for all comparisons, Mann–Whitney U 
test; Figure 4A), though this is likely to underestimate the number of antigenic mutations 
in MSI tumors as frameshift mutations were not included in our analysis. A substantial 
majority of antigenic mutations were in tumors with greater than median CD8A expres-
sion in both the whole series (78.4%), and the POLE-mutant subgroup (83.9%), though 
the strength of correlation between the two variables was modest, possibly as a result 




































































Figure 4. Antigenic mutation burden and tumor CD8A expression according to POLE mutation.
(A) The number of mutations predicted to generate antigenic neopeptides in individual TCGA tumors was 
calculated using exome and RNAseq data (see Materials and methods). Box and whisker plots signify IQR ± 
1.5xIQR, mean and median as previously. Comparison between groups was made by the unadjusted two-
sided Mann–Whitney U test. (B) Relationship between number of antigenic missense tumor mutations and 
tumor CD8A expression. POLE-mutant samples are highlighted in gray, together with possible mechanisms 
of immune escape in two cases; ***P<0.0001.
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dISCuSSIon
By complementary analysis of two independent series totaling nearly 400 patients, and 
including over 60 POLE proofreading-mutant tumors, we have shown that POLE-mutant 
endometrial cancers are characterized by a striking CD8+ lymphocytic infiltrate, a gene 
signature of T cell infiltration, and marked upregulation of cytotoxic T cell effector mark-
ers. Furthermore, we show that, as a consequence of their remarkable mutation burden, 
POLE proofreading-mutant cancers are predicted to display substantially more antigenic 
peptides than other tumors, providing a possible explanation for our findings. Although 
our data demonstrate correlation rather than causation, the strong association between 
cytotoxic lymphocyte infiltration and favorable outcome in multiple cancers19-22,41 leads 
us to speculate that an enhanced T cell antitumor response may contribute to the excel-
lent prognosis of POLE-mutant endometrial cancers.
During the last few years, a combination of next generation sequencing technology, 
improved in silico peptide-MHC-binding prediction,37 and the clinical application of 
immune checkpoint inhibitors43-45 have helped facilitate remarkable insights into the 
mechanisms of tumor immunoediting and immune escape. The intriguing observation 
that clinical benefit from CTLA-4, PD-1, and PD-L1 inhibition is greater in melanoma 
and cigarette smoking-associated lung cancer than most other malignancies can now 
be interpreted in light of the understanding that in these highly mutated tumors, 
adaptive immune resistance is a key enabler of disease progression,17 and its inhibition 
can restore the ability of T cells to respond to antigenic peptides presented by these 
cancers.43 In keeping with this, in melanoma response to checkpoint inhibitors has very 
recently been shown to correlate both with the number of predicted antigenic tumor 
mutations,40 and with the degree of cytotoxic T lymphocyte tumor infiltration before 
treatment.46 In light of these data, the association between the number of predicted 
antigenic peptides and T cell response in POLE-mutant endometrial cancers in our study 
is noteworthy, as is the marked increase in T cell exhaustion markers, as these have 
recently been shown to identify tumor neoantigen–specific CD8+ cells in patients with 
cancer.47,48 Despite upregulation of these immunosuppressors in POLE-mutant endome-
trial cancers, we also found substantial increases in cytotoxic differentiation markers and 
effectors suggesting that the degree of adaptive immune resistance in these cancers may 
be insufficient to fully suppress CD8+ T cell cytotoxicity.49 Collectively, our data suggest 
a complex interaction between the antigenic landscape of POLE-mutant endometrial 
cancers and the immune response. In this regard, molecular analysis of recurrences from 
the few patients with POLE-mutant endometrial cancers who do experience relapse 
may provide insights into mechanisms of immune escape. Finally, these patients may 
be good candidates for immune checkpoint inhibitor therapy, as might those patients 
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with POLE proofreading-mutant tumors of other histologies, for which outcomes are 
more uncertain.
Interestingly, while as anticipated we observed moderately increased T cell infiltration 
in MSI tumors,25 this was not associated with the marked increase in cytotoxic effec-
tor markers seen in POLE mutants. Although some studies have reported improved 
prognosis of MSI endometrial cancers, this is inconsistent,50 in contrast with the clear 
association of MSI with favorable outcome in early colorectal cancer.26 Comparison of 
the immune response between MSI tumors of both types may provide insights into this 
discordance.
Our study has limitations. Because of differing sample preservation (FFPE vs. fresh 
frozen), we were unable to validate either the IHC or RNAseq analysis between series, 
although the results from both analyses were highly concordant. Furthermore, the ret-
rospective nature of our study meant that we were unable to investigate the repertoire 
and antigen response of T cells in patients with POLE-mutant cancers. This and other 
functional analyses will require prospective investigation.
In summary, we have demonstrated that ultramutated POLE proofreading-mutant 
endometrial cancers are characterized by a robust intratumoral T cell response, which 
correlates with, and may be caused by an enrichment of antigenic neopeptides. Our 
study provides a plausible mechanism for the excellent prognosis of these cancers, and 
further evidence of the link between somatic mutation and immunoediting in cancers.
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Supplementary Figure 1. Tumor-infiltrating lymphocytes and Crohn-like reaction in POLE-mutant endo-
metrioid endometrial cancers.
(A) Representative H&E-stained sections demonstrating tumor-infiltrating lymphocytes (TILs) in POLE-wild-
type, microsatellite-stable (MSS), POLE-wild-type, microsatellite-unstable (MSI) and POLE proofreading 
domain-mutant (POLE) ECs in both low- and high-grade tumors. Scale bar corresponds to 50μm. (B) Rep-
resentative H&E stained section demonstrating Crohn-like reaction (indicated by arrows) in a POLE-mutant 
tumor. Scale bar corresponds to 500μm. (C) Frequency of lymphocytic infiltrate by EC molecular subtype. 
(D) Frequency of Crohn-like reaction by EC molecular subtype. Comparison between groups in C and D was 



























































































Supplementary Figure 2. CD3+ tumor infiltrate according to EC molecular subtype.
(A) Representative images of CD3+ staining in microsatellite-stable and -unstable POLE-wild-type cancers 
(MSS & MSI) compared to a POLE proofreading domain-mutant (POLE) tumor at low magnification (upper 
panels) and high magnification in the center of the tumor (CT) and invasive margin (IM) (middle and lower 
panels). Scale bar in upper panel indicates 500μm, bar in middle and lower panels indicates 100μm. (B) 
Quantification of CD3+ cell numbers per high power (200 x 200μm) field in intraepithelial and intrastromal 
compartments within the center of the tumor (CT) and invasive margin (IM) according to EC molecular sub-
type. Horizontal bars indicate the median. Comparison between groups was made by unadjusted Mann-
Whitney test; * and ** indicate P<0.05, and P<0.01, respectively.
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Supplementary Figure 3. Number of TIA-1+ cytolytic T cells according to molecular subtype.
(A) Representative high magnification image of TIA-1+ staining in a POLE proofreading domain-mu-
tant (POLE) tumor. Scale bar indicates 50μm. (B) Quantification of TIA-1+ cell numbers per high power 
(200x200μm) field in intraepithelial and intrastromal compartments within the center of the tumor (CT) 
and invasive margin (IM) for MSS, MSI and POLE-mutant tumors. Horizontal bars indicate the median. Com-




















































































































Supplementary Figure 4. CD20+ and FOXP3+ tumor infiltrate according to EC molecular subtype.
(A) Percentages of tumors displaying dense intrastromal CD20+ infiltrate in the center of the tumor (CT) 
and invasive margin (IM). (B) Quantification of number of FOXP3+ cells in tumor regions by EC molecular 
subtype. Horizontal bars indicate the median. Statistical comparisons in A and B were made by unadjusted 
two-sided Mann-Whitney test; * and ** indicate P<0.05 and P<0.01, respectively.
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Supplementary Figure 5. Expression of T cell markers and cytotoxic effectors by EC molecular subtype.
Expression of genes encoding T cell subunits CD8α (CD8A), CD3ε (CD3E), cytotoxic effector molecules in-
terferon γ (IFN), perforin (PRF) and granzyme H (GZMH), and IFNγ-induced cytokines CXCL9 and CXCL10 
was compared between molecular subtypes using RSEM normalized TCGA RNAseq data. Box and whiskers 
signify IQR ± 1.5xIQR, mean and median as previously. Statistical comparison between groups was made by 
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Supplementary Figure 6. T cell exhaustion markers according to tumor CD8A expression and EC molecu-
lar subtype.
(A) Correlation between CD8A expression and T cell exhaustion markers (P<0.0001, all cases). (B) T cell ex-
haustion makers according to EC molecular subtype. Box and whiskers signify IQR ± 1.5xIQR, mean and 
median as previously. Statistical comparison between groups was made by unadjusted Mann-Whitney test; 
*, **, and *** correspond to P<0.05, P<0.01, and P<0.001, respectively.
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POLE mutations and immune response in endometrial cancer
Supplementary table 1. Demographic and clinicopathological characteristics of cases by EC
molecular subtype.
mSS mSI POLE total
PorteC, lumC & umCg cases
Age, median (range), years 62.5 (36-84) 68.8 (35-89) 63.5 (46-82) 65.0 (35-89)
FIGO stage (2009), n
I/II 48 39 45 132
III/IV 6 10 2 18
Grade, n
1/2 45 39 33 117
3 9 10 14 33
Type, n
EEC 54 49 47 150
NEEC 0 0 0 0
Total, n 54 49 47 150
tCgA series*
Age, median (range), years 64 (34-90) 63 (35-88) 57 (33-87) 63 (33-90)
FIGO stage (2009), n
I/II 116 57 14 187
III/IV 40 12 4 56
Unknown 1 1 0 2
Grade, n
1/2 97 45 9 151
3 60 24 9 93
Type, n
EEC 114 69 18 201
NEEC 43 0 0 43
Total, n 157 69 18 244
*TCGA analysis excludes one NEEC for which MSI status could not be determined. Secondly, all POLE-proof-
reading mutant ECs were MSS with exception of one TCGA tumor (TCGA-AP-A051) which was assigned to 
the POLE-mutant subgroup on basis of characteristic mutation signature.
Abbreviations: MSS, microsatellite-stable POLE-wild-type; MSI, microsatellite-unstable POLE-wild-type; 
POLE, POLE proofreading-mutant; EEC, endometrioid endometrial cancer; NEEC, non-endometrioid endo-
metrial cancer.
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POLE proofreading mutation, immune response 
and prognosis in endometrial cancer




Endometrial cancers (ECs) with POLE proofreading mutations are typified by ultramuta-
tion and excellent prognosis. We investigated whether these were related, and found 
that POLE-mutant ECs display a robust T cell response that corresponds to an enrichment 
of antigenic tumor neopeptides. Enhanced immunogenicity may explain the favorable 
outcome of POLE-mutant ECs.
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POLE ProoFreAdIng mutAtIon, Immune reSPonSe And PrognoSIS In 
endometrIAl CAnCer
The proofreading exonuclease activity intrinsic to the replicative DNA polymerases epsi-
lon and delta (Pols ε and δ) is essential to maintain fidelity of DNA replication and prevent 
mutagenesis. While a role for defective polymerase proofreading in human cancer has 
long been postulated, this has only recently been confirmed, with the demonstration 
that germline mutations in the exonuclease domains of POLE and POLD1 (which encode 
the principal subunits of Pols ε and δ respectively) predispose to cancer.1 Subsequently, 
we and others have shown that somatic POLE proofreading mutations occur in 7-12% 
endometrial cancers (ECs),2,3 1-2% colorectal cancers (CRCs), as well as cancers of the 
brain, stomach and pancreas (TCGA unpublished, http://www.cbioportal.org, accessed 
June 2015). In keeping with the essential contribution of polymerase proofreading to 
replication fidelity, POLE proofreading-mutant ECs are ultramutated.3 However, perhaps 
less predictably, they also have an excellent prognosis.3,4 We hypothesized that these 
two characteristics may be related – more specifically, that tumor neopeptides caused 
by ultramutation may stimulate an cytolytic immune response, analogous to previous 
observations in hypermutated mismatch repair-deficient CRCs.5 In a recent study,6 we 
investigated this in two large EC cohorts.
Following the observation that POLE proofreading mutants had a higher density of 
tumor-infiltrating lymphocytes (TILs) than other ECs, we confirmed that this represented 
a CD8+ cytotoxic T cell infiltrate likely to be capable of cytolytic activity, as evidenced by 
co-staining for the activation marker TIA-1. Consistent with these data, examination of 
RNAseq data from the independent TCGA EC series confirmed significant enrichment 
for immune-related pathways and a highly specific 200-gene tumor T cell infiltration 
signature in POLE proofreading-mutant ECs. This analysis also demonstrated that POLE-
mutant tumors displayed significantly increased expression of CD8A and other T cell 
cytotoxic differentiation and effector markers known to predict favorable outcome in 
cancer,7 including T-bet, Eomes, IFN-γ, perforin, and granzymes B, H, K and M. Using a 
bioinformatic approach to investigate the possible contribution of antigenic tumor neo-
peptides to the antitumor immune response, we found that POLE proofreading-mutant 
ECs were predicted to display substantially more antigenic peptides than other ECs, 
providing a potential explanation for our findings.
Taken together, our data suggest that enhanced immunogenicity contributes to the 
excellent prognosis of POLE proofreading-mutant ECs, and are concordant with a 
recent study, which showed that dendritic cells pulsed by POLE-mutant tumor lysates 
stimulated greater CD4+ and CD8+ cell proliferation than those pulsed by ECs lacking 
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POLE mutations.8 However, this begs the question of why POLE-mutant ECs are not 
eliminated by this enhanced cytotoxic T cell response? We found no evidence of an 
increased frequency of loss of HLA class I protein expression in POLE-mutant ECs, and 
functional mutations in the antigen presentation machinery also appeared relatively 
uncommon (2 of 18 cases). In contrast, we found striking increases in the expression 
of immunosuppressive checkpoint molecules and regulatory T cell markers, including 
LAG3, TIM-3, TIGIT, PD-1, CTLA-4 and FOXP3, in POLE-mutant ECs, suggesting that this 
may be the principal mechanism of immune evasion in these tumors.
In short, our data suggest that POLE proofreading-mutant ECs evoke a striking antitumor 
immune response, which is likely to contribute at least partly to their excellent prognosis 
(Figure 1). In addition to validating our results in further independent EC series, it will 
be important to determine whether an enhanced cytotoxic T cell reaction also occurs in 
other POLE proofreading-mutant cancers. Interestingly, recent data suggest this may be 
the case in glioblastomas.9 Given the association between benefit from immune check-
point inhibitors and tumor mutation burden,10 our study also suggests that the few 
patients with advanced or recurrent POLE proofreading-mutant cancers may be promis-
ing candidates for these agents. Finally, a pressing question is why some POLE-mutant 
tumors do not appear to stimulate as potent an immune reaction as others? Is it simply 
that these tumors are less mutated? Or do they harbor novel mechanisms of immune 
escape? Thus, while much remains unknown, further study of POLE-mutant cancers may 
provide insights into antitumor immune response and evasion that are generalizable 
more broadly, with potential benefits for a wide range of cancer patients.
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Figure 1. Possible mechanism linking POLE proofreading mutation, immune response and favorable en-
dometrial cancer prognosis.
POLE encodes the catalytic and proofreading subunit of DNA polymerase ε (Pol ε), the leading strand rep-
licase in humans. Cancer-associated POLE exonuclease domain mutations perturb proofreading activity, 
resulting in tumor ultramutation. Enhanced presentation of mutated antigenic neopeptides stimulates 
both a cytolytic T cell response and upregulation of immunosuppressive checkpoints; however, increased 
eff ector cytokine expression (not shown) suggests that the T cell response is functional and at least partly 
contributes to the favorable prognosis of POLE proofreading domain-mutant endometrial cancers.
118 Chapter 3
reFerenCeS
 1. Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, et al. Germline mutations 
affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and 
carcinomas. Nat Genet 2013;45(2):136-144.
 2. Church DN, Briggs SE, Palles C, Domingo E, Kearsey SJ, Grimes JM, et al. DNA polymerase 
epsilon and delta exonuclease domain mutations in endometrial cancer. Hum Mol Genet 
2013;22(14):2820-2828.
 3. The Cancer Genome Atlas Research Network. Integrated genomic characterization of endome-
trial carcinoma. Nature 2013;497(7447):67-73.
 4. Church DN, Stelloo E, Nout RA, Valtcheva N, Depreeuw J, ter Haar N, et al. Prognostic significance 
of POLE proofreading mutations in endometrial cancer. J Natl Cancer Inst 2015;107(1):402.
 5. Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin 
Oncol 2010;7(3):153-162.
 6. van Gool IC, Eggink FA, Freeman-Mills L, Stelloo E, Marchi E, de Bruyn M, et al. POLE proofread-
ing mutations elicit an antitumor immune response in endometrial cancer. Clin Cancer Res 
2015;21(14):3347-3355.
 7. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dy-
namics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 
2013;39(4):782-795.
 8. Bellone S, Centritto F, Black J, Schwab C, English D, Cocco E, et al. Polymerase epsilon (POLE) 
ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer 
patients. Gynecol Oncol 2015;138(1):11-17.
 9. Erson-Omay EZ, Caglayan AO, Schultz N, Weinhold N, Omay SB, Ozduman K, et al. Somatic POLE 
mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis. 
Neuro Oncol 2015;17(10):1356-1364.
 10. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clini-




Immunological profiling of molecularly classified 
high-risk endometrial cancers identifies POLE-
mutant and microsatellite-unstable carcinomas as 
candidates for checkpoint inhibition
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High-risk endometrial cancer (EC) is an aggressive disease for which new therapeutic 
options are needed. Aims of this study were to validate the enhanced immune response 
in highly mutated ECs and to explore immune profiles in other EC subgroups. We 
evaluated immune infiltration in 116 high-risk ECs from the TransPORTEC consortium, 
previously classified into four molecular subtypes: (i) ultramutated POLE exonuclease 
domain-mutant ECs (POLE-mutant); (ii) hypermutated microsatellite-unstable (MSI); (iii) 
p53-mutant; and (iv) no specific molecular profile (NSMP). Within The Cancer Genome 
Atlas (TCGA) EC cohort, significantly higher numbers of predicted neoantigens were 
demonstrated in POLE-mutant and MSI tumors compared to NSMP and p53 mutants. 
This was reflected by enhanced immune expression and infiltration in POLE-mutant and 
MSI tumors in both the TCGA cohort (mRNA expression) and the TransPORTEC cohort 
(immunohistochemistry) with high infiltration of CD8+ (90% and 69%), PD-1+ (73% and 
69%) and PD-L1+ immune cells (100% and 71%). Notably, a subset of p53-mutant and 
NSMP cancers were characterized by signs of an antitumor immune response (43% and 
31% of tumors with high infiltration of CD8+ cells, respectively), despite a low number 
of predicted neoantigens. In conclusion, the presence of enhanced immune infiltra-
tion, particularly high numbers of PD-1 and PD-L1 positive cells, in highly mutated, 
neoantigen-rich POLE-mutant and MSI endometrial tumors suggests sensitivity to im-
mune checkpoint inhibitors.
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IntroduCtIon
The development of novel immunotherapeutic strategies such as checkpoint inhibitors 
has the potential to transform the field of oncology. So far, durable responses have been 
established in subsets of patients, for example with metastatic melanoma, non-small 
cell lung cancer, and mismatch repair-deficient cancers including two patients with 
endometrial cancer (EC).1-7 While the clinical efficacy of immune checkpoint inhibitors is 
evident in a subset of patients, selecting the patients who may benefit from this therapy 
remains challenging. A key mechanism for the benefit of immune checkpoint inhibition 
in these cancers is the induction of a strong neoantigen-driven T cell response against 
the tumor. Indeed, comprehensive analysis of large genomic datasets such as The Cancer 
Genome Atlas (TCGA) have provided a clear link between mutational load and activation 
of the immune system, implicating the involvement of neoantigens in driving cytotoxic 
T cell responses in cancer.8-10 Furthermore, several clinical trials have shown a strong 
association between the presence of high numbers of predicted neoantigens, immune 
infiltration and response to cancer immunotherapy.11-15 In particular, the presence of 
CD8+ cytotoxic T cells and expression of the immune checkpoints PD-1 and PD-L1 have 
been proposed as important predictors of objective tumor regression.3,16 
Characterization of the immune contexture of individual tumors may provide guidance 
in selecting appropriate immunotherapy for each individual patient, especially when 
integrated with an analysis of genomic alterations.10,17,18 A molecular classification has 
recently been proposed by The Cancer Genome Atlas (TCGA), which identified four 
genomically distinct EC subgroups: an ultramutated group characterized by somatic 
mutations in the exonuclease domain of POLE (encoding the catalytic subunit of DNA 
polymerase epsilon), a microsatellite-unstable (MSI) hypermutated group with many 
substitutions as well as insertions and deletions due to mismatch repair deficiency, a 
copy-number high (serous-like) group with frequent TP53 mutation and a copy-number 
low (microsatellite-stable, MSS) group with no specific molecular profile (NSMP).19
In line with this, we, and others, have recently demonstrated high numbers of predicted 
immunogenic mutations and enhanced antitumor immune infiltration in ultramutated 
POLE-mutant and, to a lesser extent, in hypermutated microsatellite-unstable EC.20-23 
These studies combined with the emerging data linking mutational load, immune ac-
tivation and response to cancer immunotherapy render POLE-mutated and MSI cancers 
plausible candidates for immune checkpoint inhibition.3,10-13,24 This is further underlined 
by recent case reports demonstrating the efficacy of anti-PD-1 inhibitors in advanced 
POLE-mutant or mismatch repair-deficient cancers, including those of endometrial 
origin.7,25,26
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In this study, we aimed to validate our previous findings of an enhanced immune re-
sponse in POLE-mutant and MSI endometrial cancers in a cohort of EC patients at high 
risk of recurrence. High-risk EC patients are a particularly relevant subgroup, as most 
have no or only very modest gain from standard local or systemic treatment after sur-
gery. Novel treatment options are therefore urgently needed. The use of a molecularly 
defined cohort of high-risk endometrial cancer also enabled us to explore the immune 
profiles of the poorly characterized NMSP and p53-mutant subgroups. With this ap-
proach we provide a rationale for the administration of checkpoint inhibition strategies 
in subsets of POLE-mutant and MSI endometrial cancer patients.
mAterIAlS And methodS
Selection of patients and tissues 
A previously described cohort of 116 high-risk EC patients was used in the current study 
(Table 1).27 In brief, tumor tissues from high-risk EC patients were selected from partner 
institutions of the TransPORTEC consortium using inclusion criteria of the PORTEC-3 
study. Patients included in the PORTEC-3 had EC with one of the following FIGO 2009 
stages and grade: 1A grade 3 with myometrial- and lymphovascular space invasion; IB 
grade 3; II, IIIA or IIIC; IIIB if only parametrial invasion; stage IA (with invasion), 1B, II or III 
with serous or clear cell histology.28 
Construction of tissue microarray
Morphologically representative paraffin-embedded tissue blocks containing at least 
70% tumor cells were selected by two experienced gynecopathologists (V.S. and T.B.). 
The selected tumor blocks were used to construct (and validate) a Tissue Microarray 
(TMA) as previously described.27 One millimeter-sized tumor (center of the tumor) and 
tumor/stroma (invasive margin) cores of each tumor block were randomly distributed 
on the TMA in triplicate.
Assessment of POLE, mSI, p53 and nSmP status
Classification of patients into the four molecular subgroups was performed as previ-
ously described.27 In brief, tumor DNA isolation was performed fully automated using 
the Tissue Preparation System (Siemens Healthcare Diagnostics).29 Bi-directional Sanger 
sequencing was used to screen exons 9, 13 and 14 of the POLE exonuclease domain for 
somatic mutations. Microsatellite instability and p53 mutational status were determined 
as previously described.27,30 
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Immunohistochemistry 
TMA sections were deparaffinized and rehydrated. Antigen retrieval was performed 
using 0.01M citrate buffer pH 6.0, and endogenous peroxidase activity was blocked. 
Slides were incubated overnight at room temperature (CD3, TIA-1, T-bet and PD-1), for 
one hour at room temperature (CD8, CD20) or overnight at 4°C (CD103) with primary 
antibodies against CD3 (1:100, clone PS-1, Diagnostic BioSystems), CD8 (1:50, clone 
C8/144B, DAKO), CD20 (1:200, clone L26, DAKO), CD103 (1:200, Integrin αEβ7, Abcam), 















Age, mean (range), years 66 (21-85) 61 (49-80) 65 (49-82) 64 (21-84) 71 (45-85) 0.004
Stage, n (%)
I 42 (36.2) 8 (53.3) 5 (26.3) 16 (38.1) 13 (32.5) 0.246
II 21 (18.1) 3 (20.0) 2 (10.5) 12 (28.6) 4 (10.0)
III 41 (35.3) 3 (20.0) 10 (52.6) 11 (26.2) 17 (42.5)
IV 11 (9.5) 1 (6.7) 2 (10.5) 3 (7.1) 5 (12.5)
Unknown 1 (0.9) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.5)
Tumor type, n (%)
Endometrioid 86 (74.1) 14 (93.3) 17 (89.5) 35 (83.3) 20 (50.0) <0.001
Serous 12 (10.3) 0 (0.0) 0 (0.0) 0 (0.0) 12 (30.0)
Clear cell 18 (15.5) 1 (6.7) 2 (10.5) 7 (16.7) 8 (20.0)
Grade, n (%)
1 13 (11.2) 0 (0.0) 2 (10.5) 8 (19.0) 3 (7.5) 0.036
2 5 (4.3) 1 (6.7) 3 (15.8) 1 (2.4) 0 (0.0)
3 98 (84.5) 14 (93.3) 14 (73.7) 33 (78.6) 37 (92.5)
Lymphovascular space invasion, n (%)
Yes 55 (47.4) 6 (40.0) 15 (78.9) 18 (42.9) 16 (40) 0.103
No 40 (34.5) 9 (60.0) 2 (10.5) 18 (42.9) 11 (27.5)
Unknown 21 (18.1) 0 (0.0) 2 (10.5) 6 (14.3) 13 (32.5)
Depth of myometrial invasion, n (%)
<50% 23 (19.8) 4 (26.7) 2 (10.5) 6 (14.3) 11 (27.5) 0.261
>50% 87 (75.0) 11 (73.3) 17 (89.5) 33 (78.6) 26 (65.0)
Unknown 6 (5.2) 0 (0.0) 0 (0.0) 3 (7.1) 3 (7.5)
Adjuvant therapy, n (%)
Yes 82 (70.7 14 (93.3) 15 (78.9) 33 (78.6) 20 (50.0) 0.134
No 10 (8.6 1 (6.7) 1 (5.3) 2 (4.8) 6 (15.0)
Unknown 24 (20.7 0 (0.0) 3 (15.8) 7 (16.7) 14 (35.0)
Characteristics are shown for the whole group, as well as for each of the molecular subgroups analyzed.
Abbreviations: MSI, microsatellite-unstable; NSMP, no specific molecular profile.
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TIA-1 (1:200, clone 2G9A10F5, Beckman Coulter), T-bet (1:400 in 10% normal goat se-
rum, sc-21003, Santa Cruz Biotechnology), PD-1 (1:200, AF1086, R&D), and PD-L1 (1 µg/
mL, clone E1L3N, Cell Signalling Technology). Slides were incubated with BrightVision 
Poly-HRP (poly-HRP-GAM/R/R, DPV0110HRP, Immunologic; CD3, TIA-1, T-bet), a goat 
HRP-polymer kit (GHP516H, Biocare Medical; PD-1), anti-mouse secondary antibody 
(K4007, DAKO, CD8, CD20) or anti-rabbit secondary antibody (K4011, DAKO, CD103) 
for 30 minutes. For CD103, a slightly different method using avidin/biotin blocking 
was used as described previously.31 PD-L1 staining was performed using the Ventrana 
Discovery Ultra Platform for automatic staining, detection was performed using the 
Discovery Amp-HQ kit (tyramide-based amplification). Antibody binding was visualized 
with 3,3’-diamino-benzidine-tetrahydrochloride (DAB) and haematoxylin counterstain-
ing. Slides were dehydrated and mounted before digitalization (Ultra Fast Scanner 1.6 
RA. Philips or ScanScope, Aperio technologies) and analysis.
Quantification of IhC
Total numbers of CD3+, CD8+, CD103+, CD27+, TIA-1+, T-bet+, CD20+, CD45RO+ and PD-1+ 
cell numbers were quantified per core. The percentage of tumor and stroma surface area 
within each core were estimated, and used to extrapolate cell counts to 100% surface 
area. Cores taken from the tumor center were included in the analysis if at least two 
out of the three cores contained >20% tumor. Cores from the infiltrative margin were 
included in the analysis if at least two out of the three cores contained >20% stroma 
and if there was tumor tissue present. Average cell counts per 100% surface area were 
recorded for the tumor center and infiltrative margin. Slides were counted manually 
by two individuals (F.E. and I.G.) that were blinded for other clinicopathological data. 
Interobserver variation was evaluated by Spearman rank correlation (median R2 0.935, 
range 0.682-0.988).
Quantification of PD-L1 was evaluated on tumor-infiltrating immune cells and tumor 
cells as previously described.1 In brief, the proportion of PD-L1 expressing tumor cells 
(tumor score) was noted as a percentage of the total number of tumor cells within that 
core. Due to very low expression of PD-L1 it was decided to consider any expression 
of PD-L1 on tumor cells as positive. Furthermore, the percentage of tumor-infiltrating 
immune cells (immune score) with moderate to strong PD-L1 expression was registered. 
Immune cells were defined positive when cells displayed clearly visible cytoplasmic 
and/or membranous staining. Patients were included in the analysis if at least two out of 
three cores were evaluated; the final score was based on the core with the highest PD-L1 
expression. For the analyses of the immune score, PD-L1 positivity was defined as >1% 
(based on the median score in the cohort).
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Immunofluorescence
Three combinations of multi-color immunofluorescent stainings were performed as 
described previously.32 The first combination consisted of anti-CD163 (polyclonal rabbit, 
ab87099, Abcam), anti-CD68 (monoclonal mouse IgG2a, clone 514H12, ABDserotec) 
and anti-keratin (monoclonal mouse IgG1, clone AE1/AE3, MAB3412, Milipore). The 
second combination consisted of anti-PD-L1 (polyclonal rabbit, clone SP142, Roche) and 
anti-PD-1 (monoclonal mouse IgG1, clone NAT105, Abcam), and the third of anti-CD8 
(mouse monoclonal IgG2b, clone 4B11, Novo Castra) and anti-PD-1 (polyclonal goat, 
R&D systems).
In short, after slides were deparaffinized and rehydrated, antigen retrieval was achieved 
by microwave oven treatment in a Tris-EDTA buffer at pH 9.0. Slides were incubated with 
the listed primary antibodies overnight. The following secondary Alexa Fluor labeled 
antibodies were used for the CD163 – CD68 – keratin and PD-L1 – PD-1 combinations: 
647 goat anti-rabbit, 546 goat anti-mouse IgG2a, and 488 goat anti-mouse IgG1 (all 
from Invitrogen, Life Technologies, Carlsbad, USA). Donkey anti-goat 488 and donkey 
anti-mouse IgG 647 were used for PD-1/CD8 detection. The slides were counterstained 
with DAPI and cover-slipped. Immunofluorescent images were acquired with an LSM700 
confocal laser scanning microscope equipped with an LCI Plan-Neofluar 25x/0.8 Imm 
Korr DIC M27 objective (Zeiss, Göttingen, Germany). Double or triple positivity of cells 
in the center of the tumor as well as at the invasive margin was determined using LSM 
Image Browser (version 4.2.0.121, Zeiss). Images from the two triple immunofluorescent 
stainings were merged using Adobe Photoshop CS6.
tCgA rnA sequencing data
TCGA RNAseq analysis was performed as previously reported.19,20 Data were 
downloaded from FireBrowse on November 11, 2014 (http://firebrowse.
org/?cohort=UCEC&download_dialog=true). In total, 245 samples with RSEM normal-
ized data were available for analysis.
Prediction of antigenic neoepitopes
Prediction of antigenic neoepitopes was performed as previously reported.20 In brief, an 
algorithm was developed to estimate the immunogenicity of individual tumors in which 
the following considerations were taken into account: i) to generate a functional neoepi-
tope a missense mutation must be expressed; ii) most functional neoepitopes are pre-
dicted to bind Major Histocompatibility Complex (MHC) class I molecules (IC50<500nM) 
by NetMHCPan;8,33,34 iii) the likelihood that a neoepitope is antigenic is reduced if the 
corresponding wild-type peptide also binds the MHC with similar affinity as T cells to 
the epitope may be centrally deleted or tolerized.35 Our strategy was similar to that 
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reported by others.8,13,34,36 For each tumor all possible 9mers for every missense mutation 
in expressed genes (defined as non-zero reads from RNAseq) and the binding affinity 
of the mutant and corresponding wild-type peptide for HLA-A*02:01 were calculated 
using NetMHCPan 2.8.33 If several peptides had an IC50<500nM, the strongest binder 
was used for analysis. We defined antigenic mutations as neoepitopes predicted to bind 
MHC molecules (IC50<500nM) for which the corresponding wild-type peptide was not 
predicted to bind MHC (IC50>500nM).
Statistical analyses
Comparison between clinicopathological characteristics of the four molecular subgroups 
was made using Kruskal-Wallis followed by Man-Whitney U (for age) and χ2 tests (for 
all other variables). Correlations between immunohistochemical stainings and the four 
molecular subgroups were evaluated using Kruskal-Wallis followed by Mann-Whitney U 
tests. The same method was used to evaluate correlations between RNA expression from 
the TCGA cohort of immune-related genes and the four molecular subgroups. Addition-
ally, analyses were performed combining POLE-mutant and MSI samples versus NSMP 
and p53-mutant samples. All tests were performed two-sided. Significance was defined 
as a P value of <0.05. Statistical analyses were performed using IBM SPSS version 22 
(SPSS Inc., Chicago, USA) and GraphPad Prism (GraphPad Software Inc., CA, USA).
reSultS
enhanced infiltration of intratumoral Cd3+, Cd8+ and Cd103+ lymphocytes in 
POLE-mutant and mSI tumors
We first sought to characterize the lymphocytic infiltrate in the four EC molecular 
subtypes by immunohistochemical analysis of CD3, CD8, CD103 and CD20 (Figure 
1A-B). Compared to NSMP and p53-mutant tumors, both POLE-mutant and MSI tumors 
demonstrated increased density of CD3+ T lymphocytes within the tumor center (POLE 
vs. NSMP, P=0.002; MSI vs. NSMP, P=0.001; MSI vs. p53, P=0.018). Staining for cytotoxic 
T lymphocyte marker CD8 and the intraepithelial T lymphocyte marker CD103 revealed 
similarly increased infiltrate in the tumor center (comparison of CD8+ cells: POLE vs. NSMP, 
P<0.001; POLE vs. p53, P=0.021; MSI vs. NSMP, P=0.016; comparison of CD103+ cells: POLE 
vs. MSI, P=0.023; MSI vs. NSMP, P=0.035; MSI vs. p53, P=0.030). Based on a median of 80.5 
CD8+ cells/core in the whole cohort, 90% of POLE-mutant, 69% of MSI, 31% of NSMP 
and 43% of p53-mutant tumors were categorized as highly infiltrated with CD8+ cells. 
There was no difference in numbers of CD20+ B lymphocytes within the tumor center. 
A combined analysis in which the two molecular subgroups with a high expected neo-
antigen load (POLE-mutant and MSI) were compared with the two molecular subgroups 
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with lower expected neoantigen load (NSMP and p53-mutant), supported the apparent 
differences in immune infiltrate between EC subtypes (Supplementary Figure 1A).
Within the infiltrative margin, CD3+, CD8+, CD103+ or CD20+ infiltration did not sig-
nificantly differ between the four molecular subgroups (Figure 1C). Combined analysis 
showed a higher infiltration of CD8+ and CD103+ in POLE-mutant and MSI (CD8, P=0.010; 






















































13 13 21 22
POLE MSI NSMP p53
10 16 29 30
POLE MSI NSMP p53
10 15 24 28
POLE MSI NSMP p53
10 13 25 27
POLE MSI NSMP p53
3  7 9 6
POLE MSI NSMP p53
4 8 28 19
POLE MSI NSMP p53
 3   4 23 19
POLE MSI NSMP p53
























Figure 1. Infiltration of CD3+, CD8+, CD103+ and CD20+ cells in POLE-mutant, MSI, NSMP and p53-mutant 
endometrial cancers.
(A) Representative immunohistochemical stainings of CD3+, CD8+, CD103+ and CD20+ cells. (B) Average 
number of positively stained intratumoral cells for each of the markers in the above panel, counted per 
core, corrected for the number of cells present. (C) Average number of positively stained cells for each of 
the markers in the above panel, counted per core within the infiltrative margin, corrected for the number 
of cells present. The numbers of cases analyzed for each molecular subgroup are listed below the x-axis. 
Boxes represent the interquartile range (IQR), with the upper whisker indicating the 75th percentile and the 
lower whisker the 25th percentile. The median and mean values are indicated by a horizontal line and cross, 
respectively. Abbreviations: POLE, POLE-mutant; MSI, microsatellite-unstable; NSMP, no specific molecular 
profile; p53, p53-mutant. *P<0.05, **P<0.01, ***P<0.001.
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Increased infiltration of Cd45ro+ and tIA-1+ lymphocytes in mSI tumors
To analyze the function of the tumors’ lymphocytic infiltrate, we performed immunohis-
tochemistry for CD45RO, CD27, T-bet and TIA-1 (Figure 2A-B). Within the tumor center, 
MSI tumors contained more CD45RO+ memory T lymphocytes compared to NSMP and 
p53-mutant tumors (MSI vs. NSMP, P=0.029; MSI vs. p53; P=0.008). MSI tumors also 
harbored more TIA-1+ cytolytic lymphocytes within the tumor center (MSI vs. NSMP, 
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Figure 2. Infiltration of TIA-1+, T-bet+, CD27+ and CD45RO+ cells in POLE-mutant, MSI, NSMP and p53-mu-
tant endometrial cancers.
(A) Representative immunohistochemical stainings of CD45RO+, CD27+, T-Bet+ and TIA-1+ cells. (B) Average 
number of positively stained intratumoral cells for each of the markers in the above panel, counted per 
core within the tumor center, corrected for the number of cells present. (C) Average number of positively 
stained cells for each of the markers in the above panel, counted per core within the infiltrative margin, 
corrected for the number of cells present. The numbers of cases analyzed for each molecular subgroup are 
listed below the x-axis. Boxes represent the interquartile range (IQR), with the upper whisker indicating the 
75th percentile and the lower whisker the 25th percentile. The median and mean values are indicated by 
a horizontal line and cross, respectively. Abbreviations: POLE, POLE-mutant; MSI, microsatellite-unstable; 
NSMP, no specific molecular profile; p53, p53-mutant. *P<0.05, **P<0.01, ***P<0.001.
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T cells and T-bet+ differentiated cells between the four molecular subgroups. Combined 
analysis of molecular groups revealed the presence of more CD45RO+ and TIA-1+ cells 
in POLE -mutant/MSI tumors compared to NSMP/p53-mutant tumors (Supplementary 
Figure 2A). Moreover, this also demonstrated higher numbers of T-bet+ differentiated 
cells within POLE -mutant/MSI tumors compared to NSMP/p53-mutant tumors (P=0.021).
Concordant with our findings in the tumor center, the infiltrative margin of MSI tumors 
contained more CD45RO+ lymphocytes (MSI vs. NSMP, P=0.002; MSI vs. p53, P=0.003) 
and more TIA-1+ cytolytic T lymphocytes (MSI vs. NSMP, P=0.002; Figure 2C). NSMP tu-
mors demonstrated more TIA-1+ lymphocytes compared to p53-mutant tumors (NSMP 
vs. p53, P=0.023). The numbers of CD27+ and T-bet+ cells did not significantly differ 
between the four molecular subgroups. Data from the combined analyses supported 
the increased density of CD45RO+ and TIA-1+ cells within POLE-mutant/MSI tumors 
(Supplementary Figure 2B).
Increase in infiltration of Pd-1+ and Pd-l1+ lymphocytes in POLE-mutant and 
mSI tumors
The increased lymphocytic infiltrate of POLE-mutant and MSI tumors, in combination 
with their expected ultramutated (POLE-mutant tumors) or hypermutated (MSI tumors) 
status, prompted us to investigate the presence of PD-1+ and PD-L1+ cells within this 
cohort (Figure 3A).
The tumor center of POLE-mutant and MSI tumors harbored high numbers of PD-1+ 
immune cells (POLE vs. NSMP, P<0.001; POLE vs. p53, P=0.050; MSI vs. NSMP, P=0.003; 
Figure 3B). This was supported by the combined analysis (Supplementary Figure 3A). 
Based on a median of 14.0 PD-1+ cells/core in all patients, 73% of POLE-mutant, 69% of 
MSI, 31% of NSMP and 48% of p53-mutant tumors were categorized as highly infiltrated 
with PD-1+ cells.
POLE-mutant and MSI tumors showed markedly increased infiltration of PD-L1+ im-
mune cells within the tumor center compared to NSMP and p53-mutant tumors (POLE 
vs .NSMP, P<0.001; POLE vs. p53, P<0.001; MSI vs. NSMP, P<0.001; MSI vs. p53, P=0.002; 
Figure 3C). The combined analysis showed similar results (Supplementary Figure 3B). In 
total, 100% of POLE-mutant, 71% of MSI, 18% of NSMP and 29% of p53-mutant tumors 
were categorized as PD-L1-positive (based on the immune score). Strikingly, only one 
tumor sample, a p53-mutant EC, contained PD-L1 expressing tumor cells (noted as a 
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Figure 3. Infiltration of PD-1+ and PD-L1+ cells in POLE-mutant, MSI, NSMP and p53-mutant endometrial 
cancers.
(A) Representative immunohistochemical stainings of PD-1+ and PD-L1+ cells. (B) Average number of PD1+ 
cells counted per core within the tumor center, corrected for the number of cells present. (C) Percentage of 
PD-L1-positive tumor-infiltrating immune cells within the tumor core and infiltrative margin core. (D) Aver-
age number of PD-1+ stained cells counted per core within the infiltrative margin, corrected for the number 
of cells present. The numbers of cases analyzed for each molecular subgroup are listed below the x-axis. 
Boxes represent the interquartile range (IQR), with the upper whisker indicating the 75th percentile and the 
lower whisker the 25th percentile. The median and mean values are indicated by a horizontal line and cross, 
respectively. Abbreviations: POLE, POLE-mutant; MSI, microsatellite-unstable; NSMP, no specific molecular 
profile; p53, p53-mutant. *P<0.05, **P<0.01, ***P<0.001.
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Within the infiltrative margin, only the POLE-mutant subgroup showed high densities 
of PD-1+ immune cells (POLE vs. NSMP, P=0.008; POLE vs. p53, P=0.007; Figure 3D). 
Combined analysis supported the presence of high numbers of PD-1+ cells within the 
POLE-mutant/MSI group compared to the NSMP/p53-mutant group (Supplementary 
Figure 3C).
Pd-l1 is preferentially expressed on myeloid cells 
Recently, several studies have shown PD-L1 expression on tumor-associated myeloid 
cells.1,37-40 Therefore, to determine whether this was also the case for our cohort, we 
performed two multi-color immunofluorescence stainings on consecutive whole slides 
of a highly infiltrated POLE-mutant tumor sample using the following combinations of 
monoclonal antibodies: CD68 - CD163 – epithelial cell marker cytokeratin, and PD-L1 - 
PD-1, respectively (Figure 4). CD68+ and/or CD163+ myeloid cells (including macrophages 
and myeloid dendritic cells) were found in the stromal regions within the center of the 
tumor, demarcated by the cytokeratin+ tumor cells (Figure 4A). PD-1+ and PD-L1+ cells 
were seen in close proximity, also predominantly located in the intratumoral stromal 
areas (Figure 4B). A co-immunofluorescent staining of PD-1 and CD8 shows frequent co-
localization, indicating that PD-1 can be expressed by (cytotoxic) T cells (Supplementary 
Figure 4). PD-L1 expression co-localized with CD68+ and CD163+, supporting the idea 
that in our cohort PD-L1 is not mainly expressed by tumor cells but by myeloid cells 
(Figure 4C-D).
tCgA rnA sequencing data demonstrates higher expression of Cd8A, Cd3e, 
ItgAe (Cd103), mS4A1 (Cd20), PtPrC (Cd45ro), Cd27,tbX21 (t-bet) and 
PdCd1 (Pd-1) in POLE-mutant and mSI tumors
Next, we compared our data with the expression of above-described immune markers 
in The Cancer Genome Atlas (TCGA) cancer cohort, which was originally used to devise 
the molecular classification of EC (Figure 5).19 Previously we have shown higher expres-
sion of, among others, CD3E, CD8A, TBX21 (T-bet) and PDCD1 (PD-1) in POLE-mutant 
compared to MSI and MSS tumors.20 We now extend this analysis to specifically compare 
the four proposed prognostic subgroups.19 Of the 244 informative samples, the TCGA 
cohort included 18 POLE-mutant, 69 MSI, 96 NSMP and 62 TP53-mutant. Analysis of the 
RNA sequencing data of this cohort demonstrated higher expression of CD8A, CD3E, 
ITGAE (CD103), MS4A1 (CD20), PTPRC (CD45RO), CD27, TBX21 (T-bet) and PDCD1 (PD-1) 
in POLE-mutant and MSI tumors compared to NSMP and TP53-mutant. TIA-1 expression 
did not differ between the four molecular subgroups. POLE-mutant ECs showed a trend 
towards increased expression of CD274 (PD-L1; P=0.057).
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Patients with POLE-mutated and mSI tumors have higher numbers of predicted 
neoantigens, regardless of their immune infiltration status
The presence of a subset of POLE-mutant and MSI tumors with a relatively low immune 
infiltration and NSMP and TP53-mutant tumors with a relatively high immune infiltration 
led us to evaluate the relationship between immune infiltrate and numbers of predicted 












Figure 4. Immunofluorescent stainings of PD-1, PD-L1 and myeloid markers.
Representative image of a POLE-mutant endometrial cancer stained with keratin (green) - CD163 (blue) - 
CD68 (red; A), and PD-1 (green) - PD-L1 (blue; B). The two triple immunofluorescent stainings from A and 
B, performed on sequentially cut slides, are layered (C), with single channel markers for the inset (D), with 
keratin (green), PD-L1 (blue), CD68 (red) and CD163 (yellow), demonstrating the co-localization of PD-L1 
with myeloid markers.
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ence of higher numbers of expected neoantigens in POLE-mutant and MSI tumors 
compared to NSMP and TP53-mutant tumors (Figure 6A). The molecular subgroups 
were dichotomized according to CD8A expression from RNAseq data, with high infiltra-
tion defined as expression above the median of the respective molecular subgroup. 
Subsequently, we quantified predicted neoantigens for high- and low-infiltrated tumors 
within the molecular subgroups (Figure 6B). No differences were found in the numbers 
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Figure 5. Expression of immune markers in according to tumor molecular subtype in TCGA series.
RSEM normalized RNAseq data were log2 transformed and analyzed according to tumor molecular subtype. 
Boxes represent the interquartile range (IQR), with the upper whisker indicating the 75th percentile and the 
lower whisker the 25th percentile. The median and mean values are indicated by a horizontal line and cross, 
respectively. Abbreviations: POLE, POLE-mutant; MSI, microsatellite-unstable; NSMP, no specific molecular 
profile; p53, p53-mutant. *P<0.05, **P<0.01, ***P<0.001.
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dISCuSSIon
In this study we demonstrate the presence of high numbers of tumor-infiltrating T cells 
in POLE-mutant and MSI tumors, both predicted to be neoantigen-rich, from a clinically 
relevant cohort of high-risk EC patients. Moreover, these two molecular subtypes harbor 
high densities of PD-1- and PD-L1-expressing immune cells, rendering them attractive 
candidates for immune checkpoint inhibition strategies.
The presence of a prominent immune infiltrate in POLE-mutant and MSI high-risk EC is 
in concordance with our previous findings in a preselected cohort including 47 POLE-
mutant, 49 microsatellite-unstable and 54 microsatellite-stable tumors, in which we 
demonstrated that POLE-mutant tumors, and to a lesser extent MSI tumors, are char-
acterized by a robust intratumoral T cell response.20 These initial findings have recently 
been extended to other unselected EC cohorts, in which high densities of peritumoral 
and tumor-infiltrating T lymphocytes have been described in POLE-mutant tumors.21,22,41 
High expression of PD-1 and PD-L1 on intraepithelial immune cells in POLE-mutant and 
MSI ECs has previously been suggested by Howitt et al., albeit in a cohort which included 
only three POLE-mutant cases.21 An interesting difference between the data presented 
by Howitt et al. and the current study, is the expression of PD-L1 on tumor cells. Howitt 
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Figure 6. Predicted number of HLA-A2-binding neoantigens across the four molecular subgroups in The 
Cancer Genome Atlas endometrial cancer cohort.
(A) Comparison between the number of predicted HLA-A2 binding neoantigens in POLE-mutant, MSI, 
NSMP and TP53-mutant subgroups based on RNAseq. (B) Comparison between patients with high and 
low infiltration (based on CD8A expression from RNAseq, relative to median within the group) of lympho-
cytes within POLE-mutant, MSI, NSMP and TP53-mutant subgroups. The numbers of cases analyzed for each 
molecular subgroup are listed below the x-axis. Boxes represent the interquartile range (IQR), with upper 
whisker indicating the 75th percentile and the lower whisker the 25th percentile. The median and mean 
values are indicated by a horizontal line and cross, respectively. Abbreviations: POLE, POLE-mutant; MSI, mi-
crosatellite-unstable; NSMP, no specific molecular profile; p53, p53-mutant. *P<0.05, **P<0.01, ***P<0.001.
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et al. describe that 20% of ECs (POLE-mutant, MSI and MSS) show PD-L1+ tumor cells, 
whereas within our high-risk cohort only 1 out of 116 tumors showed any expression of 
PD-L1 on the tumor cells (using the same PD-L1 antibody). Our use of tissue microarrays 
may have led to an underestimation of PD-L1+ tumor cells, as PD-L1 expression is known 
to be heterogeneously distributed.42 Moreover, consecutive full slides of one POLE-
mutant case were stained using multi-color immunofluorescence: PD-L1 expression was 
predominantly found in the intratumoral stromal regions in close proximity with PD-1+ 
cells. Furthermore, PD-L1 expression co-localized with CD68+ and CD163+, suggesting 
that in this case PD-L1 is primarily expressed by myeloid cells rather than tumor cells. 
PD-L1+ immune cells have previously been described by (among others) Heeren et al. 
and Herbst et al.; the latter also showed that PD-L1 positivity on immune cells, but not 
on tumor cells, was associated with response to immune checkpoint inhibition.1,38
Comparisons of outcomes from our immunohistochemical analyses in the TransPORTEC 
high-risk cohort and analyses of the RNA sequencing data from The Cancer Genome 
Atlas (TCGA) showed similar results for five out of ten markers, namely CD3, CD8, CD103, 
CD45RO and PD-1. The immunohistochemical analyses of the TransPORTEC cohort did 
not reveal significant differences in numbers of CD20+ and CD27+ cells between the 
four molecular subgroups, while analysis of the TCGA cohort demonstrated increased 
expression of CD20+ and CD27+ cells within the POLE-mutant and MSI subgroups. This 
inconsistency may be attributed to the use of a TMA for immunohistochemical analyses 
of CD20+ and CD27+ cells. These immune cells frequently reside in tertiary lymphoid 
structures in the myometrium, which are frequently seen in POLE-mutant tumors.20,43-45 
The areas containing these structures may not have been present in the TMA. Secondly, 
outcomes regarding TIA-1- ,T-bet- and PD-L1-positivity were discordant. These differ-
ences may be due to the known discrepancy between mRNA and protein expression.46 
Another possible explanation for these discrepancies may be the relatively high pro-
portion of clear cell EC (15.5%) within the TransPORTEC high-risk cohort, while only 
endometrioid, serous and mixed histologies were included in the TCGA study.
The presence of high numbers of CD8+ and PD-1+ cells in POLE-mutant and MSI tumors 
may suggest the presence of high numbers of tumor-specific T cells targeting neoanti-
gens within these subgroups of patients. Similarly, our analysis of the TCGA EC cohort 
demonstrates that POLE-mutant and MSI tumors are characterized by a significantly 
higher number of mutations predicted to result in major histocompatibility complex-
binding neoantigens, and a correspondingly higher number of tumor-infiltrating CD8+ 
T cells, as assessed by CD8A mRNA levels. This link between neoantigen accumulation 
and infiltration by immune cells is supported by a recent genomic characterization of 
colorectal cancers, in which an association between high neoantigen load, overall lym-
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phocytic infiltration, tumor-infiltrating lymphocytes and survival was demonstrated.10
Surprisingly, the number of predicted immunogenic mutations did not directly reflect 
the levels of CD8A mRNA expression within each molecular subgroup (Figure 6). 
Similarly, in our immunohistochemical analysis, we found MSI tumors, expected to be 
neoantigen-rich, with almost no signs of CD8+ T cell infiltration, and p53-mutant tumors, 
expected to have low numbers of neoantigens, with an enhanced intratumoral immune 
response. One explanation for this apparent discrepancy between immune infiltration 
and the number of predicted neoantigens could be that the nature (i.e. clonal versus 
subclonal) of the neoepitopes, instead of the crude number of predicted neoantigens, 
determine the degree of immune response.13 Another explanation may be that within 
our analyses only predicted binding to HLA-A*02:01 was taken into account rather than 
to individual HLA alleles. Furthermore, immune responses may be impeded by impair-
ment of MHC class I expression due to mutations in HLA, β2-microglobulin and JAK-1 in 
highly mutated ECs.20,47 Therefore, a logical next step in understanding the interaction 
between neoepitopes and immune response within the four molecular subgroups 
would be the direct identification and characterization of tumor-specific T cells target-
ing these neoantigens, as has recently been performed by Gros et al. in melanoma.24 
With regard to the p53-mutant tumors with an enhanced antitumor immune response 
despite low expected neoantigen load, we hypothesize that this response may be aimed 
at self-antigens or cancer/testis antigens instead of neoepitopes. Taking into account 
their unfavorable survival outcomes, further investigation of the highly infiltrated p53-
mutant subset will be of great interest as this may provide new insight in the selection 
of candidates for immune checkpoint therapies.
The data on mutational load, neoantigens and immune infiltration reported by us and 
others suggest that checkpoint inhibition may be a strategy of particular interest for 
treating advanced stage patients with POLE-mutant and MSI tumors. Recent case reports 
provide proof of principle by demonstrating the efficacy of anti-PD-1 inhibitors in a lim-
ited number of advanced stage POLE-mutant or mismatch repair-deficient cancers.7,25,26 
Moreover, a Phase II trial evaluating immune related objective responses to pembro-
lizumab in patients with or without mismatch repair (MMR) deficiency, demonstrated 
objective responses in 40% of patients with MMR-deficient colorectal cancer and 71% of 
patients with MMR-deficient non-colorectal cancers (including two EC). Contrastingly, 
no objective responses were observed in the MMR-proficient colorectal cancers. More-
over, data from this study adds to the growing body of evidence suggesting that high 
numbers of somatic mutations (in this case due to MMR deficiency) and high numbers 
of predicted neoantigens play an important role in the sensitivity to checkpoint inhibi-
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tion.11-13,15 Furthermore, an in-depth analysis of patients treated with anti-PD-1 therapy 
prioritized PD-L1 expression as being the most closely associated with objective tumor 
regression.48 Further analyses of non-responders may uncover other mutations affecting 
epitope presentation, T cell infiltration and response to checkpoint inhibition.
From a clinical point of view, as checkpoint inhibitors are associated with significant costs 
and potential toxicities, it is essential to select individual patients that will benefit from 
these therapies. Patients with low/intermediate-risk disease carrying POLE mutations 
have an excellent prognosis under standard treatment, and therefore checkpoint inhibi-
tion is unlikely to be appropriate for this group.19,49-51 However, (although infrequently 
occurring) POLE-mutant and MSI patients with recurring or metastatic disease are pos-
sible candidates.7,25,26 Clinical trials, in which high-risk EC patients are grouped according 
to molecular subtype, will be required to determine clinical benefit of immunotherapy.
Importantly, the data thus far regarding POLE-mutant EC may be applicable to other 
tumor types harboring POLE mutations. While POLE mutations are found in 7-12% of 
EC, they are also found in other malignancies including colorectal cancers, cancers of 
the brain, breast, pancreas and stomach, albeit at lower frequencies.19,27,49,52-57 Although 
a prognostic advantage of this mutation has now been established in glioblastoma and 
stage II/III colorectal cancer, patients with recurrent or metastatic hypermutated disease 
may also benefit from immunotherapeutic strategies such as checkpoint inhibitors as 
proposed for EC.7,56,58 Basket trials stratifying patients according to tumor molecular 
alterations such as POLE mutations should be initiated to investigate whether these 
patients may also benefit from checkpoint inhibition.
In summary, taking into account the strong immune infiltration, high numbers of PD-1+ 
and PD-L1+ lymphocytes, large numbers of somatic mutations and neoantigens, and the 
recently demonstrated clinical efficacy in these cohorts of patients, POLE-mutant and 
MSI tumors are expected to benefit from checkpoint inhibition.21,25,59
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Supplementary Figure 1. Infiltration of CD3+, CD8+, CD103+ and CD20+ cells in POLE-mutant/MSI com-
pared to NSMP/p53-mutant endometrial cancers.
(A) Average number of positively stained cells for each of the markers in the above panel, counted per 
core within the tumor center, corrected for the number of cells present. (B) Average number of positively 
stained cells for each of the markers in the above panel, counted per core within the infiltrative margin, 
corrected for the number of cells present. The numbers of cases analyzed for each molecular subgroup are 
listed below the x-axis. Boxes represent the interquartile range (IQR), with the upper whisker indicating the 
75th percentile and the lower whisker the 25th percentile. The median and mean values are indicated by 
a horizontal line and cross, respectively. Abbreviations: POLE, POLE-mutant; MSI, microsatellite-unstable; 























































































Supplementary Figure 2. Infiltration of CD45RO+, CD27+, T-Bet+ and TIA-1+ cells in POLE-mutant/MSI com-
pared to NSMP/p53-mutant endometrial cancers.
(A) Average number of positively stained cells for each of the markers in the above panel, counted per core 
within the tumor center, corrected for the number of cells present. (B) Average number of positively stained 
cells for each of the markers in the above panel, counted per core within the infiltrative margin, corrected 
for the number of cells present. The numbers of cases analyzed for each molecular subgroup are listed 
below the x-axis. Boxes represent the interquartile range (IQR), with the upper whisker indicating the 75th 
percentile and the lower whisker the 25th percentile. The median and mean values are indicated by a hori-
zontal line and cross, respectively. Abbreviations: POLE, POLE-mutant; MSI, microsatellite-unstable; NSMP, 
no specific molecular profile; p53, p53-mutant.*P<0.05, **P<0.01, ***P<0.001.




































































Supplementary Figure 3. Infiltration of PD-1+ and PD-L1+ cells in POLE-mutant/MSI compared to NSMP/
p53-mutant endometrial cancers.
(A) Average number of PD-1+ stained cells counted per core within the tumor center, corrected for the 
number of cells present. (B) Average number of PD-1+ stained cells counted per core within the infiltrative 
margin, corrected for the number of cells present. (C) Percentage of tumor-infiltrating immune cells with 
moderate to strong PD-L1 expression per core within cores taken from the tumor and infiltrative margin, 
corrected for the number of cells present. The number of cases analyzed for each molecular subgroup are 
listed below the x-axis. Boxes represent the interquartile range (IQR), with the upper whisker indicating the 
75th percentile and the lower whisker the 25th percentile. The median and mean values are indicated by 
a horizontal line and cross, respectively. Abbreviations: POLE, POLE-mutant; MSI, microsatellite-unstable; 
NSMP, no specific molecular profile; p53, p53-mutant.*P<0.05, **P<0.01, ***P<0.001.
PD-1 CD8/PD-1CD8
Supplementary Figure 4. Immunofluorescent staining of CD8 and PD-1.
Representative image of a POLE-mutant endometrial cancer stained with CD8 and PD-1, demonstrating 
co-localization of CD8 and PD-1 on immune cells.
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Pathogenic POLE proofreading domain mutations are found in many malignancies 
where they are associated with ultramutation and favorable prognosis. The extent to 
which this prognosis depends on their sensitivity to adjuvant treatment is unknown, as 
is the optimal therapy for advanced-staged or recurrent POLE-mutant cancers.
methods
We examined the recurrence-free survival of women with POLE-mutant and POLE-
wild-type endometrial cancers in the observation arm of the randomized PORTEC-1 
endometrial cancer trial (N=245 patients with stage I endometrial cancer for analysis). 
Sensitivity to radiotherapy and selected chemotherapeutics was compared between 
Pole-mutant mouse-derived embryonic stem (mES) cells, generated using CRISPR-Cas9 
(Pole mutations D275A/E275A, and cancer-associated P286R, S297F, V411L) and isogenic 
wild-type cell lines.
results
In the observation arm of the PORTEC-1 trial (N=245), women with POLE-mutant endo-
metrial cancers (N=16) had an improved recurrence-free survival (10-year recurrence-
free survival 100% vs. 80.1% for POLE-wild-type; HR, 0.143; 95% confidence interval, 
0.001-0.996; P=0.049). Pole mutations did not increase sensitivity to radiotherapy nor 
to chemotherapeutics in mES cells. In contrast, Pole-mutant cells displayed significantly 
increased sensitivity to cytarabine and fludarabine (IC50 Pole P286R-mutant vs. wild-
type: 0.05 vs. 0.17 μM for cytarabine, 4.62 vs. 11.1 μM for fludarabine; P<0.001 for both 
comparisons).
Conclusions
The favorable prognosis of POLE-mutant cancers cannot be explained by increased sen-
sitivity to currently used adjuvant treatments. These results support studies exploring 
minimization of adjuvant therapy for early-stage POLE-mutant cancers, including endo-
metrial and colorectal cancers. Conversely, POLE mutations result in hypersensitivity to 
nucleoside analogs, suggesting the use of these compounds as a potentially effective 
targeted treatment for advanced-stage POLE-mutant cancers.
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IntroduCtIon
Somatic mutations in the proofreading (exonuclease) domain of DNA polymerase ε (en-
coded by the POLE gene) are found in a wide variety of human malignancies, including 
7-12% of endometrial cancers, ~1% of colorectal cancers and sporadically in cancers of 
the brain, stomach, breast, and pancreas.1-4 During DNA replication, the proofreading 
activity of polymerase ε recognizes and excises misincorporated nucleotides, thereby 
increasing replication fidelity. Pathogenic POLE proofreading domain mutations (here-
after referred to as ‘POLE mutations’) are associated with an exceptionally high number 
of single nucleotide variants: cancers with such POLE mutations often harbor more than 
100 mutations/Mb.2,5 Despite this so-called ‘ultramutated’ phenotype, patients with 
POLE-mutant cancers have a favorable prognosis. This has been shown in early-stage 
endometrial cancer, where impact was particularly strong in high-grade endometrioid 
tumors, stage II/III colorectal cancer, and was suggested for glioblastomas.1,4,6-12 The ma-
jority of patients in these studies received additional treatment after surgery. Therefore, 
we evaluated in an endometrial cancer series and in a cell-based model whether the 
favorable prognosis of POLE-mutant cancers might be caused by increased sensitivity to 
adjuvant treatment. POLE mutations can also be found in advanced-stage disease, where 
the prognostic impact remains uncertain, and in cancer types with poor prognosis such 
as glioblastomas. Because these POLE mutations reside in the proofreading domain that 
excises non-matched nucleotides, we investigated the efficacy of nucleoside analogs as 
potential targeted therapies for advanced-stage POLE-mutant cancers.
mAterIAlS And methodS
endometrial cancer patient cohort
Clinical data of women with endometrial cancer who did not receive adjuvant treatment 
(N=369) were collected from the randomized PORTEC-1 trial, which compared external 
beam radiotherapy with observation in stage I endometrial cancer.13 POLE mutational 
status was determined as described previously7 with the addition of screening POLE 
exon 14 using Sanger sequencing (primers available upon request). For 119 endome-
trial cancers, POLE mutational status could not be determined, because screening of 
exons 9, 13 and 14 failed or because no material was available. Twenty-three cases were 
designated ‘POLE-wild-type’ despite failure of exon 14 sequencing, based on screening 
of POLE exons 9 and 13. Women with endometrial cancers harboring a POLE mutation 
but also another relevant molecular alteration (i.e. p53 mutation or mismatch repair 
deficiency, based on previous analyses14) were excluded (POLE-mutant & p53-mutant, 
n=3; POLE-mutant, p53-mutant, mismatch repair-deficient, n=2), in accordance with our 
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previous publication.14 This resulted in 245 endometrial cancer patients for analysis. De-
tails on the specific POLE mutations identified in the endometrial cancers can be found 
in Supplementary Table 1.
generation of the cell-based model
Different POLE proofreading domain mutations (P286R, S297F, V411L, and D275A/
E277A) were recreated in wild-type mouse-derived embryonic stem (mES) cell lines us-
ing CRISPR-Cas9. All cell lines in this study were derived from wild-type primary diploid 
129/OLA mouse-derived embryonic stem cell line E14.15 Cell lines were cultured for 
three to six weeks from thawing to use in experiments. Cell culture was tested every 
other month for mycoplasma contamination using MycoAlert Myocplasma Detection 
Kit (LT07-318; Lonza, Switzerland). As this study is limited to experiments with mES cells, 
no live animals were used, an Institutional Animal Care and Use Committee approval 
was not required.
In order to make these mES cells Pole-mutant, a CRISPR guide RNA was designed for 
each mutation using the web resources available at http://crispr.mit.edu. Pairs of these 
oligonucleotides (Supplementary Table 2) were ordered from Integrated DNA Tech-
nologies (Leuven, Belgium), annealed, and, after BbsI digestion (New England Biolabs), 
cloned into a modified expression plasmid pX330 (Addgene #42230; now containing 
the CRISPR-Cas9 system and a puromycin-resistance marker). Plasmids were isolated us-
ing an endotoxin-free Midiprep kit (Qiagen), and gRNA inserts were verified by Sanger 
sequencing. As template for homologous recombination, PCR fragments (~2.4 kbp) 
containing the specific Pole proofreading domain mutations as well as silent mutations 
in the PAM sequences were generated as described previously (oligonucleotides in 
Supplementary Table 3).16 Introduction of the specific substitutions was confirmed by 
Sanger sequencing.
Wild-type mES cells were transfected with the mutation-specific Cas9- and CRISPR 
guideRNA-expressing plasmid and PCR-based repair template using Lipofectamine 2000 
(#11668019, Thermo Fisher Scientific). For this transfection, the manufacturer’s protocol 
was followed with minor alterations: use of knockout DMEM, more Lipofectamine for 
each transfection (14.4µl in 125µl medium), a higher DNA input (3-4μg), and a 20 minute 
incubation of diluted DNA in Lipofectamine at room temperature. Puromycin (1.5 μg/
ml for two days; A11138-03, Thermo Fisher Scientific) was added to the medium for 
positive selection of transfected cells. Drug-resistant cells were seeded at a low den-
sity. Independent clones were manually picked, expanded and reseeded as single cells. 
Isolated clones were again manually picked to ensure purity of the resultant cell line. 
To identify targeted clones, DNA and RNA were isolated from drug-resistant clones and 
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regions were amplified by PCR (oligonucleotides sequences in Supplementary Table 4). 
Pole proofreading domain mutations were designed to yield a restriction site; therefore, 
PCR products amplified from genomic DNA were subjected to restriction site digestion 
to verify knockin (BtgZI for D275A/E277A, BstUI for P286R, MboII for S297F, and AcuI for 
V411L; all New England Biolabs). Amplified genomic DNA and cDNA products of clones 
with an introduced restriction site were purified, and mutations were confirmed by 
Sanger sequencing analysis.
For each Pole-mutant mES cell line, metaphase spreads were made, and fluorescence 
in situ hybridization was performed using biotin-16-dUTP-labelled or digoxigenin-11-
dUTP-labeled (#11093070910 and #11093088910 respectively, Roche) bacterial artificial 
chromosome clones RP24-154A19 and RP24-388K6 (BACPAC Resource Center, Chori). 
Chromosome numbers were equal for all cell lines used in subsequent experiments, 
and all cell lines contained two copies of the Pole allele (Supplementary Figure 1). 
Spontaneous mutant frequencies of the Pole-mutant mES cell lines were determined 
at the Hypoxanthine Phosphorybosyl Transferase (Hprt) gene as described previously.17 
Additional details on these experiments can be found in the Supplementary Methods.
treatment sensitivity of meS cells
Pole proofreading domain-mutant and wild-type mES cells were treated with 5-fluo-
rouracil (F6627, Sigma Aldrich), methotrexate (S1210, Selleckchem), paclitaxel (S1150, 
Selleckchem), cytarabine (S1648, Selleckchem), gemcitabine (S1714, Selleckchem), 
fludarabine (S1229, Selleckchem), cladribine (S1199, Selleckchem), clofarabine (S1218, 
Selleckchem), doxorubicin, cisplatin, or etoposide. To determine the sensitivity to these 
compounds, mES cells were seeded in 96-well tissue culture plates (5000 cells/well). The 
following day, cells were treated with increasing concentrations of each compound and 
incubated for 24-72 hours (24 hours: cytarabine, gemcitabine, clofarabine, paclitaxel, 
doxorubicin; 48 hours: cisplatin, cladribine, fludarabine, methotrexate, etoposide; 72 
hours: 5-fluorouracil). Seventy-two hours after treatment was initiated, cells were 
detached with 0.05% trypsin-EDTA and resuspended in PBS containing 2% FCS. Adher-
ent cells were quantified using flow cytometry. Sensitivity to ionizing radiation was 
determined similarly: mES cells were seeded in 6-well tissue culture plates (50,000 cells/
well). The following day, cells were irradiated with a single dose of up to 8 Gy. Seventy-
two hours after irradiation, cells were detached with 0.05% trypsin-EDTA and manually 
counted. In each experiment, for every cell line, cell counts were normalized to counts of 
vehicle-treated cells. At least three independent experiments were conducted per cell 
line for each treatment.
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Statistical analyses
For PORTEC-1 participants in the observation arm, recurrence-free survival (RFS) was 
calculated, defined as the time from randomization to recurrence, with censoring at 
date of last contact or death in patients without recurrence. RFS was evaluated using the 
Kaplan-Meier method and compared between POLE-mutant and POLE-wild-type endo-
metrial cancers using a Cox proportional hazards model with Firth’s correction, owing to 
the absence of events in the POLE-mutant group.18 To analyze treatment sensitivity in the 
cell-based model, IC50 values of mES cell lines were calculated for each experiment by non-
linear regression analysis (variable slope) of the normalized cell counts. Outliers in IC50 val-
ues were identified with Grubbs test for each cell line. For each Pole-mutant cell line, IC50’s 
were compared to IC50’s of the isogenic wild-type cell line using independent-samples 
t-tests (with Holm-Bonferroni correction when indicated). Levene’s test for equality of 
variances was used to determine when to assume equal variances. All statistical tests were 
two-sided, and a P value of less than 0.05 was considered statistically significant; this was 
adjusted downward in case of Holm-Bonferroni correction. All analyses were performed in 
R (3.3.0 version, package ‘coxphf’), Graphpad Prism 7, or SPSS 23.0 software.
reSultS
Prognosis of patients with POLE-mutant endometrial cancers who did not 
receive adjuvant treatment
The prognostic significance of POLE mutations was evaluated in the observation arm 
of the randomized PORTEC-1 trial, which included 245 stage I endometrial cancers for 
analysis (Figure 1).7,13,14 None of the women with POLE-mutant endometrial cancers 
(0/16) developed a recurrence, compared to 44 recurrences (19.2%) in 229 patients with 
POLE-wild-type tumors; this difference in RFS was statistically significant (10-year RFS 
100% vs. 80.1%; HR, 0.143; 95% confidence interval (CI), 0.001-0.996; P=0.049 based 
on Cox regression with Firth’s correction). These results suggest a favorable prognosis 
of early-stage POLE-mutant cancers in the absence of adjuvant treatment, indicating 
that the increased sensitivity to adjuvant treatment does not explain the good clinical 
outcome of these tumors.
treatment sensitivity conferred by POLE mutations in a model system
To support the PORTEC-1 data, we investigated the effect of POLE mutations on treat-
ment sensitivity in a model system. To this end, we recreated three common somatic, 
cancer-associated POLE proofreading domain mutations (P286R, S297F, and V411L),2 as 
well as a proofreading-deficient positive control (double mutation of exonuclease active 
sites, D275A/E277A)19 in isogenic mouse-derived embryonic stem (mES) cell lines using 
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CRISPR-Cas9. For each Pole mutation, a minimum of two independent homozygous cell 
lines was used for subsequent experiments. Consistent with the mutational burden in 
POLE-mutant cancers, these Pole mutations gave rise to a mutator phenotype in mES 
cells with the severity of the phenotype depending on the substitution (P286R ~8x 
higher than wild-type, D275A/E277A, S297F, V411L ~4x; Supplementary Figure 2).
Sensitivity to adjuvant treatments used for cancer types that harbor POLE mutations 
was determined in the mES cells. Pole mutations did not result in increased sensitivity to 
ionizing radiation or to selected chemotherapeutic agents (i.e. 5-fluorouracil, cisplatin, 
paclitaxel, doxorubicin, etoposide and methotrexate; Table 1, Figures 2 and 3, Supple-
mentary Table 5).
Based on the role of the polymerase ε proofreading domain in the recognition and exci-
sion of mispaired nucleotides, we investigated nucleoside analogs as potential novel 
targeted therapies for POLE-mutant cancers. Indeed, Pole mutations resulted in increased 
sensitivity to cytarabine and fludarabine: sensitivity to both compounds was significantly 
increased for the Pole D275A/E277A-mutant cell lines, but was even more pronounced 
in cells with somatic Pole hotspot mutations (Figure 4, Table 1, Supplementary Tables 
5 and 6). Because somatic POLE mutations in cancers are heterozygous, sensitivity to 


































Figure 1. Recurrence-free survival of endometrial cancer patients in the observation arm of the PORTEC-1 
study according to POLE mutational status.
Among endometrial cancer patients who did not receive adjuvant treatment, none of the women with 
POLE-mutant endometrial cancers developed a recurrence (0/16, 10-year RFS 100%), as compared to 44 
recurrences in 229 women with POLE-wild-type tumors (19.2%, 10-year RFS 80.1%). This difference in recur-
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Figure 2. Sensitivity to ionizing radiation in Pole-mutant and Pole-wild-type cell lines.
Non-linear regression of relative survival after ionizing radiation is shown for homozygous Pole-mutant and 
Pole-wild-type mouse embryonic stem cells. The Pole D275A/E277A double mutation results in proofread-
ing deficiency.19 The Pole P286R, S297F, and V411L mutations are somatic POLE hotspot mutations.2 As a 
radiosensitive positive control cell line, a DNA ligase IV knockout mouse-derived embryonic stem cell line 
(DNA ligase IV Δ/Δ) was used. Sensitivity to ionizing radiation did not significantly differ between Pole-
mutant and Pole-wild-type cells (for details on these comparisons see also Table 1). Dots and error bars 
indicate mean and standard error of the mean respectively.
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Figure 3. Sensitivity to different chemotherapeutic agents in Pole-mutant and Pole-wild-type cell lines.
Non-linear regression of relative survival after treatment with chemotherapeutic agents is shown for homo-
zygous Pole-mutant and Pole-wild-type mouse embryonic stem cells. The Pole D275A/E277A double mu-
tation results in proofreading deficiency.19 The Pole P286R, S297F, and V411L mutations are somatic POLE 
hotspot mutations.2 Sensitivity to 5-fluorouracil, cisplatin, doxorubicin, and etoposide did not significantly 
differ between Pole-mutant and Pole-wild-type cells. For methotrexate, a significant difference was found 
between IC50s of the Pole P286R-mutant cell line and the Pole-wild-type cell line. For paclitaxel, a significant 
difference was found between IC50s of the Pole S297F-mutant and the Pole-wild-type cell lines. These differ-
ences in both methotrexate and paclitaxel sensitivity did not remain significant after correction for multiple 
comparisons (for details on these comparisons, see also Table 1). Dots and error bars indicate mean and 
standard error of the mean, respectively.
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cytarabine and fludarabine was also assessed in a heterozygous Pole S297F-mutant cell 
line. This resulted in sensitivity lower than in the homozygous Pole-mutant lines, but 
higher than in the wild-type, reaching significance for cytarabine (mean IC50 0.14μM vs. 
0.17μM; P=0.025 for cytarabine; mean IC50 7.58μM vs. 11.1μM; P=0.169 for fludarabine; 
Supplementary Figure 3).
dISCuSSIon
In this study, we present two independent lines of evidence to show that the prognostic 
benefit of POLE proofreading domain mutations is independent of adjuvant treatment. 
First, we provide clinical data from the PORTEC-1 endometrial cancer trial to show that 
the favorable outcome associated with POLE mutations is also observed in women who 
did not receive adjuvant therapy. Second, in an in vitro model we demonstrate that POLE 
mutations confer increased sensitivity neither to ionizing radiation, nor to commonly 
used chemotherapeutics. We also show that Pole mutations result in significantly in-
creased sensitivity to specific nucleoside analogs currently used to treat hematological 
malignancies.
This study is limited by the composition of the endometrial cancer cohort: the relatively 



































Figure 4. Cytarabine and fludarabine sensitivity in Pole-mutant and Pole-wild-type cell lines.
Non-linear regression of relative survival after nucleoside analog treatment is shown for Pole-mutant and 
Pole-wild-type mouse embryonic stem cells. The POLE D275A/E277A double mutation results in proofread-
ing deficiency.19 The Pole P286R, S297F, and V411L mutations are somatic POLE hotspot mutations.2 All ho-
mozygous Pole-mutant cell lines were significantly more sensitive to cytarabine and fludarabine than the 
isogenic Pole-wild-type cell line (also after multiple comparisons correction, see Table 1). Dots and error 
bars indicate mean and standard error of the mean, respectively.
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favorable outcome of stage I disease made it more challenging to confirm the prognos-
tic effect of POLE mutations. Its composition also precluded the joined examination of 
POLE mutational status and other prognostically relevant, clinical factors: this should 
be addressed in future research. Because POLE-mutant cancers are characterized by an 
antitumor immune response,20-22 it should be noted that in the cell-based model, an in-
teraction between the immune system and radiotherapy or chemotherapy could not be 
assessed. However, the results of the endometrial cancer cohort and the in vitro findings 
are consistent regarding the prognosis of POLE-mutant tumors and its independence of 
adjuvant therapy. These results are supported by previous studies on endometrial and 
colorectal cancer. McConechy et al. observed no endometrial cancer-related deaths or 
evidence of recurrent or progressive disease among 14 patients with POLE-mutant can-
cers who did not receive adjuvant treatment.9 Moreover, among 23 patients with stage 
II POLE-mutant colorectal cancers, no recurrences were found irrespective of adjuvant 
chemotherapy.4 Our in vitro findings are in line with another preclinical study in which 
no significant difference in sensitivity to paclitaxel was found between POLE-mutant and 
POLE-wild-type endometrial cancer cell lines.22 This study reported increased resistance 
to carboplatin in the POLE-mutant cell lines. However, the cell lines used in this study 
were, contrary to those in our study, non-isogenic, and one carried a POLE polymerase 
domain variant of unknown pathogenicity. Finally, considering the mechanisms of ac-
tion of the commonly used anticancer treatments and the presumed lack of a role herein 
of DNA polymerase epsilon’s proofreading activity, a POLE mutation is unlikely to alter 
sensitivity to these therapies.
We are the first to study cancer-associated POLE proofreading domain mutations in mam-
malian cells. Remarkably, sensitivity to nucleoside analogs cytarabine and fludarabine 
was much greater in the cancer-associated Pole mutants than in the Pole proofreading-
deficient cell lines,23 supporting the presence of defects besides proofreading alone.2,5 
In contrast, these POLE mutations resulted in only a four- to eight-fold increase in the 
spontaneous mutation frequency at the Hprt gene, which seems low compared with the 
ultramutated phenotype found in POLE-mutant cancers.2,5 Our mutation data are sup-
ported by forward mutation assays with mammalian proteins.5 The mutation frequen-
cies in this study were, however, lower than those previously observed in yeast,24 which 
may be due to different mechanisms of mutability between yeast and mammals. Future 
studies are needed to unravel the mechanisms behind the ultramutated phenotype of 
POLE-mutant cancers.
In conclusion, these findings suggest that the favorable prognosis of POLE-mutant can-
cers cannot be explained by increased sensitivity to adjuvant therapy but could be due 
to increased immunogenicity as described in previous studies or to the accumulation of 
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deleterious mutations (‘error catastrophe’).20-22,25 These results support clinical trials such 
as the PORTEC-4A trial, which prospectively evaluates observation alone for early-stage 
POLE-mutant cancers; this may provide an opportunity to decrease overtreatment and 
may spare these patients unnecessary side effects.26 In patients with advanced-stage or 
aggressive tumors, POLE mutations identify candidates for targeted therapies. Recent 
results with immune checkpoint inhibitors for POLE-mutant cancers are promising.27,28 
This study proposes nucleoside analogs cytarabine and fludarabine as targeted treat-
ment option for POLE-mutant cancers, potentially as an alternative to or in combination 
with immune checkpoint inhibition, which should be the subject of future research. As 
the prognostic value and therapeutic implications of POLE mutations seem generaliz-
able across cancer types, the results of this study support further individualization of 
treatment for a wide variety of malignancies.
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SuPPlementAry methodS
Preparation of metaphase spreads
For each Pole proofreading domain-mutant mouse embryonic stem cell line, cells were 
treated with colcemid (0.21µg/ml for 2.5 hours; #15210040, Thermo Fisher Scientific) to 
arrest cells in metaphase. After treatment, cells were washed with PBS, detached with 
0.05% trypsin-EDTA (Thermo Fisher Scientific), collected and centrifuged at 1000 rpm for 
5 minutes. The pellet was resuspended in hypotonic solution (0.2% sodiumcitrate and 
0.2% KCL). After centrifugation, the hypotonic solution was removed. Cells were resus-
pended carefully in fixative solution (4:1, methanol:acetic acid) and centrifuged again. 
This fixation was performed three times before the cells were spread onto glass slides. 
Slides were mounted with DAPI-containing mounting medium (#H-1200, Vectashield). 
At least fifty metaphases were examined for each cell line. Chromosome numbers were 
equal for all cell lines used in subsequent experiments.
Fluorescence in situ hybridization
Bacterial artificial chromosomes (BAC) were ordered from the BACPAC Resource Cen-
ter (Chori, USA): RP24-154A19 containing the Pole gene (5qF), and RP24-388K6 more 
proximal of the CRISPR/Cas9 target sequences (5qA3). DNA from the BAC clones was 
isolated using the Nucleobond Xtra Midi kit (MN740410.10, Macherey Nagel). To use 
the BAC clones as FISH probes, BAC clones were labeled with either biotin-16-dUTP 
(#11093070910, Roche) or digoxigenin-11-dUTP (#11093088910, Roche) using a nick 
translation kit (Roche and Enzo Life Sciences) as described previously.1 Prior to precipita-
tion, Yeast tRNA (#15401011, Invitrogen; ratio yeast tRNA:BAC is 5:1), fish sperm DNA 
(#1146740001, Roche; ratio fish sperm:BAC is 5:1) and Cot-I (#18440016, Invitrogen; ratio 
Cot-I:BAC is 10:1) was added to the probes. Probes were then diluted in hybridization 
mix (50% formamide, 10% dextran sulphate, 2x SSCP; 0.3M NaCl, 0.03M sodium citrate, 
0.04M sodium phosphate).
Metaphase spreads were treated with RNase (10µg per slide, diluted in 2xSSC; 0.3M 
NaCl, 0.03M sodium citrate, pH7) for 10 minutes at 37°C, washed three times in 2xSSC, 
incubated with 0.005% pepsin/0.02M HCl (#10108057001, Roche) at 37°C for 5 minutes, 
and washed twice in PBS. Slides were then fixed in 1% formaldehyde/PBS, washed twice 
in PBS and dehydrated in a graded ethanol series. Ten µl of the probe mix (100ng per 
probe) was added to each slide, after which slides were placed at 80°C for 75 seconds 
for denaturation. Hybridization was performed overnight at 37°C in a moist chamber. 
Slides were washed in stringent wash buffer (K5799, Dako) for 5 minutes at 60°C, twice 
for 3 minutes in wash buffer, and 3 times 5 minutes in Dig-buffer (0.1M Tris, 0.15M NaCl, 
pH7.5) with 0.05% Tween20 (TNT) at room temperature. For detection, slides were 
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incubated with Cy3-labeled streptavidin (1:500, Sigma Aldrich) and FITC-labeled mouse 
anti-digoxigenin antibody (1:250, Sigma Aldrich) for 10 minutes at 37°C. After dehydra-
tion, slides were mounted with mounting medium containing DAPI (Vectashield). A 
minimum of twenty metaphases was examined for each cell line. All cell lines contained 
two copies of the Pole allele (Supplementary Figure 1).
Assessment of mutator phenotypes at the Hypoxanthine Phosphorybosyl 
Transferase (Hprt) gene
Spontaneous mutagenesis at the Hprt gene was determined as described previously.2 In 
brief, cells were cultured in medium containing HAT supplement (#21060-017, Gibco) for 
two consecutive passages to eliminate preexisting Hprt-deficient cells. Subsequently, 
cells were cultured in HT-supplemented medium (#41065-012, Gibco) for one passage, 
followed by two passages in medium without HAT- or HT-supplement, during which 
spontaneous Hprt mutations can accumulate. Afterwards, cells were continuously 
grown in medium with 40 µM 6-thioguanine to select for Hprt-deficient cells. After ap-
proximately ten days, colonies were fixed, stained with methylene blue and counted. 
These counts were corrected for cloning efficiencies.
As controls for this assay, a wild-type and a mismatch repair-deficient mouse embryonic 
stem cell line were used. The mismatch repair-deficient cell line resulted from a knock-
out of Msh6 using CRISPR-Cas9 (guide RNA forward 5’-caccgGGAGCCTCCGCTTCCC-
GCGG-3’, reverse 5’-aaacCCGCGGGAAGCGGAGGCTCC-3’, plasmid Addgene #42230), 
generated similarly to the Pole-mutant cell lines. Msh6 deficiency of the resultant cell 
line was verified by Sanger sequencing of a PCR product amplified from the CRISPR/
Cas9 targeted locus (forward primer 5’-AAAGCACCTTGTACAGCTTC-3’, reverse primer 
5’-GCTTGCCCAATACTCCGAAG-3’), Western Blot for Msh6 (antibody Abcam #14204) and 
by verifying its resistance to low doses of 6-thioguanine (A4882, Sigma Aldrich; 4hr 40 
µM pulse treatment).
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Supplementary Figure 1. Fluorescent In Situ Hybridization of Pole on metaphase spreads of Pole-mutant 
cell line.
FISH was performed using a probe containing the Pole gene (5qF; biotin-labeled probe detected with Cy3-
labeled streptavidin [red]) and a probe proximal of the CRISPR-Cas9 target sequences on the same chro-
mosome (5qA3; digoxigenin-labeled probed detected with FITC-labeled anti-digenoxigenin [green]) with 
DAPI nuclear counterstaining. For each mouse-derived embryonic stem cell line, a minimum of twenty 
metaphases was analyzed: all cell lines showed normal, comparable intensity of the probes on two chromo-










































































Supplementary Figure 2. Spontaneous mutant frequency of Pole-mutant cell lines.
The spontaneous mutant frequency of different homozygous Pole proofreading domain-mutant mouse-
derived embryonic stem cells at the Hypoxanthine Phosphorybosyl Transferase (Hprt) gene was deter-
mined. Wild-type (WT) and Msh6-deficient (Msh6 -/-) mouse-derived embryonic stem cell lines were used 
as controls. D275A/E277A is a Pole proofreading-deficient cell line due to double D275A and E277A muta-
tions. P286R, S297F and V411L indicate cell lines with the cancer-associated POLE P286R, S297F, or V411L 
mutations, respectively. For these Pole hotspot mutations, a minimum of two independent cell lines was 
tested (#1 up to #4). The mean and standard error of the mean based on at least two experiments are shown.

























Pole S297F m/m #2 Pole S297F m/m #4
Pole S297F m/m #3
Pole S297F m/+
Pole S297F m/m #1
Supplementary Figure  3. Sensitivity to nucleoside analogs cytarabine and fludarabine in Pole S297F-
mutant and Pole-wild-type cell lines.
Non-linear regression of relative survival after treatment with nucleoside analogs cytarabine and fluda-
rabine is shown for Pole S297F-mutant and Pole-wild-type mouse embryonic stem cells. With regard to 
the Pole S297F-mutant cell lines, one heterozygous Pole S297F-mutant (m/+) and four homozygous Pole 
S297F-mutant (m/m #1 - #4) cell lines were tested. Sensitivity for the homozygous Pole S297F-mutant cell 
lines was significantly higher compared to Pole-wild-type (for details on these comparisons see also Table 
1 and Supplementary Table 5). A heterozygous Pole S297F mutation resulted in sensitivity lower than the 
homozygous mutant cell lines, but higher than wild-type, reaching significance for cytarabine (mean IC50 
0.14μM vs. 0.17μM; P=0.025 for cytarabine; mean IC50 7.58μM vs. 11.1μM; P=0.169 for fludarabine). Dots and 
error bars indicate mean and standard error of the mean, respectively.
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Supplementary table 1. POLE mutations identified in endometrial cancers in the observation arm of the 
PORTEC-1 trial.
POLE proofreading domain mutation Frequency (n=16)
No. (%) with P286R 7 (44)
No. (%) with V411L 5 (31)
No. (%) with S297F 3 (19)
No. (%) with S459F 1 (6)
Supplementary table 2. Oligonucleotide guide RNA sequences to introduce Pole proofreading domain 
mutations through CRISPR-Cas9.
Pole mutation Forward/reverse Sequence 5’-3’
























External oligo exon 9II Forward TCTGCAAGGTGGCAGTGTAATTAC
Reverse GGACCAGCCTCATCTGACTT
External oligo exon 13II Forward GGCCTCTAAGAAACGGCTTTGG
Reverse CTTCTCGACTCGTTGCAGCAGG
Joining PCR exon 9 Forward CCAATTGGACAACATAGTGGAC
Reverse GTACATGCTGAGGCCATGAATTG
Joining PCR exon 13 Forward GGCTTTGGGTCATAGGGATTTG
Reverse CTAGGATAAGACACCACAGGGC
*Primers were used to generate a template for homologous recombination, to be used with CRISPR-Cas9 
in cell transfection, containing Pole proofreading domain mutations as well as silent mutations in the PAM 
sequences. This template was made using two-stage PCR amplification.
‡The mutation-specific primers together with the common external oligonucleotides were used to gener-
ate overlapping PCR fragments with the different substitutions. Fragments were pooled and amplified with 
the joining primers in a subsequent PCR.
§Pole proofreading domain mutations are shown in bold and underlined. Silent mutations in the PAM se-
quence are underlined.
IIExon 9 contains the D275, E277, P286 and S297 amino acids. Exon 13 contains the V411 amino acid.
Supplementary table 4. Oligonucleotide sequences to identify targeted colonies after transfection.





gDNA Exon 9 
(D275A/E277A, 
P286R, S297F)
Forward GTCCCTTGCTAGTGCTGTCC (95° 30 s, 65° 30 s, 72° 
2 min) 34xReverse TACCTGGGATGCCTACTTGC
gDNA Exon 13
(V411L)
Forward CCCCACGTAGTAGGCAGCTC (95° 30 s, 63° 30 s, 72° 
2 min) 34xReverse GAGCCAATGGGCTTACGTGCC
cDNA Spanning exons 
7-14
Forward GAATCCATGTGGCCCACTGG (95° 30 s, 59° 30 s, 72° 
1 min) 34xReverse AGTCTGGGGCTGTTCAGTGG
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Supplementary table 6. Sensitivity to nucleoside analogs gemcitabine, cladribine and clofarabine con-




gemcitabine (nm) Cladribine (µm) Clofarabine (µm)
IC50
(mean ± Sd) P (95% CI)
IC50
(mean ± Sd) P (95% CI)
IC50
(mean ± Sd) P (95% CI)
WT 16.7 ± 5.74 NA 0.16 ± 0.03 NA 0.23 ± 0.08 NA
Pole D275A/E277A
#1 19.6 ± 6.90 0.379 (-9.69, 3.92) 0.19 ± 0.04 0.049 (-0.06,-0.0002) 0.23 ± 0.06 0.936 (-0.12, 0.13)
#2 18.5 ± 4.12 0.594 (-9.03, 5.46) 0.19 ± 0.05 0.218 (-0.07, 0.02) 0.21 ± 0.05 0.664 (-0.09, 0.14)
Pole P286R
#1 19.2 ± 4.35 0.465 (-9.81, 4.82) 0.22 ± 0.07 0.197 (-0.16, 0.05) 0.22 ± 0.09 0.893 (-0.13, 0.15)
#2 17.2 ± 0.37 0.901 (-8.20, 7.32) 0.21 ± 0.06 0.046 (-0.09, -0.01) 0.19 ± 0.04 0.384 (-0.07, 0.16)
Pole S297F
#1 15.9 ± 0.55 0.820 (-6.97, 8.57) 0.19 ± 0.03 0.112 (-0.07, 0.01) 0.15 ± 0.05 0.172 (-0.05, 0.22)
#2 15.3 ± 0.94 0.685 (-6.34, 9.23) 0.13 ± 0.03 0.126 (-0.01, 0.06) 0.12 ± 0.04 0.067 (-0.01, 0.23)
#3 16.5 ± 1.94 0.962 (-7.71, 8.06) 0.13 ± 0.01 0.047 (0.0005, 0.07) 0.13 ± 0.02 0.068 (-0.01, 0.22)
#4 15.4 ± 0.52 0.661 (-5.24, 7.90) 0.13 ± 0.02 0.082 (-0.004, 0.06) 0.15 ± 0.05 0.135 (-0.04, 0.20)
Pole V411L
#1 17.8 ± 3.12 0.725 (-8.09, 5.83) 0.21 ± 0.03 0.015 (-0.08, -0.01) 0.21 ± 0.06 0.695 (-0.10, 0.14)
#2 17.1 ± 3.88 0.914 (-7.53, 6.81) 0.17 ± 0.03 0.566 (-0.04, 0.02) 0.19 ± 0.09 0.547 (-0.11, 0.19)
*Sensitivity to nucleoside analogs gemcitabine, cladribine and clofarabine was determined for all Pole 
proofreading domain-mutant cell lines and compared to the sensitivity of the Pole-wild-type (WT) mouse 
embryonic stem cell line; the corresponding P-values are shown. None of the P-values remained statistically 
significant after Holm-Bonferroni correction for multiple comparisons.
Abbreviations: SD, standard deviation; CI, confidence interval; NA, not applicable.
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Somatic POLE exonuclease domain mutations 
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colorectal carcinogenesis, determining driver 
mutation landscape, clonal neoantigen burden 
and immune response
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AbStrACt
Genomic instability, a hallmark of cancer, is generally thought to occur in the mid to 
late stages of tumorigenesis, following the acquisition of permissive molecular aber-
rations such as TP53 mutation or whole genome doubling. Tumors with somatic POLE 
exonuclease domain mutations are notable for their extreme genomic instability (their 
mutation burden is among the highest in human cancer), distinct mutational signature, 
lymphocytic infiltrate and excellent prognosis. To what extent these characteristics are 
determined by the timing of POLE mutations in oncogenesis is unknown. Here, we have 
shown that pathogenic POLE mutations are detectable in non-malignant precursors of 
endometrial and colorectal cancer. Using genome and exome sequencing, we found 
that multiple driver mutations in POLE-mutant cancers display the characteristic POLE 
mutational signature, including those in genes conventionally regarded as initiators 
of tumorigenesis. In POLE-mutant cancers, the proportion of monoclonal predicted 
neoantigens was similar to other cancers, but the absolute number was much greater. 
We also found that the prominent CD8+ T cell infiltrate present in POLE-mutant cancers 
was evident in their precursor lesions. Collectively, these data indicate that somatic POLE 
mutations are an early, quite possibly initiating, event in the endometrial and colorectal 
cancers in which they occur. The resulting early onset of genomic instability may ac-
count for the striking immune response and excellent prognosis of these tumors, as well 
as their early presentation.
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IntroduCtIon
Next generation sequencing (NGS) technologies have hugely advanced our understand-
ing of the mechanisms of tumorigenesis. The ability to analyze the entire genome or 
exome at depth in large numbers of tumors has substantially increased the list of driver 
genes – that is those which, when mutated, promote tumor growth. It has also revealed 
that such driver mutations are not always present in the dominant tumor clone.1,2 This 
is clinically relevant, because targeting subclonal drivers is likely to kill only a subpopu-
lation of tumor cells, while successful targeting of clonal variants may lead to tumor 
eradication. Thus, differentiating early, clonal mutations from late, subclonal ones may 
not only increase our understanding of the mechanisms of oncogenesis, but also inform 
the clinical management of patients.2 
Fundamentally, all mutations are caused in part by a failure to recognize or repair defects 
in DNA sequence or chromosome structure. In many cancers, this is a consequence of 
specific defects in the cellular processes responsible for maintaining genomic integrity.3 
One recently described example is the genomic instability caused by missense mutations 
in the exonuclease (proofreading) domains of the major replicative DNA polymerases 
POLE and POLD1.4 Polymerase proofreading recognizes and corrects mispaired bases 
incorporated during DNA replication; its perturbation as a result of these mutations 
is associated with an exceptional number of SNVs (though not indels), and a distinct 
mutational signature typified by C:G→A:T transversions where the mutated cytosine is 
in the context TCT, and C:G→T:A transitions where the mutated cytosine is in the context 
TCG.4-6 POLE and POLD1 exonuclease domain mutations may occur in the germline, 
where they cause polymerase proofreading-associated polyposis (PPAP) – a condition 
characterized by intestinal polyposis and tumors of the colorectum and uterus, among 
other organs.7 Somatic POLE exonuclease domain mutations (hereafter simply referred 
to as POLE mutations) occur in sporadic tumors of the endometrium (7-15% cases),8,9 
colorectum (1-2%),10,11 and less commonly in other cancers (although for reasons that 
are unclear, somatic POLD1 exonuclease domain mutations are very uncommon). POLE-
mutant colorectal and endometrial cancers have an excellent prognosis,8,11-13 probably 
owing to a robust antitumor immune response against the multitude of immunogenic 
neoantigens they are predicted to harbor.11,14,15 Very recent reports also suggest that 
these tumors may be highly responsive to immune checkpoint inhibition.16 
While it is clear that somatic POLE mutation causes a mutator phenotype17 and acts as 
a cancer driver,4,5 several questions about its contribution to tumorigenesis remain un-
answered. One of the most important of these relates to the timing of these mutations 
in cancer development. If POLE mutations are late events, their consequences may be 
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restricted to a subclone of tumor cells, the targeting of which may fail to meaningfully 
alter tumor behavior. In contrast, if POLE mutations occur early, they could rapidly cause 
a large number of clonal alterations that may alter prognosis or response to therapy. 
This is particularly pertinent in the light of recent data suggesting that long-term benefit 
from immune checkpoint inhibition is limited to patients whose cancers harbor neoan-
tigens in the dominant tumor clone.18 In contrast to germline mutations in DNA repair 
pathways in rare inherited syndromes (such as the mismatch repair gene variants that 
cause Lynch syndrome), the acquisition of genomic instability in sporadic cancers has 
largely been believed to be a mid- to late-stage event during carcinogenesis.19 For ex-
ample, in sporadic colorectal cancer – a tumor type in which the molecular progression 
of precancers (adenomas) to invasive carcinomas has been well-characterized – mis-
match repair deficiency (MMR-D) or chromosomal instability (CIN) occur after initiating 
(epi)mutations in APC, BRAF or KRAS, or other events such as whole genome doubling 
or loss of chromosome 18q.19-24 Thus, in addition to its clinical relevance, the demonstra-
tion that the POLE mutator phenotype operates from the first stages of tumor initiation 
would also reveal a novel pathway of sporadic tumorigenesis. A recent case report of a 
pathogenic POLE mutation in an endometrial cancer and its precursor25 suggests that 
these mutations may occur early in tumor development, but the single case precludes 
generalization of this result.
In this study, we comprehensively examined the timing of pathogenic somatic POLE 
exonuclease domain mutations in sporadic endometrial and colorectal cancers using 
tumor whole genome sequencing (WGS), public sequencing data from The Cancer 
Genome Atlas (TCGA),8,10 and targeted sequencing of additional cohorts of cancers and 
precancers.
mAterIAlS And methodS
Patients and tumor samples
Details of the cohorts and cases analyzed in this study are shown in Supplementary 
Tables 1 and 2. Fifty-one formalin-fixed paraffin-embedded (FFPE) endometrial cancers 
carrying known pathogenic somatic POLE exonuclease domain mutations identified in 
our previous studies12,14,26 were reviewed for the presence of a concomitant and spatially 
discrete area of endometrial intraepithelial neoplasia (EIN) by examination of hematoxy-
lin and eosin (H&E)-stained slides by two expert gynecological pathologists (V.S. & T.B.). 
389 FFPE colorectal polyps (tubular adenomas, tubulovillous adenomas and serrated 
adenomas – hereafter referred to as adenomas), for which POLE screening had not previ-
ously been performed, were identified from 261 participants in the CORGI study, which 
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recruited patients with a family history of colorectal cancer and a personal history of a 
colorectal polyp or colorectal malignancy in the absence of a known tumor predisposi-
tion syndrome. Six fresh frozen tumors with pathogenic somatic POLE mutations (five 
endometrial, one colorectal) were identified from a Leuven endometrial cancer cohort 
used in our previous study,12 a prospective clinical sequencing program (HICF2) at the 
University of Oxford, or the University of Birmingham tissue bank. TCGA colorectal 
(COADREAD)10 and endometrial (uterine corpus endometrial carcinoma – UCEC)8 cancer 
data were downloaded from the Genomic Data Commons (GDC) Data Portal (https://
portal.gdc.cancer.gov; June 2017). An additional series of 78 FFPE endometrial cancers 
including 32 cases with pathogenic somatic POLE mutations were identified from the 
LUMC archives (2001-2015).14 Further details of the cohorts used in this study are pro-
vided in Supplementary Table 1. Molecular analyses were performed on a single tumor 
or precursor lesion region in each case.
dnA extraction 
After review to confirm adequate tumor cellularity, DNA was extracted from fresh frozen 
or microdissected FFPE tumors and precursors using standard methods (Roche FFPE-T 
DNA kit, Machery Nagel Nucleospin DNA FFPE XS / FFPE DNA kit or Qiagen Blood and 
Tissue kit) and resuspended in buffer or water.
dnA sequencing
Full details of the sample preparation and the sequencing methods utilized in this study 
are provided in the Supplementary Methods. Briefly, endometrial epithelial neoplasias 
(EIN) and paired carcinomas were sequenced for mutations in 30 cancer genes using 
molecular inversion probe capture, and a custom version of the 72 gene Ion AmpliSeq 
Cancer Hotspot panel v2 (including 80 genes; ThermoFisher) (Supplementary Tables 
3 and 4). Whole genome sequencing (WGS) of fresh frozen tumors was performed by 
Illumina HiSeq, and aligned to the reference genome by BWA mem or Isaac.27 FFPE en-
dometrial cancers from the LUMC series were analyzed using the Lifetech/ThermoFisher 
Ion AmpliSeq Comprehensive Cancer Panel comprising 409 cancer genes (http://www.
lifetechnologies.com/order/catalog/product/4477685). Mutation calling was performed 
by LoFreq28 (EINs), Mutect, Mutect229 or Strelka30 (WGS, TCGA cases), or Ion Torrent 
variantCaller (EINs, LUMC FFPE tumors). Copy number profiles were derived using Se-
quenza.31 Variant annotation was done using Annovar32 or Variant Effect Predictor.33 
definition of driver genes
Driver genes were defined using the IntOGen driver gene repository (https://www.into-
gen.org/search) and included both PanCancer (Pooled_driver) and tumor type-specific 
(perProject_driver) variants (Supplementary Tables 5 and 6).34 High confidence driver 
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mutations (defined as either truncating mutations in genes likely to be tumor suppres-
sors or recurrent missense mutations in any endometrial or colorectal cancer-specific or 
pan-cancer gene from the IntOGen set), were determined for a subset of driver genes by 
manual curation, blinded to tumor molecular characteristics.
Clonality of POLE mutations
Most (36 of 38) endometrial and colorectal cancers with pathogenic POLE mutations 
were disomic at the POLE locus (chr12q24) and were informative for clonality analysis. 
Of these, 20 of 22 endometrial cancers, and 12 of 14 colorectal cancers had available 
copy number annotation. As all 32 of these showed near-diploid genomes (>80% of the 
genome), we assumed diploid genomes for the four remaining cases.
Mutations were filtered to include only autosomal variants in diploid regions of the 
genome, called with depth of at least 20x. Mutation allele frequency distributions were 
generated using the R ‘histogram’ function, and tumor cellularity inferred as twice the 
mid-point of the allele frequency bin with highest mutation density, excluding bins with 
a lower bound below allele frequency 0.1. These values were then subjected to manual 
curation. The hypothesis that the mutation was present in every tumor cell was tested 
by a one-sided binomial test, based on the numbers of reference and variant reads at 
the POLE mutation site and the inferred tumor cellularity. Specifically, for a mutation 
with coverage R, in a tumor with cellularity C, the number of variant reads was modelled 
as a random variable X, with distribution: X ~ Binom(R, C / 2). In each case we calculated 
the probability, p, of finding the observed number of variant reads, v, or fewer, P(X≤v). 
Mutations were considered subclonal for p≤0.05.
mutational signatures
Previously reported mutational signatures were obtained from http://cancer.sanger.
ac.uk/cosmic/signatures/ on 1st June 2017. The complement of mutational processes 
active in the life-history of each tumor sample was inferred by classification of mutations 
into 96 categories following Alexandrov,6 and the use of non-negative least squares 
regression, implemented in the R package ‘nnls’. For this analysis, only mutational signa-
tures previously reported as active in that cancer type (endometrial signatures 1, 2, 5, 6, 
10, 13, 14 and 26; colorectal signatures 1, 5, 6, and 10) were used for the regression. For 
cases analyzed by whole exome sequencing, mutational signatures were re-scaled to 
exomic trinucleotide frequencies. A mutational process was deemed to have been active 
in the life-history of a tumor if the associated mutational signature had a coefficient of at 
least 2 percent of the total coefficients in the best-fitting model. Mutations likely to be 
due to POLE exonuclease domain mutation (POLE) were identified by considering muta-
tional signatures as multinomial probability distributions caused by specific mutational 
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processes. The probability of each mutation under all mutational processes active in that 
tumor was calculated, and mutations were assigned to the “POLE” mutational process in 
cases where the probability under that process was at least twice the probability under 
any other process.
POLE consensus mutational signature scores in driver genes
Tumor mutations were obtained from calling based on tumor/normal .bam files (POLE 
mutant cases) or TCGA MAF files (MMR-P, MMR-D cases), and classified into 96 categories 
following Alexandrov.6 For each tumor, the distribution of mutations across the 96 types 
was calculated, and re-scaled to trinucleotide frequencies based on sequencing type, thus 
obtaining an individual tumor mutational signature. Tumors were then categorized into 
three groups according to POLE mutation and mismatch repair status (i.e. POLE-mutant, 
MMR-P and MMR-D), and a consensus mutational signature was calculated for each group 
as the average of the individual-tumor signatures among samples in the group, weighted 
by the number of mutations in each sample. The probability of all non-silent mutations 
(‘nonsynonymous SNV’, or ‘stopgain’) in driver genes (as defined above) under each of the 
three consensus mutational signatures was then calculated, and the ratio of the probability 
of each mutation under the POLE consensus mutational signature compared to that under 
each of the other two consensus mutational signatures was obtained. For each individual 
gene, a ‘POLE score’ was then calculated as the base two logarithm of the minimum value 
of these ratios across all the non-silent mutations within that gene.
Immunohistochemistry
Immunohistochemistry (IHC) for CD8 was performed as previously reported.14 The 
number of CD8+ cells was quantified for the epithelial and stromal regions of the EIN. For 
the final CD8 count per case, the mean of these regions in ten high-power fields (HPF; 
625μm x 425μm) was calculated. A similar method was used to quantify CD8 density in 
colorectal adenomas, although the small lesion size meant that estimates were obtained 
from the mean of two or three HPFs.
Clonal neoantigen prediction
We estimated the number of clonal neoantigens using a modification of our previously-
reported algorithm,11 modified to predict peptide binding against patient-specific HLA 
molecules (determined from WGS or WES data using OptiType35). Neoantigens were 
defined as mutations predicted to specify peptides that bound patient HLA molecules 
with affinity <500nm. Copy number information was obtained from the GDC data portal, 
as described above. Clonality was determined as described above. Neoantigens were 
considered clonal if the binomial test P-value was over 0.05.
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Statistical analysis
Analyses were performed using R (CRAN network) or Prism (GraphPad Software). Statis-
tical comparison between groups was made using the non-parametric Mann-Whitney U 
test. All P values were two sided, unless otherwise specified. Statistical significance was 
accepted at P<0.05.
ethical approval
Patient consent for research on tumor tissue was obtained at the recruiting centers 
under local ethical approval. Molecular analysis of anonymized tissue was performed 
under Oxford Research Ethics Committee A approval (05/Q1605/66).
reSultS
Somatic POLE exonuclease domain mutations are detectable in sporadic 
endometrial and colorectal precancers 
As somatic POLE exonuclease domain mutations have been best characterized in endo-
metrial and colorectal cancers, we first examined whether these mutations were present 
in precursors of these malignancies. Expert histopathological review of 51 POLE-mutant 
endometrial cancers revealed four with a concomitant and spatially discrete area of 
endometrial intraepithelial neoplasia (EIN), the precursor of endometrioid carcinoma 
(Supplementary Table 2). Microdissection and targeted sequencing of these lesions by a 
30-gene molecular inversion probe capture NGS panel (Supplementary Table 3), a cus-
tom 80 gene Ion Ampliseq Cancer Hotspot panel (Supplementary Table 4) and Sanger 
sequencing revealed that in all cases, the POLE mutation present in the carcinoma was 
also detectable in the paired precursor (Figure 1A-B; Supplementary Table 7). While some 
other driver mutations were also shared between the precursors and paired cancers 
(median 4 shared mutations per pair, relative to a median of 7 mutations per EIN and 
median of 10 mutations per carcinoma), the progression from EIN to malignancy was as-
sociated with both the loss (median 3 mutations lost in carcinomas compared to paired 
EINs) and, more frequently, gain (median 6 mutations gained in carcinomas compared 
to paired EINs) of driver mutations (Figure 1A-B; Supplementary Table 7). Notably, many 
of the driver mutations gained were replacements of a glutamic acid or arginine codon 
with a nonsense codon (E→* or R→*), consistent with the characteristic mutational bias 
associated with POLE mutation (C:G→A:T transversions where the mutated cytosine is in 
the context TCT, and C:G→T:A transitions where the mutated cytosine is in the context 
TCG) (Figure 1B; Supplementary Table 7).4-6
We were unable to perform a corresponding analysis of colorectal tumors, because 
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Figure 1. Pathogenic, somatic POLE exonuclease domain mutations in precursors of endometrial and 
colorectal cancers.
Expert histopathological review of 51 endometrial cancers with pathogenic POLE exonuclease domain mu-
tations revealed four with concomitant and spatially discrete area of endometrial intraepithelial neoplasia 
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residual precursor is uncommon in colorectal carcinomas. However, screening of 389 
colorectal adenomas from 261 patients revealed three (0.8% adenomas, 1.1% patients) 
with somatic POLE mutations (Figure 1C), a frequency concordant with that found in 
colorectal cancers.11 Unfortunately, the limited amount of DNA available from these 
lesions precluded analysis of other driver mutations.
mutational landscape and driver gene alterations suggest that somatic POLE 
mutation is an early event in sporadic endometrial and colorectal cancers
To further investigate the timing and consequences of POLE mutations in tumor de-
velopment, we performed WGS on six cancers (five endometrial, one colorectal), all of 
which harbored the most common pathogenic POLE exonuclease domain variant – a 
proline to arginine substitution at codon 286 (POLE P286R; Figure 2A). Each displayed 
a substantially elevated mutation burden (122–731 mutations/Mb), and characteristic 
preponderance of C:G→A:T substitutions in the context TCT (Figure 2A-B; Supplementary 
Table 8).6 In keeping with their early occurrence, both the POLE mutations themselves, 
and other mutations consistent with the known POLE mutational signature (see Materi-
als and methods, Mutational signatures) appeared clonal in all six cases (Figure 2C). This 
was also the case in 17 of 17 endometrial cancers and 12 of 13 colorectal cancers with 
pathogenic POLE exonuclease domain mutations from the TCGA series (Supplementary 
Figure 1 and 2). This analysis showed that POLE mutations were unlikely to occur as late 
events after the most recent common ancestor in cancer evolution.
We next examined the timing of POLE mutations in carcinogenesis in more detail by 
analysis of driver genes, including some known usually to be mutated early in the 
pathogenesis of endometrial or colorectal cancer. To assess the likelihood that muta-
tions in these genes were secondary to an earlier POLE mutation, we developed a metric 
to score them according to the probability that they were caused by the mutational 
process dominant in POLE-mutant cancers (presumably caused by the POLE mutation 
itself ), rather than the mutational processes operative in other tumors (see Materials 
and methods, POLE consensus mutational signature score for details). For this analysis, 
(EIN). (A) Hematoxylin and eosin (H&E)-stained section from one case with results of Sanger sequencing 
of the malignant and precursor components. (B) Targeted sequencing of paired endometrial lesions by 
two orthogonal next generation sequencing panels revealed that POLE mutations (bold, underlined) were 
present in both EIN and carcinomas in all cases (validated by Sanger sequencing in all cases). In each case, 
progression of EIN to endometrial carcinoma was associated with the gain of driver mutations, several of 
which were glutamic acid or arginine to stop codon mutations (E→* or R→*) consistent with the POLE exo-
nuclease domain-mutant mutational signature (semibold). †The amount of DNA available from the EIN in 
case Q1-4 was insufficient for molecular inversion probe sequencing. Details of identified driver mutations 
are provided in Supplementary Table 7. (C) H&E-stained section from colorectal adenoma with the results of 
Sanger sequencing and allelic discrimination PCR for the wild-type G allele and mutant T allele.
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Figure 2. Whole genome sequencing of cancers with POLE exonuclease domain mutations.
(A) Mutation burden and single nucleotide variant (SNV) type determined by whole genome sequenc-
ing (WGS) of five endometrial cancers (EC– Oxf001, POLE_040, POLE_049, POLE 072, POLE_147) and one 
colorectal cancer (CRC – Bir001) with somatic POLE P286R exonuclease domain mutations. (B) Relative pro-
portion of SNV mutations according to trinucleotide context averaged across the six POLE-mutant cases. 
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we combined our cohort of POLE-mutant tumors with POLE-mutant cases from TCGA, 
using MMR-P and MMR-D TCGA cases as comparators. Strikingly, in POLE-mutant tu-
mors, almost all known cancer driver genes displayed evidence of the POLE consensus 
mutational signature, with the notable exception of POLE itself (Figures 3 and 4; Supple-
mentary Tables 8–10), consistent with the postulate that the POLE signature is a direct 
effect of the polymerase proofreading mutation. In contrast, MMR-P and MMR-D tumors 
rarely showed evidence of the POLE consensus mutational signature (Figures 3 and 4; 
Supplementary Tables 8–10). In total, among 206 endometrial and/or colorectal cancer 
driver genes examined in the cases from the combined endometrial and colorectal can-
cer cohorts, 50% (1,065/2,118) of those in POLE-mutant samples had a POLE signature 
score >0, compared to 14% (628/4,427) in MMR-D and MMR-P cancers (P<1x10-26).
To minimize the possibility of confounding by non-pathogenic mutations in the 
complete set of driver genes, we repeated these analyses considering only manually 
curated, high-confidence pathogenic mutations, and obtained similar results (P<1x10-26; 
Supplementary Figures 3 and 4). As mutation of the tumor suppressors PTEN and APC 
are well recognized as early, if not initiating, events in the pathogenesis of endometrial 
and colorectal cancers respectively, we specifically examined whether somatic variants 
in these genes varied according to tumor POLE mutation status. Among high-confi-
dence pathogenic PTEN mutations in endometrial cancers, the proportion with POLE 
consensus mutational signature scores >0 was substantially and significantly greater 
among POLE-mutant cases than among MMR-P and MMR-D tumors (10 of 14 (71.4%) 
vs. 14 of 82 (17.1%) mutations respectively; P=7.8x10-3, Fisher’s Exact Test). Analysis of 
high-confidence pathogenic APC mutations in colorectal cancers revealed similar results 
(corresponding proportions 9 of 14 (64.3%) vs. 10 of 69 mutations (14.5%); P=0.012, 
Fisher’s Exact Test).
Further analysis of these cohorts and of targeted sequencing data from an additional se-
ries of endometrial cancers from the Leiden University Medical Center (LUMC), including 
32 POLE-mutant tumors, confirmed the over-representation of E→*, R→* and arginine to 
glutamine substitutions (R→Q) among POLE-mutant cases, concordant with the results 
The upper panel shows the unscaled proportions across the whole genome, while the lower panel shows 
the inferred mutational signature in a hypothetical genome where all trinculeotide frequencies are rep-
resented in equal proportions. (C) Frequency histograms and kernel density plots showing variant allele 
fraction (VAF) of all SNV mutations, and SNVs likely due to POLE exonuclease domain mutation (POLE). POLE 
mutations and other driver gene mutations are highlighted by arrows (details provided in Supplementary 
Table 8). Only mutations in diploid regions of autosomes, and with coverage >20x are shown. The relatively 
low proportion of SNVs categorized as being due to POLE mutation reflects the stringency of the classifica-
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Somatic POLE mutations are early events in sporadic cancers
from the paired endometrial lesions and consistent with the known trinucleotide bias 
of the POLE mutational signature (Supplementary Figures 5-7; Supplementary Tables 
7-11). Interestingly, this was evident not only in well-characterized drivers such as PTEN 
in endometrial cancer and APC in colorectal cancer as noted above, but also in recurrent, 
clonal driver mutations found rarely in that tumor type. For example, in the combined 
TCGA/LUMC endometrial cancer cohorts, truncating mutations in the tumor suppressors 
APC, NF1 and RB1 were very rare in POLE-wild-type tumors (1.1%, 1.5% and 1.5% respec-
tively), but common among POLE-mutant cases (38.8%, 34.7% and 34.7% respectively; 
P<0.001 for each comparison, Fisher’s exact test), where they almost invariably occurred 
at glutamic acid or arginine codons (Supplementary Figures 5-7; Supplementary Tables 
9 and 11).
Collectively, these data suggested that somatic POLE mutation occurs early in endome-
trial and colorectal cancers, and that its attendant mutator phenotype defines a distinct 
pathway of carcinogenesis from the initial stages of this process.
Somatic POLE mutations are associated with a prominent t cell infiltrate in both 
precancerous and cancerous lesions
Somatic POLE exonuclease domain mutations in endometrial and colorectal cancers 
are associated with enhanced tumor immunogenicity and favorable prognosis.11,14,15 We 
speculated that the early acquisition of somatic POLE mutations would cause a rapid 
acquisition of mutations, some of which would produce neoantigens capable of elicit-
Figure 3. POLE signature mutations in endometrial cancer driver genes.
Heatmap showing modelled probability that mutations in endometrial cancer driver genes (defined based 
on IntOGen – see Materials and methods, Definition of driver genes; Supplementary Table 5) were due to 
a prior POLE exonuclease domain mutation. Results are shown for samples with a pathogenic POLE muta-
tion and MMR-D and MMR-P comparators. Each nonsynonymous mutation in a driver gene was assigned 
a probability that it was caused by the mutational process that generates the distinct POLE mutational 
signature, rather than by the mutational processes responsible for the consensus mutational signatures of 
POLE-wild-type DNA mismatch repair-proficient (MMR-P) and mismatch repair-deficient (MMR-D) tumors 
(see Materials and methods, POLE consensus mutational signature scores in driver genes, for details). For 
each gene/sample combination, a ‘POLE-score’ was then calculated as the minimum value of these ratios, 
and plotted as a heatmap. Scores are shown for both individual POLE-mutant tumors and the combined 
POLE-mutant subgroup; results for tumors within the POLE-wild-type, mismatch repair-proficient (MMR-
P) and POLE-wild-type, mismatch repair-deficient (MMR-D) subgroups are combined for clarity. Scores for 
POLE itself are shown for reference. Details of mutations are provided in Supplementary Tables 8 and 9.
Figure 4. POLE signature mutations in colorectal cancer driver genes.
Corresponding heatmap to Figure 3 showing results for known colorectal cancer driver genes, (defined 
base on IntOGen – see Materials and methods, Definition of driver genes; Supplementary Table 4). Details 
of mutations are provided in Supplementary Tables 8 and 10.
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Figure 5. T cell infiltrate in POLE-mutant precursor lesions.
(A) Representative images of immunohistochemistry (IHC) for the cytotoxic T cell marker CD8 in endometri-
al intraepithelial neoplasias (EIN) and paired concomitant endometrioid adenocarcinomas and in colorectal 
adenomas according to POLE mutation status. (B) Quantification of CD8+ infiltrate density (number of CD8+ 
cells per high power field (HPF) calculated as the mean of 10 high power fields) in POLE-wild-type and 
POLE-mutant paired endometrial intraepithelial neoplasia (EIN) and endometrial carcinoma (EC) (n=4 EIN–
carcinoma pairs for each genotype) and in POLE-wild-type and POLE-mutant colorectal adenomas (Ad; n=5 
POLE-wild-type lesions, and the single POLE-mutant adenoma informative for analysis). Symbols (square, 
circle, triangle and diamond) correspond to paired EIN and endometrial carcinomas for POLE-wild-type 
(open symbols) and POLE-mutant (closed symbols) cases. For colorectal adenomas open and closed tri-
angles correspond to unpaired POLE-wild-type and POLE-mutant adenomas respectively. Statistical com-
parisons in (B) were performed by unadjusted Mann-Whitney U test.
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ing an antitumor immune response. Consistent with this prediction, all POLE-mutant 
EINs displayed a prominent CD8+ infiltrate (Figure 5A), which was significantly greater 
than that in POLE-wild-type EINs (median 59.4 vs. 14.8 CD8+ cells per high power field 
(HPF); P=0.029 Mann-Whitney U test), and exceeded that observed in the POLE-wild-
type endometrial carcinomas, although this difference was not statistically significant 
(median 59.4 vs. 24.7 CD8+ cells per HPF, P=0.11; Figure 5B). The increased CD8+ cell 
density in POLE-mutant EINs could not obviously be explained by other factors such as 
patient age, or the stage or grade of the paired carcinoma (Supplementary Table 2). In 
contrast, the differences in CD8+ density between EINs and paired carcinomas among 
both POLE-wild-type and POLE-mutant cases were less marked (median 14.8 vs. 24.7; 
P=0.34, and 59.4 vs. 116.9; P=0.11 respectively). The single POLE-mutant colorectal ad-
enoma for which IHC was possible also demonstrated a dense CD8+ infiltrate (154.9 vs. 
median 34.0 CD8+ cells per HPF; Figure 5A-B).
Figure 6. Clonality of predicted neoantigens in POLE-mutant colorectal cancers.
Neoantigens were predicted based on the binding affinity of mutant peptides for patient class I HLA mol-
ecules, and assigned clonal or subclonal status (see Materials and methods, Clonality of POLE mutations). 
The number of clonal and subclonal neoantigens for POLE-wild-type, mismatch repair-proficient (MMR-P), 
POLE-wild-type, mismatch repair-deficient (MMR-D) and POLE-mutant colorectal cancers from the TCGA 
series is shown. Cases in each molecular subgroup were selected to provide broadly similar proportions 
of disease stages and patient ages: molecular subgroups did not differ significantly in either parameter. 
Comparison of the number of clonal neoantigen burden between groups was performed by unadjusted 
Mann-Whitney U test.
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Somatic POLE mutations in colorectal cancer are associated with enhanced 
predicted clonal neoantigen burden 
Recent data have shown that the presence of predicted neoantigens within the major 
tumor clone correlates with benefit from immune checkpoint inhibitor therapy.18 As the 
limited amount of FFPE-derived DNA from precursor lesions was inadequate for clonal-
ity analysis and neoantigen prediction, we examined predicted neoantigen clonality in a 
subset of TCGA colorectal cancers including MMR-P, MMR-D and POLE-mutant subtypes, 
broadly matched for patient age and tumor stage. We used an approach similar to our 
previous reports,11,14 modified to incorporate patient-specific HLA haplotypes obtained 
using OptiType35 and estimates of tumor clonality derived from analysis of variant al-
lele frequencies (see Materials and Methods, Clonal neoantigen prediction). Analysis of 
our combined cohort by this pipeline confirmed that POLE-mutant colorectal cancers 
harbored a substantially greater number and density of predicted clonal neoantigens 
(0.12 per Mb) than tumors lacking POLE mutations, including both MMR-P (0.0029 per 
Mb; P=0.0002, Mann-Whitney U test) and hypermutated MMR-D cases (0.044 per Mb; 
P=0.03; Figure 6; Supplementary Figure 8).
dISCuSSIon
In this study, we have presented multiple lines of evidence to show that pathogenic, 
somatic POLE exonuclease domain mutations are usually early and, as far as we can 
detect, initiating events in endometrial and colorectal tumorigenesis. We show that 
the acquisition of POLE mutation causes a distinct pattern of mutations in cancer driver 
genes, substantially increased mutation burden and an enhanced immune response, 
detectable even in precancerous lesions. Furthermore, we show that early somatic POLE 
exonuclease domain mutations are likely to cause an enrichment of clonal neoantigens 
that may explain their good prognosis and excellent response to immune checkpoint 
inhibitors.
APC mutation has traditionally been regarded as the initiating event in sporadic colorectal 
cancers that develop along the canonical pathway,19 while mutation of PTEN is thought 
to play a similar role in sporadic endometrioid endometrial cancers.36 Our evidence sug-
gests that in sporadic colorectal and endometrial cancers with pathogenic somatic POLE 
mutations, the POLE mutation is antecedent to either of these events. The consequent 
mutator phenotype it causes influences the type of mutations in these genes and that of 
the other earliest driver mutations in these cancers, as well as determining their overall 
mutational landscape.6 Whether any of these POLE-induced driver mutations represent 
targetable alterations will be an important topic for future research. Similarly, while the 
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increased burden of predicted clonal neoantigens in POLE-mutant tumors may explain 
their enhanced immunogenicity, further work is required to understand the molecular 
factors that determine this and its therapeutic implications. A further intriguing possibil-
ity is that the mutator phenotype and mutational bias drives cancers into an evolution-
ary cul-de-sac of sub-optimal fitness. The presence of APC mutations as an alternative to 
CTNNB1 mutations in some POLE-mutant endometrial cancers is an exemplar, and there 
are likely to be others, such as NF1 and RB1 mutations in endometrial cancer and atypical 
(Q61P, K117N and A146T) KRAS mutations in colorectal cancer. Examination of this hy-
pothesis by comparing the oncogenic effects of these uncommon mutations with those 
caused by more typical variants in model systems would be of considerable interest.
Our data add to the expanding body of evidence suggesting that the effects of genomic 
instability in cancer depend upon both its severity and timing. For example, upregulation 
of APOBEC cytosine deaminase enzymes is common in many types of cancers, resulting 
in an increased mutation rate and characteristic mutation spectrum.6 However, APOBEC 
overexpression often occurs as a late event in advanced tumors and causes a more modest 
mutator phenotype than POLE mutations.2,6 Speculatively, these features may explain why 
the impact of APOBEC on prognosis appears more variable than that of POLE mutation.37,38 
The early acquisition of somatic POLE mutations in sporadic cancers may also help to 
explain their association with young age at diagnosis, given the prediction that the early 
gain of a mutator phenotype will accelerate the process of malignant transformation.39
Our study has limitations. The number of precursor lesions informative for detailed 
analysis was limited, in keeping with the relative rarity of POLE mutations in endometrial 
cancer, and the frequency with which precancerous and cancerous lesions occur in the 
same tumor section. Moreover, although the spatial separation of the precancerous and 
cancerous compartments, and the discordance in molecular alterations between the 
two components in each case suggests otherwise, we cannot exclude the possibility that 
the apparent precursor lesion is in fact adenocarcinoma colonizing endometrial glands. 
It will therefore be important to validate our results in additional cohorts, although 
we note that a very recent study has documented a pathogenic POLE mutation in an 
endometrial cancer precursor.25 Furthermore, all our results are based on the analysis 
of a single sample of each cancer, meaning that the effects of intratumor heterogene-
ity on the pattern of driver mutations and clonal neoantigens in POLE-mutant tumors 
requires further definition. However, the absence of multi-region sequencing is unlikely 
to have confounded the principal conclusions of our study regarding the timing of these 
pathogenic mutations in cancers.
In summary, we show that pathogenic, somatic POLE exonuclease domain mutations 
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are early, quite possibly initiating, events in sporadic cancers, and strongly shape sub-
sequent tumor evolution. Our observation provides further insights into the distinct 
biology of these tumors, and may help explain their increased immunogenicity and 
excellent prognosis.
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Endometrial epithelial neoplasias (EIN) and paired endometrial cancers were analyzed by 
a custom molecular inversion probe (MIP) panel covering 30 genes commonly mutated 
in endometrial and colorectal cancers (Supplementary Table 3), and a clinical-grade Ther-
moFisher Ion AmpliSeq Cancer Hotspot Panel v2, which includes 376 amplicons across 
80 genes (Supplementary Table 4). For the MIP panels, libraries were sequenced on an 
Illumina NextSeq and aligned to GrCh37 using BWA mem. Variants were called using 
LoFreq1 and annotated by VEP.2 Only variants with VAF >0.1 were used for analysis. For 
the Ion AmpliSeq panel, library preparation was performed according to the manufac-
turer’s protocol using 50ng of genomic DNA. Libraries were normalized to 60pM, loaded 
on a PI chip using the Ion Chef System (ThermoFisher), and sequenced with the Ion 
Proton System (ThermoFisher). The generated reads were aligned to the human refer-
ence genome (GRCh37) using the TMAP 5.0.7 software with default parameters (https://
github.com/iontorrent/TS). The Ion Torrent specific variant caller was used for variant 
calling (ThermoFisher) and Geneticist Assistant (Softgenetics) for variant interpretation. 
Variants were removed with a variant allele frequency of <0.1 and/or with a coverage of 
<100. Called mutations were visually inspected using the Integrative Genomics Viewer 
(IGV) software (http://software.broadinstitute.org/software/igv/). All POLE mutations 
were confirmed by Sanger sequencing as previously reported,3 with the exception of 
one EIN with low DNA yield, for which competitive allele-specific PCR (LGC Genomics) 
assay was used (details of primers and reaction conditions available on request). FFPE 
colorectal adenomas were screened for somatic POLE exonuclease domain mutations by 
a combination of Sanger sequencing and competitive allele-specific PCR as described 
previously.4 
DNA from fresh frozen endometrial tumors and paired normal samples for whole 
genome sequencing (WGS) was quantified using the Qubit® 2.0 fluorometer (Life Tech-
nologies, Paisley, UK), and fragmented using the Covaris M220 ultrasonicator (Covaris, 
Inc., Woburn, MA) to an average fragment size of 250-300bp. Approximately 50ng was 
used as input for the NEBNext® Ultra™ DNA Library Prep Kit for Illumina® (New England 
Biolabs, Hitchin, UK). Libraries were prepared as per the manufacturer’s guidelines, with 
size selection for a 250bp insert size, dual indexing and 9 cycles of library amplifica-
tion. Libraries were sequenced to a median depth of ~50x on Illumina’s HiSeq X Ten 
(150bp paired end reads) at BGI Tech Solutions Ltd, Hong Kong. Somatic mutations 
were called from DNA sequencing data using Mutect2.5 Variants flagged as ‘PASS’ or 
‘clustered_events’ were accepted as somatic. Variants were annotated using Annovar.6 
Copy number profiles were derived using Sequenza7 for a subset of samples, and manu-
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ally curated to remove probable model artefacts. DNA from the colorectal cancer was 
prepared for WGS using the Truseq PCR-free library preparation kit (Illumina) as per 
manufacturers guidelines and sequenced on an Illumina HiSeq 2500. Sequenced reads 
were aligned to the GrCh37 reference genome using the Isaac aligner,8 and variant call-
ing performed using Strelka.9
FFPE endometrial cancers from the LUMC series were analyzed using the Lifetech/
ThermoFisher Ion AmpliSeq Comprehensive Cancer Panel comprising 409 cancer genes 
(http://www.lifetechnologies.com/order/catalog/product/4477685). Extracted genomic 
DNA was quantified by Qubit and library preparation performed according to the manu-
facturer’s protocol (LifeTechnologies, cat. no. 4477685 and 4480442). Details of PCR con-
ditions and library purification and quantification were as previously reported.10 Diluted 
libraries were loaded onto the Ion PI chip v2 BC (cat. no. 4484270) and sequenced on 
the Ion Proton sequencer (cat. no. 4476610). Signal processing and base calling were 
performed using the Ion Proton Torrent suite (version 4.4). Variant calling was performed 
using variantCaller and Ion Reporter software (Thermo). Variant call format (VCF) files 
were annotated using Variant Effect Predictor (VEP)2 and filtered to remove variants with 
(i) read depth of <50, quality of depth (QD) of <2 or fewer than 10 supporting reads; (ii) 
flow evaluator alternate allele observation count of <20; (iii) genotype quality (GQ) of 
<90; (iv) variants in homopolymer runs of >5; (v) variants ≤3 bases from the end of an 
amplicon; (vi) minor allele frequency of >1% in ExAc, 1000 Genomes or UK10K; (vii) a 
variant allele fraction of <0.1. Data were then manually curated to remove likely arte-
factual variants (e.g. variant absent from COSMIC, and/or present in more cases than a 
known endometrial cancer gene such as PIK3CA or PTEN).
Somatic mutations in TCGA cancers were called from BAMs using Mutect2.5 Additional 
cases from the TCGA COADREAD and UCEC data sets were downloaded as Mutect Muta-
tion Annotation Format (MAF) files from the GDC Data Portal. Variant annotation and 
model curation was performed as for the WGS cases. Copy number data was down-
loaded for COADREAD data from the same source. ‘Segment Mean’ (S) was transformed 
using the following formula to find copy number index (I): I = round((2^S)x2). Segments 
outside chr6.p with copy number index equal to 2 were assumed to be diploid.
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Supplementary Figure 2. Legend on next page
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Supplementary Figure  1. Clonality of POLE mutations and mutational processes in TCGA endometrial 
cancers.
Frequency histograms and kernel density plots showing variant allele fraction (VAF) of all SNV mutations, 
and SNVs likely due to POLE exonuclease domain mutation (POLE). Only mutations in diploid regions of 
autosomes, and with coverage >20x are shown. The relatively low proportion of SNVs categorized as be-
ing due to POLE mutation reflects the stringency of the classification used (see Materials and methods, 
Mutational signatures). VAF of POLE mutations are highlighted. Vertical red line indicates clonal peak used 
to calculate cellularity.
Supplementary Figure 2. Clonality of POLE mutations and mutational processes in TCGA colorectal cancers.
Frequency histograms and kernel density plots showing variant allele fraction (VAF) of all SNV mutations, 
and SNVs likely due to POLE exonuclease domain mutation POLE Only mutations in diploid regions of auto-
somes, and with coverage >20x are shown. The relatively low proportion of SNVs categorized as being due 
to POLE mutation reflects the stringency of the classification used (see Materials and methods, Mutational 
























































































































































































































































































































   
   










   
   




























Supplementary Figure 3. POLE signature in high-confidence endometrial cancer driver mutations.
Corresponding heatmap to Figure 3, limited to high-confidence endometrial cancer driver mutations. High 
confidence driver mutations were defined as those causing protein truncations known to perturb function 
of tumor suppressors and missense variants at recurrently-mutated hotspot codons in either tumor sup-
pressors and oncogenes. Each driver gene mutation was assigned a probability that it was caused by the 
mutational process that generates the distinct POLE mutational signature, rather than by the mutational 
processes responsible for the consensus mutational signatures of POLE-wild-type DNA mismatch repair-
proficient (MMR-P) and mismatch repair-deficient (MMR-D) tumors (see Materials and methods, POLE 
consensus mutational signature scores in driver genes, for details). For each gene/sample combination, 
a ‘POLE-score’ was then calculated as the base two logarithm of the minimum value of these ratios, and 
plotted as a heatmap. Scores are shown for both individual POLE-mutant tumors and the combined POLE-
mutant subgroup; results for tumors within the POLE-wild-type, mismatch repair-proficient (MMR-P) and 
POLE-wild-type, mismatch repair-deficient (MMR-D) subgroups are combined for clarity.
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Supplementary Figure 4. POLE signature in high-confidence colorectal cancer driver mutations.
Corresponding heatmap to Figure 4, limited to high-confidence endometrial cancer driver mutations. High 
confidence driver mutations were defined as those causing protein truncations known to perturb function 
of tumor suppressors and missense variants at recurrently-mutated hotspot codons in either tumor sup-
pressors and oncogenes. Each driver gene mutation was assigned a probability that it was caused by the 
mutational process that generates the distinct POLE mutational signature, rather than by the mutational 
processes responsible for the consensus mutational signatures of POLE-wild-type DNA mismatch repair-
proficient (MMR-P) and mismatch repair-deficient (MMR-D) tumors (see Materials and methods, POLE 
consensus mutational signature scores in driver genes, for details). For each gene/sample combination, 
a ‘POLE-score’ was then calculated as the base two logarithm of the minimum value of these ratios, and 
plotted as a heatmap. Scores are shown for both individual POLE-mutant tumors and the combined POLE-
mutant subgroup; results for tumors within the POLE-wild-type, mismatch repair-proficient (MMR-P) and 
POLE-wild-type, mismatch repair-deficient (MMR-D) subgroups are combined for clarity.
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Supplementary Figure 5. Driver mutations in TCGA endometrial cancers.
Comparison of mutation type and frequency in selected driver genes according to tumor molecular sub-
type. POLE wt – POLE-wild-type group includes tumor irrespective of DNA mismatch repair status. POLE 
mut – pathogenic somatic POLE exonuclease domain mutations. Glutamic acid to stop mutations (E→*) 
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occur when a glutamic acid codon (GAG or GAA) is preceded by an A (e.g. AGAG or AGAA), creating an AGA 
trinucleotide which is commonly mutated to ATA in POLE-mutant tumors, causing a stop codon (TAG or 
TAA). Arginine to stop mutations (R→*) occur when the POLE hotspot trinucleotide TCG is followed by an A, 
resulting in a TCGA to TTGA mutation. Arginine to glutamine substitutions (R→Q) occur when the reverse 
complement of this hotspot, CGA is mutated to CAA.
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Supplementary Figure 6. Driver mutations in TCGA colorectal cancers.
Comparison of mutation type and frequency in selected driver genes according to tumor molecular sub-
type. POLE wt – POLE-wild-type group includes tumor irrespective of DNA mismatch repair status. POLE 
mut – pathogenic somatic POLE exonuclease domain mutations. Glutamic acid to stop mutations (E→*) 
occur when a glutamic acid codon (GAG or GAA) is preceded by an A (e.g. AGAG or AGAA), creating an AGA 
trinucleotide which is commonly mutated to ATA in POLE-mutant tumors, causing a stop codon (TAG or 
TAA). Arginine to stop mutations (R→*) occur when the POLE hotspot trinucleotide TCG is followed by an A, 
resulting in a TCGA to TTGA mutation. Arginine to glutamine substitutions (R→Q) occur when the reverse 
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Supplementary Figure 7. Driver mutations in LUMC endometrial cancers.
Comparison of mutation type and frequency in selected driver genes according to tumor molecular sub-
type in a cohort of FFPE tumors from the Leiden University Medical Center (LUMC). POLE wt – POLE-wild-
type group includes tumor irrespective of DNA mismatch repair status. POLE mut – pathogenic somatic 
POLE exonuclease domain mutations. Glutamic acid to stop mutations (E→*) occur when a glutamic acid 
codon (GAG or GAA) is preceded by an A (e.g. AGAG or AGAA), creating an AGA trinucleotide which is com-
monly mutated to ATA in POLE-mutant tumors, causing a stop codon (TAG or TAA). Arginine to stop muta-
tions (R→*) occur when the POLE hotspot trinucleotide TCG is followed by an A, resulting in a TCGA to TTGA 
mutation. Arginine to glutamine substitutions (R→Q) occur when the reverse complement of this hotspot, 
CGA is mutated to CAA.
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Supplementary Figure 8. Clonality of neoantigens in TCGA colorectal cancers.
Frequency histograms for cases corresponding to Figure 6 showing variant allele fraction (VAF) of all SNV 
mutations and predicted neo-antigens. Only mutations in diploid regions of autosomes, and with coverage 
>20x were considered. Vertical red line indicates inferred clonal peak used to calculate cellularity.
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Supplementary table 1. Cohorts analyzed and molecular analyses performed.
Cohort Sample type Analyses performed Previous reports
Paired endometrial 
cancers and EINs 
FFPE tumor and paired 
precursor lesions
Molecular inversion 
probes capture panel 
sequencing





cancers identified in Refs 
12, 14, 26







Fresh frozen tumors Whole genome 
sequencing
POLE mutant invasive 
endometrial cancers from 
Leuven cohort identified 




Fresh frozen tumors Re-analysis of genome 




Fresh frozen tumors Re-analysis of genome 
and exome sequencing 
TCGA (Ref 10)
Endometrial cancers FFPE tumors Thermo Comprehensive 
Cancer Panel
Cases identified in Refs 
14, 26
Abbreviations: EIN, endometrial intraepithelial neoplasia; FFPE, formalin-fixed paraffin-embedded; IHC, im-
munohistochemistry.
Supplementary table 2. Details of cases used for molecular analyses.
Case Patient 
age
Sample type Pathological characteristics tumor cell 
fraction 
LUMC 33 61 EIN 60%
EEC FIGO stage I, grade 2, LVSI negative 70%
LUMC H0284 46 EIN 50%
EEC FIGO stage III, grade 3, substantial LVSI 70%
LUMC L2-18 49 EIN 70%
EEC FIGO stage I, grade 1, LVSI negative 70%
LUMC Q1-4 61 EIN 60%
EEC FIGO stage I, grade 1, LVSI negative 70%
OXF 001 55 EEC FIGO stage I, grade 2, LVSI negative 70%
POLE 040 60 Mixed EEC-serous FIGO stage I, grade 3, LVSI negative 60%
POLE 049 57 Mixed-EEC-serous FIGO stage I, grade 3, LVSI negative 75%
POLE 072 55 EEC FIGO stage II, grade 3, LVSI negative 70%
POLE 147 53 EEC FIGO stage I, grade 3, LVSI negative 60%
BIR 001 61 CRC T4, N1 adenocarcinoma of descending colon 75%
Abbreviations: EIN, endometrial intraepithelial neoplasia; EEC, endometrioid endometrial adenocarcino-
ma; FIGO, International Federation of Gynecology and Obstetrics; LVSI, lymphovascular space invasion.
209
7
Somatic POLE mutations are early events in sporadic cancers
SuPPlementAry tAbleS AVAIlAble onlIne
The following supplementary tables are available online at: https://onlinelibrary.wiley.
com/doi/abs/10.1002/path.5081. 
Supplementary table 3. Genes included in custom molecular inversion probe panel.
Supplementary table 4. Genes included in custom Ion AmpliSeq Cancer Hotspot Panel.
Supplementary table 5. List of IntOGen endometrial cancer driver genes used in study.
Supplementary table 6. List of IntOGen colorectal cancer driver genes used in study.
Supplementary table 7. Driver mutations detected in paired endometrial intraepithelial neoplasias (EIN) 
and endometrial carcinomas.
Supplementary table 8. Driver mutations in POLE-mutant cancers analyzed by whole genome sequenc-
ing.
Supplementary table 9. Driver mutations in TCGA endometrial cancers by tumor molecular subgroup.
Supplementary table 10. Driver mutations in TCGA colorectal cancers by tumor molecular subgroup.
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dISCuSSIon And Future PerSPeCtIVeS
POLE exonuclease domain mutations (hereafter referred to as ‘POLE mutations’) are 
found in a wide variety of human malignancies, including endometrial cancer. In all 
tumor types, cancers with POLE mutations are characterized by an exceptionally high 
mutational burden and a specific mutational signature.1,2 Despite their so-called ‘ultra-
mutated’ phenotype, patients with POLE-mutant cancers have significantly better out-
comes compared to patients with POLE-wild-type tumors. This prognostic benefit has 
thus far been shown for early-stage endometrial and stage II/III colorectal cancers, and 
has been suggested for glioblastomas.1,3-10 The studies described in this thesis aimed 
to gain insight into somatic POLE exonuclease domain mutations and especially into 
the underlying mechanism(s) by which these POLE mutations contribute to low risk of 
recurrence. This chapter puts the main findings of this thesis into perspective of current 
literature, and discusses the implications of these findings for the treatment of patients 
with POLE-mutant cancers, in particular endometrial cancer.
explaining the favorable clinical outcome of POLE exonuclease domain-mutant 
cancers
Three hypotheses that could explain or contribute to the favorable prognosis of POLE-
mutant cancers were studied and will be discussed below.
1. Induction of an antitumor immune response
To explain the good prognosis of POLE-mutant cancers, we hypothesized that the ul-
tramutated phenotype would result in the presentation of neoantigens on the tumor 
cell surface. These neoantigens would elicit an antitumor immune response, which may 
contribute to the favorable outcome of these patients. To support this hypothesis, this 
thesis and work of others provide several lines of evidence that will now be discussed.
POLE-mutant cancers were predicted to display more neoantigens than POLE-wild-type 
cancers (chapters 4 and 5).11 This prediction was based on in silico algorithms that as-
sessed the binding affinity to MHC class I of all possible mutant peptides relative to that 
of the wild-type peptide. Similar prediction algorithms have been used in many reports 
to date to identify neoantigens.12-18 Previous studies also showed, however, that only a 
small fraction of mutations in expressed genes resulted in the presentation of neoan-
tigens that elicit T cell reactivity.13,15,19-21 Therefore, the in silico algorithms could more 
accurately predict reflect the landscape of immunogenic neoantigens in cancers when 
filtering of the exome or RNA sequencing data would be improved. Still, the observed 
difference in predicted neoantigen numbers between POLE -mutant and POLE-wild-type 
is very large (~100-fold) with the currently employed methods. Therefore, regardless of 
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more stringent filtering, these differences suggest that POLE mutations indeed result in 
the presentation of immunogenic neoantigens.
An in vitro study supported the concept of increased immunogenicity of POLE-mutant 
cancers. In this study, autologous dendritic cells pulsed with lysate from POLE-mutant 
endometrial cancers induced stronger proliferation of cytotoxic T cells and T helper cells 
than lysate derived from POLE-wild-type cancers.22 This suggests that POLE-mutant can-
cers are capable of eliciting an immune response and that this capacity is greater than 
in their wild-type counterparts. Whether the increased immunogenicity of POLE-mutant 
cancers is indeed caused by a higher neoantigen load remains to be elucidated.
POLE-mutant (endometrial) cancers are characterized by the presence of an enhanced 
cytotoxic T cell response (chapters 4 and 5).9,22,23 In POLE-mutant cancers, tumor-
infiltrating lymphocytes are present in larger numbers than in POLE-wild-type cancers. 
Moreover, these lymphocytes demonstrate upregulation of activation and effector 
markers, suggesting the T cells are cytotoxically active. These findings are supportive 
of increased immunogenicity of POLE-mutant cancers. Furthermore, the association 
between the presence of such an immune infiltrate and prognosis is well-established: 
a meta-analysis showed in a pooled cohort of over 12,000 patients with various tumor 
types that tumor-infiltrating lymphocytes have a positive effect on clinical outcomes.24 
A similar association has been previously described for endometrial cancers, albeit in a 
limited number of studies.25,26 
For the T cells to contribute to the favorable prognosis, these lymphocytes would have to 
be tumor-reactive, recognizing the antigen presented by the tumor cell as being foreign. 
Evidence for this tumor reactivity is provided by the response of POLE-mutant cancers to 
immune checkpoint inhibition. It is important to note that this response is also clinically 
very relevant (details on therapeutic implications are given below). Through immune 
checkpoint inhibition, T cells are relieved of certain inhibitory signals (such as PD-1-PD-
L1 signaling), leading to a release of their cytotoxic potential. Although the search for a 
robust biomarker to predict response to checkpoint inhibitors is still ongoing, response 
rates are higher in cancers with a high mutational load.27,28 This is illustrated by the 
40-53% objective response rates found in (mostly colorectal) cancers with mismatch 
repair deficiency, compared to 0% response in non-hypermutated cancers.29,30 Following 
this rationale, the first few women with advanced-stage endometrial cancers carrying 
POLE mutations have been treated with anti-PD-1 antibodies and showed sustained 
responses.31-33 These responses suggest that upon PD-1/PD-L1 blockade, T cells that are 
tumor-reactive are ‘unleashed’, resulting in effective antitumor activity contributing to 
prolonged survival.
Discussion and future perspectives 215
8
Finally, a parallel can be drawn between POLE-mutant cancers and melanomas to 
provide evidence, albeit circumstantial, supportive of this ‘antitumor immune response-
hypothesis’. In melanomas, another highly mutated tumor type, lymphocytes have been 
identified in the tumor microenvironment that are reactive to neoantigens presented by 
the cancer cells.15,20 Furthermore, the tumor-reactive T cells expanded in the peripheral 
blood after immune checkpoint inhibitor treatment, suggesting a role for these T cells 
in tumor regression.20 Thus, the mutational load in melanomas is apparently sufficient 
to generate neoantigens that can be recognized by autologous T cells. Compared to 
melanomas, POLE-mutant cancers carry on average ten times as many mutations (10 
mutations per Mb for melanomas vs more than 100 mutations per Mb for POLE-mutant 
cancers).34 It can therefore be expected that the presence of neoantigens and their 
recognition by T cells are also common in POLE-mutant cancers.
In summary, we and others showed that the ultramutated POLE-mutant (endometrial) 
cancers display an enhanced cytotoxic T cell response. This T cell response is accompa-
nied by - and most likely caused by - a significant increase in the number of neoantigens 
presented at the tumor cell surface. Together, this provides a plausible mechanism by 
which POLE exonuclease domain mutations contribute to the good clinical outcome of 
the majority of patients.
A question worthy of further exploration is why POLE-mutant cancers, despite the 
antitumor immune response, are not eliminated by the immune system. Defects in 
antigen processing or presentation occurred at a similar frequency in POLE-mutant as 
in POLE-wild-type (chapter 4). Immunosuppressive molecules such as PD-1 and CTLA-4 
were upregulated in POLE-mutant cancers compared to POLE-wild-type. However, con-
sidering the overall increase in expression of cytotoxic effector markers, the upregula-
tion of immunosuppressive mediators appeared insufficient to fully suppress the T cell 
response in POLE-mutant endometrial cancers (chapter 4). Therefore, further research 
on immune escape mechanisms in POLE-mutant cancers, e.g. on the presence of im-
munosuppressive cells in the tumor microenvironment, is warranted.
The above-described immune-related mechanism does not explain the high survival 
rate of patients with POLE-mutant cancers completely. In chapter 3, POLE-mutant endo-
metrial cancers were evaluated for the presence of tumor-infiltrating and peritumoral 
lymphocytes. Although these lymphocytes were prominently present in the majority 
of cases, ~15% of POLE-mutant endometrial cancers showed no evidence of a strong 
T cell response. In colorectal cancer, a lack of lymphocytic infiltrate seems associated 
with poorer clinical outcome in the ‘hypermutated’, mismatch repair-deficient cases.35,36 
The number of POLE-mutant endometrial cancers studied to date is too small to per-
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form similar within-subgroup analyses. Considering the genomic similarities between 
POLE-mutant and mismatch repair-deficient cancers, the degree of immune response 
is likely to have prognostic impact in POLE-mutant cancers as well. Therefore, also other 
mechanisms that could (in part) account for the excellent prognosis of POLE-mutant 
cancers were investigated.
2. Increased sensitivity to adjuvant treatment
The favorable prognosis of POLE-mutant cancers was, as described, found in sev-
eral independent studies.1,3-10,37 In these studies, the majority of patients (~66%) with 
POLE-mutant cancers received some type of adjuvant therapy (i.e. radiotherapy and/
or chemotherapy). Therefore, increased sensitivity to adjuvant treatment might also 
contribute to the good outcome of POLE-mutant cancers. Outcomes were, however, 
consistently favorable for patients in the PORTEC-1 endometrial cancer trial and in the 
colorectal cancer cohort regardless of adjuvant therapy (chapter 6).4,9 Moreover, in a 
mouse-derived embryonic stem cell model, POLE mutations did not result in greater 
sensitivity to ionizing radiation or to commonly used chemotherapeutics, including cis-
platin, paclitaxel, and doxorubicin. This is in line with another preclinical study in which 
no significant difference in sensitivity to paclitaxel was found between POLE-mutant and 
POLE-wild-type endometrial cancer cell lines, while demonstrating increased resistance 
to carboplatin in their POLE-mutant cell line. The cell lines used in this study were, 
however, non-isogenic.38 Moreover, the exonuclease activity of DNA polymerase epsilon 
is presumed not to have a role in the mechanisms of actions of the commonly used 
anti-cancer treatments: a POLE mutation is therefore unlikely to alter sensitivity to these 
therapies, providing further support for the clinical and in vitro findings. It should be 
noted that in the described model systems, an interaction between radiotherapy and 
the immune system could not be assessed.39 Nevertheless, the clinical data and the in 
vitro data together suggest that the clinical outcome of POLE-mutant cancers is inde-
pendent of the administered adjuvant treatment. Thus, increased sensitivity to adjuvant 
therapy does not seem to explain the favorable prognosis of POLE-mutant cancers.
3. Error catastrophe
The third possible explanation for the excellent clinical outcome of POLE-mutant cancers 
may originate from one of their characteristic features: the ultramutator phenotype. This 
may be the Achilles’ heel of POLE-mutant cancers. On one hand, the high mutation rate 
causes cells to rapidly accumulate mutations. This increases the genetic variation, which 
in turn facilitates adaptation of malignant cells to changing microenvironments, e.g. im-
mune evasion.40-42 On the other hand, rapid accumulation of mutations may compromise 
tumor viability. Many random mutations can arise that are neither directly beneficial, 
nor immediately deleterious. These mutations will not be subject to strong positive or 
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negative selection and can become fixed in the genome. Subsequently, these mutations 
may collectively exert a negative effect and can result in so-called error catastrophe.42,43 
Error catastrophe occurs when the mutational burden exceeds a certain threshold 
above which the combined negative effect of the acquired mutations prevails, and 
cellular viability decreases. Considering the exceptionally high mutational load of 
POLE-mutant cancers, error catastrophe may take place and may thus contribute to 
the favorable outcome of these tumors. In the primary cancer, the mutation rate may 
have struck a balance between the potential to adapt to new states and maintenance 
of tumor viability, preventing tumor regression. This is supported by a study of bial-
lelic mismatch repair-deficient brain cancers: after acquisition of a POLE mutation, the 
number of mutations rapidly increased to a certain threshold without surpassing it.44 
The high mutational burden may, however, render POLE-mutant cancer cells unfit to 
effectively metastasize: this could account for the rare incidence of distant metastases. 
Following Paget’s ‘seed and soil’-hypothesis, also in this scenario the immune system 
plays a pivotal role.45 
The existence of an ‘error threshold’ is supported by the infrequency at which POLE exo-
nuclease domain mutations co-occur with other defects that induce replication errors. 
Indeed, in yeast, combined polymerase ε proofreading defects and complete mismatch 
repair deficiency proved synthetically lethal for the majority of cells.46 We found similar 
results in preliminary experiments in the mouse embryonic stem cell model described 
in chapter 6. When attempting to knock-out Msh6, one of the mismatch repair genes, a 
mismatch repair-deficient clone was often obtained in the wild-type cell line (approxi-
mately 1 in 4 cells), while this proved rarely successful in the POLE exonuclease domain-
mutant cell lines (~1 in 175 cells, Figure 1). These findings suggest that the absence of 
both DNA repair pathways results in a rapid and catastrophic accumulation of mutations 
incompatible with cellular survival. This synthetic lethality may also be the reason why 
POLE-mutant cancers generally are microsatellite stable.47 
To gain further insight into error catastrophe, future studies could investigate cell 
death in POLE-mutant compared to POLE-wild-type cancers. We examined levels of 
apoptosis in the endometrial cancer series described in chapter 4 by performing im-
munohistochemistry of cleaved caspase-3. Cleaved caspase-3 is the effector marker of 
both intrinsic and extrinsic apoptotic pathways.48 In POLE-mutant and POLE-wild-type 
microsatellite-unstable endometrial cancers, cleaved caspase-3+ apoptotic cells were 
present in significantly higher numbers compared to POLE-wild-type microsatellite-












































Figure 1. Knockout of Msh6 in POLE exonuclease domain-mutant mouse embryonic stem cells.
A knock-out of Msh6, one of the mismatch repair genes, was attempted in POLE-wild-type (WT) and in 
POLE exonuclease domain-mutant mouse embryonic stem (mES) cells using CRISPR-Cas9. To this end, stem 
cells were transfected with a guide RNA targeting Msh6. Successfully transfected cells were positively se-
lected using puromycin. The number of cells that survived a 6-thioguanine pulse, which selects for loss of 
mismatch repair, was counted and is shown (box and whisker signify mean and standard deviation, respec-
tively). Results are shown for different homozygous POLE-mutant cell lines, namely double-mutant D275A/


























Figure 2. Apoptosis based on immunohistochemistry of cleaved caspase-3 in endometrial cancer accord-
ing to molecular subgroup.
Apoptosis based on cleaved caspase-3 (CC3) counts was compared between POLE exonuclease domain-
mutant (POLE), microsatellite-unstable (MSI), and POLE-wildtype, microsatellite-stable (MSS) endometrial 
cancers. For each endometrial cancer, the number of cleaved caspase-3-positive cells was counted in ten 
high power fields (HPFs; 325μmx225μm), consisting of at least 70% tumor tissue. The mean of these ten 
high power fields is used for each case. For each molecular subgroup, boxes represent the interquartile 
range, with the upper whisker indicating the 95th percentile and the lower whisker the 5th percentile. The 
median and mean values are indicated by a horizontal line and cross respectively. *P=0.0005, **P=0.0072.
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Future studies could also focus on cases that apparently escaped error-induced extinc-
tion, e.g. POLE-mutant endometrial cancers with combined (partial) mismatch repair 
deficiency or POLE-mutant cancers that present at an advanced stage or that recur. 
A starting point for such future studies could stem from an interesting finding in the 
yeast study on polymerase ε proofreading and mismatch repair: among the colonies 
that survived with combined polymerase ε proofreading- and mismatch repair defects 
were colonies that had acquired secondary mutations in POLE. These secondary muta-
tions resulted in a slower accumulation of mutations.46 It would be of interest to explore 
whether such ‘antimutator’ variants also occur alongside POLE exonuclease domain 
mutations in human cancers and if present, what their effect is on the mutational bur-
den. At the same time, as many POLE mutations outside the exonuclease domain remain 
‘variants of unknown significance’, fundamental research is warranted to understand the 
functional consequences of such variants.
In conclusion, this thesis together with work of others proposes an enhanced antitumor 
immune response and a catastrophic accumulation of mutations as most likely mecha-
nisms to explain the high survival rate of patients with POLE-mutant cancers. While these 
and other explanations require further research, they may provide a starting point for 
more tailored (adjuvant) treatment of POLE-mutant cancers, as will be discussed below.
Implications for endometrial cancer treatment: current practice and future 
directions
Early-stage endometrial cancer is treated primarily with surgery; the indication for 
adjuvant treatment depends on risk factors for recurrence (chapter 1). Despite the use 
of risk-based indications, vaginal brachytherapy for patients with high-intermediate 
risk endometrial cancer still yields significant overtreatment: six out of seven patients 
would not have had a recurrence without vaginal brachytherapy.49-51 To reduce over-
treatment, screening for POLE mutations could be of use. POLE mutations predict an 
excellent prognosis in endometrial cancer.51 Moreover, as discussed before, this prog-
nostic benefit does not seem to depend on adjuvant treatment. Therefore, it could be 
argued that for patients with early-stage endometrial cancers carrying POLE mutations, 
surgery alone may suffice, thus reducing overtreatment. For POLE-mutant early-stage 
endometrial cancers, no additional treatment versus vaginal brachytherapy is currently 
under prospective evaluation in the PORTEC-4A trial.52 In this randomized trial, vaginal 
brachytherapy based on standard clinicopathological indications (chapter 1, Table 
2) is compared to molecular profile-based indication for either observation, vaginal 
brachytherapy or external beam radiotherapy. The PORTEC-4A trial is the first to bring 
molecular profile-based adjuvant treatment for endometrial cancer into the clinic, and 
results are eagerly awaited.
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This discussion has thus far focused mostly on POLE mutations in early-stage endometrial 
cancer and the high survival rate observed in this patient group. However, as mentioned 
briefly, POLE mutations can also be found in advanced-stage endometrial cancer. The 
frequency of POLE mutations in advanced-stage disease is yet to be determined: a col-
laborative study by Bosse et al. show 1 (1.6%) POLE-mutant cancers among 61 grade 3, 
stage III-IV endometrial cancers, while this was more common in the TCGA endometrial 
cancer cohort (7.2%, 4/55 stage III-IV endometrial cancers).1,53 Also the prognostic impact 
of POLE mutations in advanced-stage disease remains uncertain. For these advanced-
stage endometrial cancers and for other cancer types with relatively poorer prognoses, 
the mechanisms underlying the good prognosis of POLE mutations can be exploited for 
therapeutic purposes. First of all, the antitumor immune response can be enhanced by 
immune checkpoint inhibition. Indeed, the first cases of advanced-stage POLE-mutant 
endometrial cancers treated with anti-PD-1 antibodies have been reported, as well as 
of pediatric, POLE-mutant, biallelic mismatch repair-deficient glioblastomas. These 
studies showed remarkably good responses of at least five months duration (maximum 
reported duration was 16 months).31-33,54 Clinical trials testing the efficacy of immune 
checkpoint inhibitors in advanced-stage cancers are currently recruiting in which 
POLE-mutant cancers are included.55-58 Whether POLE mutational status itself or other 
factors such as the mutational load, the number or type of predicted neoantigens or 
the expression of CD8, PD-1 and/or PD-L1 are the strongest markers to predict response 
to checkpoint inhibition remains to be elucidated. The outcomes of ongoing trials may 
further advance this field.
If immune checkpoint inhibitors also yield promising results in larger series of POLE-
mutant cancers, these drugs may be quickly approved for this new indication. How 
fast this process of approval can be has been shown for the use of pembrolizumab in 
advanced-stage mismatch repair-deficient solid tumors: while the results of the first 
phase II study were only published in 2015, pembrolizumab was granted accelerated 
approval for this indication by the American Food and Drug Administration in May 
2017.29 In the Netherlands, PD-1 inhibitors pembrolizumab and nivolumab have been 
approved thus far only for the treatment of, among others, advanced-stage melanoma 
and advanced-stage non-small-cell lung carcinoma, although response rates in these 
tumors are similar to, or even lower than, those observed in mismatch repair-deficient 
cancers (e.g. for pembrolizumab: ~33% in melanoma,~45% in PD-L1+ non-small-cell lung 
cancer, 40-53% in mismatch repair-deficient colorectal cancers).29,30,59-63 Nonetheless, the 
use of immune checkpoint inhibitors should be carefully considered because of the high 
treatment costs. While the exact costs of anti-PD-1 therapy are not known because of 
confidential price agreements between the Dutch government and the manufacturers, 
they are likely to approximate or even exceed the threshold value of €80,000 per quality-
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adjusted life year, similarly to the anti-CTLA-4 antibody ipilimumab.64-66 These costs raise 
important ethical and political discussions on how much society is willing - and able - to 
pay for such treatments. Ongoing trials investigating immune checkpoint blockade for 
POLE-mutant cancers will provide more insight into the response rates, and thereby into 
the cost-effectiveness of these therapies.
Along with the immune response observed in patients with POLE-mutant cancers, 
the ultramutated phenotype of these tumors may be exploited for treatment. As the 
mutational burden seems to plateau just below the threshold for cellular viability, drugs 
that drive the mutation rate past this threshold could be of interest.44 The possibility to 
induce error catastrophe has been demonstrated in RNA viruses by using nucleoside 
analogs. RNA viruses have remarkably high mutation rates. Nucleoside analogs result in 
a critical increase of these mutation rates by mispairing after incorporation in the DNA 
or by preventing the DNA chain from being elongated during replication.42,67,68 Taking 
advantage of their already ultramutated phenotype, a similar approach could be benefi-
cial for cancers with POLE mutations. Moreover, the effects of nucleoside analogs may be 
increased in POLE-mutant cells: contrary to their wild-type counterparts, POLE-mutant 
cells may not be able to excise the analog once incorporated.
In mouse embryonic stem cells, we explored the sensitivity conferred by POLE exo-
nuclease domain mutations to nucleoside analogs (chapter 6). POLE-mutant cells were 
indeed found to be significantly more sensitive to the nucleoside analogs cytarabine 
and fludarabine compared to POLE-wild-type cells: sensitivity to both compounds was 
increased approximately three-fold. Increased sensitivity to cytarabine is supported by 
a previous study in POLE-mutant chicken lymphoma and human lymphoblast cell lines, 
which showed an estimated six-fold increase in sensitivity.69 
Sensitivity to cytarabine (and fludarabine) was thus far demonstrated in cell lines ho-
mozygous for the specific POLE mutations. For the S297F hot spot mutation, sensitivity 
to these two nucleoside analogs was also evaluated in the heterozygous state: sensitiv-
ity was lower than in the homozygous POLE-mutant lines, but higher than wild-type, 
reaching significance for cytarabine. Tsuda et al. also showed moderate sensitivity in 
heterozygous lines.69 As the majority of cancers – if not all – are heterozygous for the 
somatic POLE mutations, the effects of cytarabine and fludarabine in POLE-mutant 
cancers remain to be determined. Moreover, while cytarabine and fludarabine are used 
in the treatment of leukemias and lymphomas, their efficacy as (mono-)treatment for 
solid tumors appears to be limited, and toxicity can be considerable.70-75 Despite these 
considerations, the sensitivity conferred by POLE mutations to certain nucleoside ana-
logs is substantial and may be very specific for POLE-mutant cells. Another advantage of 
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nucleoside analog treatment may be that by the induction of additional mutations, the 
probability of neoantigen formation increases. This may further enhance the antitumor 
immune response. Therefore, studies on the use of nucleoside analogs and other similar 
treatments in the context of POLE mutations are warranted.
To be able to optimally exploit the high mutational burden of POLE-mutant cancers, 
it is important to understand the mechanisms leading to this mutator phenotype. The 
somatic mutations found in cancers often lie close to, or within, the exonuclease domain 
motifs, and frequently concern residues that are highly conserved across species (chap-
ter 2). An in vitro study showed that POLE mutations such as P286R, S459F, and V411L, 
despite not being located at the exonuclease domain catalytic sites, severely diminished 
proofreading activity. The degree to which each mutation reduced this activity, how-
ever, varied.76 Interestingly, when somatic POLE hot spot mutations such as P286R were 
introduced into yeast and mouse embryonic stem cells, they resulted in a higher muta-
tion rate than could be explained by proofreading deficiency alone (chapter 6).77,78 dNTP 
pool imbalances have been put forth by a study in yeast to explain the ultramutator 
phenotype.79 However, this explanation remains to be tested for cancer-associated vari-
ants and for mammalian cells, as their dNTP pool regulation differs greatly from yeast. 
Another explanation for the high mutational load is provided by structural analyses 
of somatic POLE mutations; the POLE substitutions found in cancers were predicted 
to perturb DNA binding.11 Based on these analyses, Barbari et al. suggested that the 
altered DNA binding may reduce the efficiency of extrinsic proofreading, for example by 
polymerase δ.78 These possible mechanisms, together with their potential utility in treat-
ment of POLE-mutant advanced-stage cancers, should be addressed in future studies.
Implementation of POLE exonuclease domain mutation screening in clinical 
practice
In consideration of the prognostic and promising therapeutic implications of POLE mu-
tations, implementation of screening for these mutations in clinical practice would be 
valuable. For which tumor types POLE mutation screening should be introduced could 
be based on the incidence and on prognostic and/or predictive implications. Endometrial 
cancer would be a logical cancer type to implement screening for: the frequency of POLE 
mutations is relatively high, and the prognostic and predictive implications of these muta-
tions in this cancer type have been described. In early-stage disease, POLE as a biomarker is 
unique in the sense that it may decrease rather than increase costs by reducing indications 
for adjuvant treatment; this will probably make POLE mutational screening cost-effective 
in this patient group. Moreover, POLE mutational screening in patients with advanced-
stage disease could help in identifying candidates for targeted therapies.
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To determine POLE exonuclease domain mutational status, the gold standard is to 
sequence exons 9 through 14 of the POLE gene. Because sequencing is not available 
in every clinical pathology laboratory, we aimed to identify histopathological and im-
munohistochemical characteristics to prescreen for POLE mutations in endometrial 
cancer (chapter 3). A combination of tumor type (endometrioid), tumor grade (high), 
peritumoral lymphocytes, and two routinely performed immunohistochemical stainings 
(MLH1 and p53) was found to increase the positive predictive value approximately five-
fold, from 7% to 33%. Although this prediction model requires validation, the majority of 
these histopathological features had been ascribed to POLE-mutant endometrial cancers 
in previous studies.80,81 Alongside these histopathological features, the age at diagnosis 
can be taken into account: the likelihood of a POLE mutation increases when a patient 
is diagnosed at a lower than average age, especially below 60 years (average age of an 
endometrial cancer patient is ~65-67 years).3,4 Moreover, although their origin remains 
to be clarified, the finding of tumor giant cells in an endometrioid-type endometrial 
cancer may also increase the likelihood of a POLE mutation being present. Together, 
these clinicopathological and immunohistochemical characteristics can aid in selecting 
cases for pathology consultation at medical centers with a molecular diagnostics labora-
tory equipped to determine POLE mutational status.
Different molecular diagnostic techniques can be used to identify POLE exonuclease 
domain mutations. While Sanger sequencing is a straightforward method, sequencing 
of all six exonuclease domain exons separately is laborious, especially when taking into 
account that in only ~1% of malignancies a pathogenic POLE mutation will be identified. 
To make Sanger sequencing more feasible, studies have screened only exons 9, 13 and 
at times exon 14, since these exons contain the majority of cancer-associated variants 
thus far identified (chapter 2). However, as massively parallel sequencing of targeted 
gene panels becomes increasingly available for clinical use, the POLE exonuclease do-
main could also be incorporated in such cancer gene panels. Ideally, these gene panels 
would be large enough to also establish mutational burden and spectrum. With this 
approach, POLE mutational status would be determined as part of the molecular work-
up and would not require an additional laboratory test; this would greatly facilitate 
its implementation. Moreover, variant identification and pathogenicity testing would 
be performed in a single test. Through this method, cancers would also be identified 
with a high mutational burden and/or with the same mutational signature due to 
other molecular alterations, e.g. POLD1 exonuclease domain mutations or POLE/POLD1 
polymerase domain variants, As the mutational load of a cancer likely influences tumor 
immunogenicity and sensitivity to immune checkpoint inhibition, a screening method 
including the number of mutations may be advantageous.
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An important aspect to keep in mind is that after implementation of POLE exonucle-
ase domain mutation screening, more POLE mutations will be identified. A fraction of 
these POLE-mutant cancers will also harbor other molecular alterations, such as TP53 
mutations. The implications of multiple prognostically relevant alterations for clinical 
outcome of patients are unknown. Large-scale collaborations are required to assemble a 
sufficient number of these relatively uncommon cases, and consequently, to determine 
which molecular alterations have the strongest impact on prognosis.
POLE exonuclease domain mutations in personalized medicine
Somatic POLE exonuclease domain mutations have the potential to become one of the 
success stories of (genomics-based) personalized medicine. After the discovery of these 
mutations during extensive genomic analyses, not only their prognostic significance was 
established in subsequent studies, but also their implications for immunotherapies. More-
over, thanks to close collaboration between clinicians, translational and basic scientists, 
the research that has led to these findings was performed over a relatively short period of 
approximately six years (Figures 3 and 4). Finally, as the prognostic and predictive value of 
somatic POLE exonuclease domain mutations seems generalizable to other cancer types, 
these mutations may provide an important step towards implementation of personalized 



































Figure 3. Journal articles on POLE exonuclease domain mutations and cancer by year.
The graph represents the number of new publications per year on POLE exonuclease domain mutations 
(EDMs) and cancer as referenced by PubMed (through October 2017). Source: PubMed, a division of the 
US National Library of Medicine and the National Institute of Health (available from: http://www.ncbi.nlm.
nih.gov/pubmed/).
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Baarmoederkanker, oftewel endometriumcarcinoom, is een kwaadaardige aandoening 
van het slijmvlies dat de baarmoeder aan de binnenzijde bekleedt. Het is de meest voor-
komende gynaecologische kanker, waarvan de incidentie door toenemende obesitas 
en vergrijzing van de bevolking stijgt. Chirurgische verwijdering van de baarmoeder 
vormt de basis van de behandeling. De indicatie voor aanvullende behandeling wordt 
gesteld op basis van de recidiefkans. Deze kans wordt bepaald met behulp van klinische 
en pathologische risicofactoren, namelijk de leeftijd van de patiënt, het FIGO-stadium 
waarin het endometriumcarcinoom zich presenteert, het histologisch tumortype, de 
mate van differentiatie (uitrijping) van de tumor, aangeduid als tumor graad, de diepte 
van ingroei in de baarmoederwand, en de aanwezigheid van tumorcellen in bloed- en/
of lymfevaten. Voor endometriumcarcinoom patiënten met een laag risico op recidief is 
de chirurgische behandeling afdoende. Vrouwen met een endometriumcarcinoom met 
een intermediaire of hoge recidiefkans kunnen adjuvant behandeld worden met radio-
therapie (vaginale brachytherapie of uitwendige radiotherapie) en/of chemotherapie. 
Deze risico-inschatting is echter niet perfect. Er blijft dan ook sprake van overbehande-
ling bij een deel van de patiënten met een relatief goede prognose, waarbij adjuvante 
behandeling niet nodig was geweest. Anderzijds is er ook onderbehandeling van pati-
enten waarbij het endometriumcarcinoom een agressiever klinisch beloop heeft dan 
op basis van de huidige risicofactoren was voorspeld. Recent is meer bekend geworden 
over de moleculair genetische basis van het endometriumcarcinoom en zijn vier sub-
groepen geïdentificeerd met verschillende moleculaire eigenschappen en prognoses. 
Om het klinische probleem van over- en onderbehandeling te verminderen zijn deze 
moleculaire veranderingen geïntegreerd in de risicobepaling, waardoor de recidiefkans 
van een patiënte met endometriumcarcinoom nauwkeuriger kan worden ingeschat. 
Eén van deze moleculaire veranderingen betreft mutaties in het exonuclease domein 
van DNA polymerase epsilon (ε).
Polymerase ε is een DNA-polymerase dat een belangrijke rol speelt bij de verdubbeling 
van het DNA voorafgaand aan celdeling. Naast de betrokkenheid bij de DNA replicatie 
kent polymerase ε ook exonuclease activiteit. Met dit exonuclease kan polymerase ε na 
het inbouwen van nieuwe nucleotiden de nieuwe DNA sequentie controleren op fouten 
en, indien aanwezig, ook de verkeerde nucleotide(n) verwijderen. Deze exonuclease 
activiteit, ook wel polymerase proofreading genoemd, levert dus een belangrijke bij-
drage aan de nauwkeurigheid van de DNA replicatie en daarmee aan de integriteit van 
het erfelijk materiaal in de cel. De exonuclease activiteit van polymerase ε is gecodeerd 
in een apart domein in het POLE gen. In dit domein kunnen erfelijke en somatische 
(niet-erfelijke, spontane) mutaties optreden. Personen met erfelijke POLE exonuclease 
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domein mutaties (hierna aangeduid als ‘POLE mutaties’) hebben, afhankelijk van de 
variant, aanleg voor het ontwikkelen van colorectaal carcinoom (darmkanker). Hetero-
zygote, somatische POLE mutaties zijn in allerlei soorten kanker gevonden, waaronder 
in endometriumcarcinomen (frequentie 7-12%), maar ook in colorectaalcarcinomen 
(1-2%) en sporadisch in tumoren van o.a. de borst, long, hersenen, huid en alvleesklier. 
Deze POLE-mutante tumoren komen vaak voor in relatief jonge patiënten. Ze vormen 
een aparte moleculaire subgroep die zich onder andere kenmerkt door een zogenoemd 
ultragemuteerd fenotype: het betreft een kanker met een uitzonderlijk hoog aantal 
mutaties. POLE-mutante tumoren kennen daarnaast een specifiek mutatiespectrum dat 
zich onderscheidt door een sterke toename in C→A en C→T nucleotide veranderingen 
in bepaalde DNA sequenties. Ondanks het hoge aantal mutaties voorspelt de aanwezig-
heid van een POLE mutatie een gunstig klinisch beloop voor de patiënt: dit is tot nu 
toe aangetoond in endometrium- en colorectaal carcinomen en is gesuggereerd voor 
glioblastomen, een agressieve vorm van hersenkanker.
Het onderzoek beschreven in dit proefschrift richt zich op somatische POLE exonuclease 
domein mutaties in het endometriumcarcinoom. Het doel hierbij is om meer inzicht te 
krijgen in deze mutaties, in het bijzonder in de onderliggende mechanismen waardoor 
POLE mutaties bijdragen aan de gunstige prognose voor de patiënt.
Een overzicht van de literatuur over POLE exonuclease activiteit, de gevolgen van POLE 
mutaties voor maligniteiten en de kenmerken van POLE-mutante tumoren – zoals hier-
boven in het kort beschreven – is uiteengezet in hoofdstuk 2.
Bij de behandeling van het endometriumcarcinoom kunnen POLE mutaties gebruikt 
worden om de indicaties voor adjuvante therapie te verfijnen. Om deze mutaties te de-
tecteren is echter een techniek nodig die niet in elk ziekenhuis beschikbaar is, en boven-
dien is deze techniek relatief duur. In hoofdstuk 3 zijn daarom de histopathologische 
en immunohistochemische kenmerken van POLE-mutante endometriumcarcinomen 
gedetailleerd in kaart gebracht. Het doel hierbij was om kenmerken van deze tumoren 
te identificeren die aangeven dat de kans groot is dat een POLE mutatie aanwezig is. Op 
deze manier zou de specialistische techniek om POLE mutaties te detecteren gerichter 
kunnen worden ingezet. In totaal werden 133 endometriumcarcinomen, waarvan 51 
een POLE mutatie droegen, geblindeerd beoordeeld op de aanwezigheid van zestien 
morfologische kenmerken. POLE-mutante endometriumcarcinomen bleken zich te ken-
merken door de aanwezigheid van een prominent immuuninfiltraat. Daarnaast bevatte 
een derde van de POLE-mutante tumoren tumorreuscellen (opvallend grote cellen met 
bizar-uitziende, grote, en soms verscheidene kernen). Het histologisch type van alle 
POLE-mutante endometriumcarcinomen was endometrioïd adenocarcinoom, waarbij 
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kenmerken van het sereus-type endometriumcarcinoom even vaak (focaal) aanwezig 
waren in POLE-mutante als in POLE-wildtype endometrioïde tumoren. Immunohistoche-
misch onderzoek toonde bij het grootste deel van de POLE-mutante endometriumcar-
cinomen p53-wildtype expressie; negatieve of focale aankleuring van p16; en normale 
expressie van de mismatch repair eiwitten. Door een combinatie van deze eenvoudig te 
scoren kenmerken steeg de kans dat een POLE mutatie aanwezig was van 7% naar 33%. 
Gezamenlijk kunnen deze histopathologische en immunohistochemische karakteristie-
ken dus bijdragen aan het vooraf selecteren van endometriumcarcinomen waarbij het 
bepalen van POLE mutaties nuttig is. Dit faciliteert de implementatie van POLE mutatie 
screening in de klinische praktijk.
Om de gunstige prognose van patiënten met POLE-mutante maligniteiten te verklaren, 
zijn twee hypothesen onderzocht die beschreven worden in de Hoofdstukken 4, 5 en 6. 
Deze hypothesen betreffen de mogelijkheid van een toegenomen anti-tumor immuun-
reactie tegen POLE-mutante tumoren, en de mogelijkheid van verhoogde gevoeligheid 
van deze tumoren voor de aanvullende behandeling met radiotherapie of chemothe-
rapie.
De anti-tumor immuunreactie in POLE-mutante tumoren is allereerst onderzocht in een 
cohort van 150 endometriumcarcinomen, waaronder 47 met een POLE mutatie (hoofd-
stuk 4). Met behulp van immunohistochemie was in POLE-mutante endometriumcarci-
nomen, in vergelijking met POLE-wildtype tumoren, een sterke toename in het aantal 
cytotoxische tumor-infiltrerende T-cellen te zien. Deze bevinding is in de endometri-
umcarcinoomserie van The Cancer Genome Atlas (TCGA, n=244) gevalideerd en verder 
uitgewerkt. Ook in het TCGA cohort waren er bij analyse van RNA-sequentie data aanwij-
zingen voor een toegenomen cytotoxische T-cel reactie in POLE-mutante endometrium-
carcinomen. Deze T-cel reactie toonde tekenen van differentiatie en activatie, maar ook 
van uitputting, passend bij chronische blootstelling aan antigenen (eiwitfragmenten die 
door (tumor)cellen aan het immuunsysteem worden gepresenteerd). Bij verdere analyse 
bleek tevens dat POLE-mutante carcinomen meer neoantigenen (antigenen ontstaan als 
gevolg van tumorspecifieke DNA mutaties) presenteren dan endometriumcarcinomen 
zonder POLE mutaties. POLE-mutante endometriumcarcinomen kenmerken zich dus 
door een sterke intratumorale T-cel reactie die geassocieerd is met, en veroorzaakt kan 
worden door, een toename in neoantigenen. Deze toegenomen anti-tumor immuunre-
actie kan (deels) een verklaring bieden voor de gunstige prognose van POLE-mutante 
endometriumcarcinomen.
De bevinding van een versterkte immuunreactie in POLE-mutante tumoren is bevestigd 
in een serie van 116 endometriumcarcinomen met een hoog risico op recidief (hoofd-
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stuk 5). In dit cohort waren alle moleculaire subgroepen van het endometriumcarcinoom 
vertegenwoordigd, namelijk tumoren met een POLE mutatie, met microsatelliet insta-
biliteit (‘hypergemuteerd’), met p53-mutante expressie en tumoren zonder specifiek 
moleculair profiel. Zowel POLE-mutante als microsatelliet-instabiele endometriumcarci-
nomen waren sterk geïnfiltreerd door CD8+ cytotoxische T-cellen. Ook in een deel van de 
endometriumcarcinomen met p53-mutante expressie en in sommige tumoren zonder 
specifiek moleculair profiel bleek een aanzienlijk CD8+-immuuninfiltraat aanwezig. In 
deze studie is ook met immunohistochemie gekeken naar de expressie van immuun 
checkpoint receptor PD-1 en diens ligand PD-L1, welke na binding de immuunreactie 
juist kunnen onderdrukken: PD-1+ en PD-L1+ immuuncellen waren in hoge mate aanwe-
zig in POLE-mutante en microsatelliet-instabiele tumoren. De toegenomen anti-tumor 
immuunreactie, met daarbij ook hoge expressie van PD-1 en PD-L1, suggereert dat 
POLE-mutante en microsatelliet-instabiele endometriumcarcinomen goede kandidaten 
zijn voor behandeling met immuun checkpoint blokkerende middelen.
Uit diverse studies is gebleken dat POLE mutaties bij endometriumcarcinomen en colo-
rectaal carcinomen een gunstig klinisch beloop voor de patiënt voorspellen. Het meren-
deel van de patiënten in deze studies werd echter aanvullend behandeld. In hoofdstuk 
6 is daarom onderzocht of de goede prognose van POLE-mutante tumoren afhangt van 
de aanvullende behandeling. Dit is allereerst bekeken in de gerandomiseerde PORTEC-1 
studie, welke uitkomsten van patiënten met endometriumcarcinoom vergeleek na 
uitwendige radiotherapie en na observatie. Ook in de observatie arm hadden patiënten 
met POLE-mutante endometriumcarcinomen significant minder recidieven dan pati-
enten met POLE-wild-type tumoren. Ter ondersteuning van deze klinische data, is de 
gevoeligheid voor radiotherapie en chemotherapie ook onderzocht in POLE-mutante 
muis embryonale stamcellen. Uit dit modelsysteem bleek dat POLE-mutante cellen 
niet gevoeliger waren dan POLE-wild-type cellen voor radiotherapie en ook niet voor 
verschillende chemotherapieën, waaronder cisplatin, paclitaxel en 5-fluorouracil. Deze 
resultaten suggereren dat de goede prognose van POLE-mutante tumoren niet ver-
klaard kan worden door toegenomen gevoeligheid voor aanvullende behandeling. Dit 
biedt steun aan vervolgstudies waarin onderzocht zal worden of patiënten met (vroeg 
stadium) POLE-mutante tumoren voldoende behandeld zijn met alleen chirurgie. Dit 
kan leiden tot vermindering van overbehandeling en voor patiënten kan dit de kans op 
nadelige bijwerkingen verminderen.
Maligniteiten met POLE mutaties staan bekend om hun ultragemuteerde fenotype, 
hun specifieke mutatie spectrum, hun opvallend aanwezige immuuninfiltraat en een 
uitstekende prognose voor de patiënt. Het is onbekend in hoeverre deze kenmerken sa-
menhangen met het moment waarop POLE mutaties optreden tijdens het ontstaan van 
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de tumor. hoofdstuk 7 beschrijft dat POLE mutaties al aanwezig zijn in (niet-maligne) 
voorloperlaesies van het endometrium- en colorectaalcarcinoom. Uit genoom- of 
exoomsequencing bleek bovendien dat bijna alle mutaties in POLE-mutante tumoren 
het karakteristieke POLE mutatie spectrum volgen. Dit was ook het geval voor mutaties 
in genen waarvan gedacht wordt dat ze betrokken zijn bij het ontstaan van de tumor. 
Daarbij bleek dat ook POLE-mutante precursorlaesies geassocieerd waren met een 
toegenomen CD8+ immuunreactie, wat een vroeg ontstaan van het ultragemuteerde 
fenotype suggereert. Daarnaast was er in POLE-mutante carcinomen een substantieel 
hoger aantal clonale immunogene mutaties aanwezig. Deze resultaten duiden erop dat 
POLE mutaties vroege, en mogelijk initiërende, gebeurtenissen zijn in sporadische (niet-
erfelijke, verworven) tumoren. Als gevolg hiervan zal genoominstabiliteit ook vroeg 
optreden: dit kan een verklaring zijn voor de uitzonderlijke immuunreactie en de goede 
prognose van deze tumoren, maar ook voor het voorkomen van POLE-mutante tumoren 
op relatief jonge leeftijd.
De belangrijkste bevindingen uit de vorige hoofdstukken worden in hoofdstuk 8 in 
perspectief van de bestaande literatuur geplaatst. Daarnaast worden in dit hoofdstuk 
de openstaande vragen met betrekking tot POLE mutaties besproken, de mogelijke 
implicaties voor de behandeling van het endometriumcarcinoom en de mogelijkheden 
tot implementatie van POLE mutatie screening. Naast de in dit proefschrift onderzochte 
hypothesen om de gunstige uitkomst van tumoren met POLE mutaties te verklaren, 
zou ook de mogelijkheid van ‘error catastrophe’, oftewel het optreden van dusdanig 
veel mutaties dat dit verdere tumorgroei negatief beïnvloedt, nader bestudeerd kun-
nen worden. Voor patiënten met POLE-mutante maligniteiten in een vroeg stadium 
is het belangrijk dat vervolgstudies zullen uitwijzen of aanvullende behandeling hen 
bespaard kan blijven zonder dat hun recidiefkans stijgt. Voor de zeldzame patiënten 
met POLE-mutante tumoren in een gevorderd stadium en voor patiënten met POLE 
mutaties in agressieve tumoren als glioblastomen zijn juist specifieke, doelgerichte 
therapieën gewenst. Immuun checkpoint blokkers en mogelijk ook nucleoside analo-
gen zijn kandidaten voor een dergelijke doelgerichte behandeling van POLE-mutante 
tumoren. Detectie van POLE mutaties in de klinische praktijk zou kunnen plaatsvinden 
met behulp van genpanels waarbij, bij voorkeur, ook het aantal mutaties in een tumor 
en diens spectrum bepaald worden. Toekomstige studies zullen moeten uitwijzen of 
deze methode in de klinische praktijk haalbaar en kosteneffectief is.
Samenvattend kunnen somatische POLE exonuclease domein mutaties, gezien hun 
implicaties voor de prognose en zeer waarschijnlijk ook voor de behandeling van de pa-
tiënt, een belangrijke stap vormen naar een meer geïndividualiseerde behandeling van 
het endometriumcarcinoom. Aangezien de bevindingen tot nu toe ook van toepassing 
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lijken op andere tumortypen, zou deze stap richting meer ‘therapie op maat’ niet alleen 
voor het endometriumcarcinoom kunnen gelden, maar ook voor colorectaal carcinoom 
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